69

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(54) Title: PSMA ANTIBODIES AND PROTEIN MULTIMERS

WO 03/034903 A2

(57) Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:
— *without international search report and to be republished upon receipt of that report*

PSMA ANTIBODIES AND PROTEIN MULTIMERS

Related Applications

This application claims the benefit under 35 U.S.C. § 119 of United States provisional
application 60/335,215, filed October 23, 2001, United States provisional application
60/362,747, filed March 7, 2002, and United States provisional application 60/_____,
filed September 20, 2002, each of which is incorporated herein by reference.

Field of the Invention

This invention relates generally to the field of cancer associated polypeptides and
antibodies that recognize native epitopes on the polypeptides. In particular, the invention
relates in part to antibodies or antigen-binding fragments thereof which bind specifically to
conformational epitopes on the extracellular domain of PSMA, multimeric forms of PSMA
proteins, antibodies that selectively bind to the multimers, and compositions containing such
antibodies or multimers.

Background of the Invention

Prostate cancer is the most prevalent type of cancer and the second leading cause of
death from cancer in American men, with an estimated 179,000 cases and 37,000 deaths in
1999, (Landis, S.H. *et al. CA Cancer J. Clin.* 48:6-29 (1998)). The number of men diagnosed
with prostate cancer is steadily increasing as a result of the increasing population of older
men as well as a greater awareness of the disease leading to its earlier diagnosis (Parker et al.,
1997, *CA Cancer J. Clin.* 47:5-280). The life time risk for men developing prostate cancer is
about 1 in 5 for Caucasians, 1 in 6 for African Americans. High risk groups are represented
by those with a positive family history of prostate cancer or African Americans.

Over a lifetime, more than 2/3 of the men diagnosed with prostate cancer die of the
disease (Wingo et al., 1996, *CA Cancer J. Clin.* 46:113-25). Moreover, many patients who
do not succumb to prostate cancer require continuous treatment to ameliorate symptoms such
as pain, bleeding and urinary obstruction. Thus, prostate cancer also represents a major cause
of suffering and increased health care expenditures.

Where prostate cancer is localized and the patient's life expectancy is 10 years or
more, radical prostatectomy offers the best chance for eradication of the disease.

Historically, the drawback of this procedure is that most cancers had spread beyond the bounds of the operation by the time they were detected. Patients with bulky, high-grade tumors are less likely to be successfully treated by radical prostatectomy.

Radiation therapy has also been widely used as an alternative to radical prostatectomy. Patients generally treated by radiation therapy are those who are older and less healthy and those with higher-grade, more clinically advanced tumors. Particularly preferred procedures are external-beam therapy which involves three dimensional, confocal radiation therapy where the field of radiation is designed to conform to the volume of tissue treated; interstitial-radiation therapy where seeds of radioactive compounds are implanted using ultrasound guidance; and a combination of external-beam therapy and interstitial-radiation therapy.

For treatment of patients with locally advanced disease, hormonal therapy before or following radical prostatectomy or radiation therapy has been utilized. Hormonal therapy is the main form of treating men with disseminated prostate cancer. Orchiectomy reduces serum testosterone concentrations, while estrogen treatment is similarly beneficial. Diethylstilbestrol from estrogen is another useful hormonal therapy which has a disadvantage of causing cardiovascular toxicity. When gonadotropin-releasing hormone agonists are administered testosterone concentrations are ultimately reduced. Flutamide and other nonsteroidal, anti-androgen agents block binding of testosterone to its intracellular receptors. As a result, it blocks the effect of testosterone, increasing serum testosterone concentrations and allows patients to remain potent--a significant problem after radical prostatectomy and radiation treatments.

Cytotoxic chemotherapy is largely ineffective in treating prostate cancer. Its toxicity makes such therapy unsuitable for elderly patients. In addition, prostate cancer is relatively resistant to cytotoxic agents.

Relapsed or more advanced disease is also treated with anti-androgen therapy. Unfortunately, almost all tumors become hormone-resistant and progress rapidly in the absence of any effective therapy.

Accordingly, there is a need for effective therapeutics for prostate cancer which are not overwhelmingly toxic to normal tissues of a patient, and which are effective in selectively eliminating prostate cancer cells.

- 3 -

Summary of the Invention

The present invention relates to antibodies or antigen-binding fragments thereof which specifically bind the extracellular domain of prostate specific membrane antigen (PSMA), compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment.

According to one aspect of the invention, isolated antibodies or an antigen-binding fragments thereof are provided. The antibodies or fragments thereof specifically bind to an extracellular domain of prostate specific membrane antigen (PSMA), and competitively inhibit the specific binding of a second antibody to its target epitope on PSMA. In a second aspect of the invention, isolated antibodies or antigen-binding fragments thereof are provided which specifically bind to an epitope on prostate specific membrane antigen (PSMA) defined by a second antibody. In each of the forgoing aspects of the invention, the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

In certain embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11 PSMA 5.4, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, and Abgenix 4.152.1.

- 4 -

In other embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, and antigen-binding fragments thereof.

In further embodiments, the antibody or antigen-binding fragments thereof is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the foregoing antibodies, preferably at least about 95% identical, more preferably at least about 97% identical, still more preferably at least about 98% identical, and most preferably is at least about 99% identical.

In some embodiments of the foregoing aspects, antigen-binding fragments of the isolated antibodies are provided. The antigen-binding fragments include (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32. In other embodiments, the antigen-binding fragment includes (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

In a further embodiments of the invention, isolated antigen-binding fragments of antibodies, which include a CDR of the foregoing antigen-binding fragments are provided. Preferably the CDR is CDR3.

According another aspect of the invention, expression vectors including an isolated nucleic acid molecule encoding the foregoing isolated antibodies or antigen-binding fragments is provided. Host cells transformed or transfected by these expression vectors also are provided.

In certain embodiments, the antibody or antigen-binding fragment thereof is selected for its ability to bind live cells, such as a tumor cell or a prostate cell, preferably LNCaP cells. In other embodiments, the antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA. Preferably cytolysis of cells expressing PSMA is mediated by

5   effector cells or is complement mediated in the presence of effector cells.

In other embodiments, the antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA. Preferably the antibody or antigen-binding fragment thereof does not require cell lysis to bind to the extracellular domain of PSMA.

In further embodiments, the antibody or antigen-binding fragment thereof is selected

10   from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD or IgE. In other embodiments, the antibody is a bispecific or multispecific antibody.

In still other embodiments, the antibody is a recombinant antibody, a polyclonal

15   antibody, a monoclonal antibody, a humanized antibody or a chimeric antibody, or a mixture of these. In particularly preferred embodiments, the antibody is a human antibody, e.g., a monoclonal antibody, polyclonal antibody or a mixture of monoclonal and polyclonal antibodies. In still other embodiments, the antibody is a bispecific or multispecific antibody.

Preferred antigen-binding fragments include a Fab fragment, a F(ab')$_2$ fragment, and a

20   Fv fragment CDR3.

In further embodiments, the isolated antibody or antigen-binding fragment is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247),

25   PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix

30   4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix

- 6 -

4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and
Abgenix 4.152.1(PTA-4653).

     In certain other embodiments, the antibody or antigen-binding fragment thereof binds
to a conformational epitope and/or is internalized into a cell along with the prostate specific
5   membrane antigen. In other embodiments, the isolated antibody or antigen-binding fragment
thereof is bound to a label, preferably one selected from the group consisting of a fluorescent
label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a
luminescent label, and a chromophore label.

     In still other embodiments, the isolated antibody or antigen-binding fragment thereof
10   is bound to at least one therapeutic moiety, such as a drug, preferably a cytotoxic drug, a
replication-selective virus, a toxin or a fragment thereof, or an enzyme or a fragment thereof.
Preferred cytotoxic drug include: calicheamicin, esperamicin, methotrexate, doxorubicin,
melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide,
bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel,
15   docetaxel, dolastatin 10, auristatin E and auristatin PHE. In other embodiments, the
therapeutic moiety is an immunostimulatory or immunomodulating agent, preferably one
selected from the group consisting of: a cytokine, chemokine and adjuvant.

     In some embodiments, the antibodies or antigen-binding fragments of the invention
specifically bind cell-surface PSMA and/or rsPSMA with a binding affinity of about 1 X
20   10^{-9}M or less. Preferably, the binding affinity is about 1 X 10^{-10}M or less, more preferably
the binding affinity is about 1 X 10^{-11}M or less. In other embodiments the binding affinity is
less than about 5 X 10^{-10}M.

     In additional embodiments, the antibodies or antigen-binding fragments of the
invention mediate specific cell killing of PSMA-expressing cells with an IC_{50}s of less than
25   about 1 X 10^{-10}M. Preferably the IC_{50}s is less than about 1 X 10^{-11}M. More preferably the
IC_{50}s is less than about 1 X 10^{-12}M. In other embodiments the IC_{50}s is less than about 1.5 X
10^{-11}M.

     In yet other embodiments, the isolated antibody or antigen-binding fragment thereof is
bound to a radioisotope. The radioisotope can emit α radiations, β radiations, or γ radiations.
30   Preferably the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi,
^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

According to another aspect of the invention, hybridoma cell lines are provided that produce an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1. In some embodiments, the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

According to a further aspect of the invention, compositions are provided that include the foregoing antibodies or antigen-binding fragments thereof and a pharmaceutically acceptable carrier, excipient, or stabilizer. Other compositions include a combination of two or more of the foregoing antibodies or antigen-binding fragments thereof and a pharmaceutically acceptable carrier, excipient, or stabilizer. In some embodiments, the compositions also include an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof. Preferred antitumor agents include a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof. Preferred immunomodulators include α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof. Preferred immunostimulatory agents include interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

According to another aspect of the invention, kits for detecting prostate cancer for diagnosis, prognosis or monitoring are provided. The kits include the foregoing isolated

- 8 -

labeled antibody or antigen-binding fragment thereof, and one or more compounds for detecting the label. Preferably the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

5   The invention in another aspect provides one or more of the foregoing isolated antibodies or antigen-binding fragments thereof packaged in lyophilized form, or packaged in an aqueous medium.

In another aspect of the invention, methods for detecting the presence of PSMA, or a cell expressing PSMA, in a sample are provided. The methods include contacting the sample

10   with any of the foregoing antibodies or antigen-binding fragments thereof which specifically bind to an extracellular domain of PSMA, for a time sufficient to allow the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the PSMA-antibody complex or PSMA-antigen-binding fragment complex. The presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell

15   expressing PSMA.

In another aspect, the invention provides other methods for diagnosing a PSMA-mediated disease in a subject. The methods include administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an amount of any of the foregoing antibodies or antigen-binding fragments thereof which specifically bind to an

20   extracellular domain of prostate specific membrane antigen. The method also includes allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the PSMA-antibody complex or PSMA-antigen-binding fragment antibody complex to the target epitope. The presence of a complex in the subject suspected of having or previously diagnosed with prostate cancer is indicative

25   of the presence of a PSMA-mediated disease.

In certain embodiments of the methods, the PSMA-mediated disease is prostate cancer. In other embodiments, the PSMA-mediated disease is a non-prostate cancer, such as those selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including

30   non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including

- 9 -

colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

In preferred embodiments of the foregoing methods, the antibody or antigen-binding fragment thereof is labeled. In other embodiments of the foregoing methods, a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

In a further aspect of the invention, methods for assessing the prognosis of a subject with a PSMA-mediated disease are provided. The methods include administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim A1 or B1, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the complex to the target epitope. The amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the prognosis.

In another aspect of the invention, methods for assessing the effectiveness of a treatment of a subject with a PSMA-mediated disease are provided. The methods include administering to a subject suspected treated for a PSMA-mediated disease an effective amount of the foregoing antibodies or antigen-binding fragments thereof, allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and detecting the formation of the complex to the target epitope. The amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

In certain embodiments of these two aspects of the invention, the PSMA-mediated disease is prostate cancer. In other embodiments, the PSMA-mediated disease is a non-prostate cancer. In those embodiments, the non-prostate cancer preferably is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma. In still other embodiments, the antibody or antigen-binding

- 10 -

fragment thereof is labeled. In further embodiments, a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

According to yet another aspect of the invention, methods for inhibiting the growth of a cell expressing PSMA are provided. The methods include contacting a cell expressing

5   PSMA with an amount of at least one of the foregoing antibodies or antigen-binding fragments thereof which specifically binds to an extracellular domain of PSMA effective to inhibit the growth of the cell expressing PSMA.

According to another aspect of the invention, methods for inducing cytolysis of a cell expressing PSMA are provided. The methods include contacting a cell expressing PSMA

10   with an amount of at least one of the foregoing antibodies or antigen-binding fragments thereof which specifically binds to an extracellular domain of PSMA effective to induce cytolysis of the cell expressing PSMA. In certain embodiments, the cytolysis occurs in the presence of an effector cell. In other embodiments, the cytolysis is complement mediated.

According to still another aspect of the invention, methods for treating or preventing a

15   PSMA-mediated disease are provided. The methods include administering to a subject having a PSMA-mediated disease an effective amount of at least one of the forgoing antibodies or antigen-binding fragments thereof to treat or prevent the PSMA-mediated disease. In some embodiments, the PSMA-mediated disease is a cancer, such as prostate cancer or a non-prostate cancer (including the nonprostate cancers described elsewhere

20   herein).

In yet a further aspect of the invention, methods for treating or preventing a PSMA-mediated disease are provided. The methods include administering to a subject having a PSMA-mediated disease or at risk of having a PSMA-mediated disease an amount of at least one of the foregoing antibodies or antigen-binding fragments thereof effective to treat or

25   prevent the PSMA-mediated disease.

In some embodiments, the PSMA-mediated disease is a cancer, such as prostate cancer or a non-prostate cancer (including the nonprostate cancers described elsewhere herein).

In other embodiments, the method also includes administering another therapeutic

30   agent to treat or prevent the PSMA-mediated disease at any time before, during or after the administration of the antibody or antigen-binding fragment thereof. In some of these

embodiments, the therapeutic agent is a vaccine, and preferably the vaccine immunizes the subject against PSMA.

In still other embodiments, the antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety, preferably a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof. Preferred cytotoxic drugs are selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

In other embodiments, the antibody or antigen-binding fragment thereof is bound to a radioisotope and the radiations emitted by the radioisotope is selected from the group consisting of α, β and γ radiations. Preferably, the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

The present invention provides methods for modulating at least one enzymatic activity of PSMA. As used in preferred embodiments of the methods, "modulating" an enzymatic activity of PSMA means enhancing or inhibiting the enzymatic activity. Thus in certain aspects of the invention, methods for inhibiting an enzymatic activity of PSMA are provided, and in other aspects of the invention, methods for enhancing an enzymatic activity of PSMA are provided. The terms "enhancing' and "inhibiting" in this context indicate that the enzymatic activity of PSMA is enhanced or inhibited in the presence of an antibody that specifically binds PSMA, or antigen-binding fragment thereof, relative to the level of activity in the absence of such an antibody or antigen-binding fragment thereof. Enzymatic activities of PSMA include folate hydrolase activity, N-acetylated α-linked acidic dipeptidase (NAALADase) activity, dipeptidyl dipeptidase IV activity and γ-glutamyl hydrolase activity.

Thus the invention in another aspect provides methods for modulating folate hydrolase activity. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a folate hydrolase polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof, under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates the folate hydrolase activity. The folate hydrolase polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue

- 12 -

homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

In another aspect of the invention, methods for modulating N-acetylated α-linked acidic dipeptidase (NAALADase) activity are provided. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a NAALADase polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates NAALADase activity. The NAALADase polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

In yet another aspect of the invention, methods for modulating dipeptidyl dipeptidase IV activity are provided. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a dipeptidyl dipeptidase IV polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates dipeptidyl dipeptidase IV activity. The dipeptidyl dipeptidase IV polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

In yet another aspect of the invention, methods for modulating γ-glutamyl hydrolase activity are provided. In certain embodiments of these methods, the activity is inhibited and in other embodiments, the activity is enhanced. The methods include contacting a γ-glutamyl hydrolase polypeptide with an amount of the foregoing isolated antibody or antigen-binding fragment thereof under conditions wherein the isolated antibody or antigen-binding fragment thereof modulates γ-glutamyl hydrolase activity. The γ-glutamyl hydrolase polypeptide can be isolated, contained in a sample such as a cell, a cell homogenate, a tissue, or a tissue homogenate, or contained in an organism. The organism preferably is an animal, particularly preferably a mammal.

Methods of specific delivery of at least one therapeutic agent to PSMA-expressing cells are provided according to another aspect of the invention. The methods include administering an effective amount of at least one of the foregoing antibodies or antigen-

binding fragments thereof conjugated to the at least one therapeutic agent. In some embodiments, the therapeutic agent is a nucleic acid molecule, an antitumor drug, a toxin or a fragment thereof, an enzyme or a fragment thereof, a replication-selective virus, or an immunostimulatory or immunomodulating agent. Preferred antitumor drugs include

5   cytotoxic drugs, drugs which act on the tumor neovasculature and combinations thereof. Preferred cytotoxic drugs include calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE. Preferred immunostimulatory or

10   immunomodulating agent included cytokines, chemokines and adjuvants.

In still another aspect of the invention, isolated antibodies that selectively bind a PSMA protein multimer are provided. In preferred embodiments, the PSMA protein multimer is a dimer, and preferably at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. Preferably the rsPSMA polypeptide

15   consists essentially of amino acids 44-750 of SEQ ID NO:1.

In a further aspect of the invention, isolated antibodies are provided that selectively bind a PSMA protein multimer and modulate one or more enzymatic activities of the PSMA protein multimer. As used in preferred embodiments of this aspect of the invention, "modulating" an enzymatic activity of a PSMA multimer means enhancing or inhibiting the

20   enzymatic activity. Thus in certain aspects of the invention, antibodies that inhibit an enzymatic activity of PSMA multimers are provided, and in other aspects of the invention, antibodies that inhibit an enzymatic activity of PSMA multimers are provided. The terms "enhancing' and "inhibiting" in this context indicate that the enzymatic activity of a PSMA multimer is enhanced or inhibited in the presence of an antibody that specifically binds the

25   PSMA multimers, or antigen-binding fragment thereof, relative to the level of activity in the absence of such an antibody or antigen-binding fragment thereof. In some embodiments, the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity and γ-glutamyl hydrolase activity. In other embodiments, the enzymatic activity is in the extracellular domain of the PSMA

30   molecule. In still other embodiments, the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

- 14 -

In a further aspect, an isolated antibody or antigen-binding fragment thereof is provided that selectively binds a PSMA protein multimer. In this aspect, the isolated antibody is raised by immunizing an animal with a preparation comprising a PSMA protein multimer. Preferred preparations used in raising the antibody include those having at least

5   about 10%, 20%, 30%, 40%, 50%, 75%, 90%, or 95% PSMA protein multimer. Preferably the PSMA protein multimer is a dimer.

In yet another aspect of the invention, compositions are provided that include one or more of the foregoing isolated antibodies, and an immunostimulatory molecule, such as an adjuvant and/or and a cytokine. Preferably the immunostimulatory molecule is IL-2 or an

10   immunostimulatory oligonucleotide. In certain embodiments, the foregoing compositions also include a pharmaceutically-acceptable carrier.

The invention also includes methods for inducing an immune response, including administering to a subject in need of such treatment an effective amount of the foregoing isolated antibodies or compositions.

15   The invention provides, in another aspect, isolated antibodies or antigen-binding fragments thereof that selectively bind a PSMA protein multimer and modulate at least one enzymatic activity of PSMA. As used in preferred embodiments of this aspect of the invention, "modulating" an enzymatic activity of a PSMA means enhancing or inhibiting the enzymatic activity. Thus in certain aspects of the invention, antibodies that inhibit an

20   enzymatic activity of PSMA are provided, and in other aspects of the invention, antibodies that inhibit an enzymatic activity of PSMA are provided. The terms "enhancing' and "inhibiting" in this context indicate that the enzymatic activity of PSMA is enhanced or inhibited in the presence of an antibody that specifically binds PSMA, or antigen-binding fragment thereof, relative to the level of activity in the absence of such an antibody or

25   antigen-binding fragment thereof. The enzyme, in certain embodiments, is selected from the group consisting of hydrolases and peptidases. Preferred hydrolases include folate hydrolase and γ-glutamyl hydrolase. In a particularly preferred embodiment of PSMA inhibition, the hydrolase is folate hydrolase and the antibody is mAb 5.4 or mAb 3.9. Preferred peptidases include NAALADase and dipeptidyl dipeptidase IV. In some embodiments, the enzyme is

30   active in cancer cells and has lesser activity in normal cells than in cancer cells or, preferably, no activity in normal cells. In preferred embodiments, the cancer cells in which the enzyme is active are prostate cancer cells. Compositions including the foregoing isolated antibodies

- 15 -

or antigen-binding fragments thereof, and a pharmaceutically acceptable carrier, also are provided by the invention.

In another aspect of the invention, compositions are provided that include an isolated PSMA protein multimer. Preferably the PSMA protein multimer is a dimer. In certain

5   embodiments, the compositions include at least about 10%, 20%, 30%, 40%, 50%, 75%, 90%, or 95% PSMA protein multimer. In other embodiments, the PSMA protein multimer comprises noncovalently associated PSMA proteins. The PSMA proteins preferably are noncovalently associated under nondenaturing conditions.

In certain embodiments of the foregoing compositions, at least one of the PSMA

10   proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. In other embodiments, the PSMA protein multimer is reactive with a conformation-specific antibody that specifically recognizes PSMA. Preferably, the PSMA protein multimer comprises PSMA proteins in a native conformation and/or the PSMA multimer is enzymatically active. In preferred embodiments, the enzymatic activity is folate hydrolase

15   activity, NAALADase activity, dipeptidyl dipeptidase IV activity and/or γ-glutamyl hydrolase activity.

In still other embodiments, the foregoing compositions also include an adjuvant and/or a cytokine or other immunostimulatory molecule. Preferred cytokines include IL-2, IL-12, IL-18 and GM-CSF. In further embodiments, the foregoing compositions also include

20   a pharmaceutically acceptable carrier.

According to yet another aspect of the invention, methods for inducing an immune response are provided. The methods include administering to a subject in need of such treatment an effective amount of one or more of the foregoing compositions.

In a further aspect, the invention includes isolated recombinant soluble PSMA

25   (rsPSMA) protein multimers, and isolated rsPSMA protein dimers. In some embodiments, the dimer includes noncovalently associated rsPSMA proteins, and preferably the rsPSMA proteins are noncovalently associated under nondenaturing conditions. In other embodiments, the isolated rsPSMA dimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

30   In a certain preferred embodiment, the isolated rsPSMA dimer is enzymatically active, with the enzymatic activity selected from the group consisting of folate hydrolase

activity, NAALADase activity, dipeptidyl dipeptidase IV activity and γ-glutamyl hydrolase activity.

In still another aspect of the invention, methods of screening for a candidate agent that modulates at least one enzymatic activity of a PSMA enzyme are provided. As used in preferred embodiments of the methods, "modulating" an enzymatic activity of PSMA means enhancing or inhibiting the enzymatic activity. Thus in certain aspects of the invention, methods for screening for a candidate agent that inhibits an enzymatic activity of PSMA are provided, and in other aspects of the invention, methods for screening for a candidate agent that enhances an enzymatic activity of PSMA are provided. The terms "enhancing" and "inhibiting" in this context indicate that the enzymatic activity of PSMA is enhanced or inhibited in the presence of a candidate agent relative to the level of activity in the absence of such an agent. The methods include mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by adding a substrate for the PSMA enzyme to the reaction mixture, and determining the amount of a product formed from the substrate by the PSMA enzyme. A change in the amount of product formed in comparison to a control is indicative of an agent capable of modulating at least one enzymatic activity of the PSMA enzyme. A decrease in the amount of product formed in comparison to a control is indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme. An increase in the amount of product formed in comparison to a control is indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme. In some embodiments the PSMA enzyme is selected from the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ-glutamyl hydrolase. In other embodiments the PSMA multimer comprises recombinant, soluble PSMA. In yet other embodiments the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

In another aspect of the invention, candidate agents that modulate at least one enzymatic activity of PSMA are provided. The candidate agents are identified according to the foregoing methods. Thus in certain aspects of the invention, candidate agents that inhibit an enzymatic activity of PSMA are provided, and in other aspects of the invention, candidate agents that enhance an enzymatic activity of PSMA are provided. In certain embodiments, the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

- 17 -

The invention also provides methods for identifying compounds that promote dissociation of PSMA dimers. The methods include contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound, measuring the amount of PSMA monomer and/or dimer; and

5   comparing the amount of PSMA monomer and/or dimer measured in the presence of the compound with that observed in the absence of the compound. An increase in the amount of PSMA monomer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer. A decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of

10   promoting dissociation of the PSMA dimer. When the amounts of PSMA monomer and PSMA dimer are measured, the methods can include calculating a ratio of PSMA monomer to PSMA dimer and comparing the ratio obtained in the presence of the compound with that obtained in the absence of the compound. In such methods, an increase in the ratio measured in the presence of the compound indicates that the compound is capable of promoting

15   dissociation of the PSMA dimer.

The use of the foregoing compositions, molecules and agents in the preparation of medicaments also is provided. In preferred embodiments, the medicaments are useful in the treatment of conditions related to hyperproliferative diseases including cancer, and diseases of inappropriate NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV

20   activity and/or γ-glutamyl hydrolase activity.

These and other aspects of the invention will be described in further detail in connection with the detailed description of the invention.

Brief Description of the Drawings

25   Figure 1 depicts PSMA reactivity of mAbs as determined by flow cytometry. Anti-PSMA mAbs (3.7, 3.9, 3.11, 3.12, 5.4, and 10.3) incubated with either parental 3T3 cells (denoted by black lines) or 3T3 cells engineered to express cell-surface PSMA (3T3-PSMA; gray lines).

Figure 2 shows a digitized image of immunoprecipitation of PSMA by mAbs.

30   Lysates from 3T3-PSMA cells or parental 3T3 cells were incubated with each mAb and then precipitated using Protein A/G agarose beads. After washing, proteins were resolved on a

- 18 -

polyacrylamide gel, blotted onto nitrocellulose membranes and visualized using the MAB544 anti-PSMA mAb.

Figure 3 shows the recognition of non-denatured PSMA by several PSMA antibodies that recognize PSMA conformation.

Figure 4 is a digitized image of a Western blot that shows the recognition of denatured PSMA by two PSMA antibodies and shows that antibodies that recognize PSMA conformation do not recognize denatured PSMA.

Figure 5 is a digitized image of a polyacrylamide gel that shows an analysis of purified recombinant, soluble PSMA (rsPSMA) and of full-length PSMA from 3T3 cells (3T3 PSMA) or LNCaP cells (LNCaP PSMA) by reduced and non-reduced SDS-PAGE.

Figure 6 is a digitized image of a polyacrylamide gel that depicts a Blue Native PAGE analysis of purified recombinant, soluble PSMA (Purified rsPSMA) and of full-length PSMA extracted from 3T3 cells (3T3 PSMA) or LNCaP cells (LNCaP PSMA).

Figure 7 shows the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase through measuring the rate of cleavage of glutamate from methotrexate di-gamma glutamate by folate hydrolase present in 0.0002 µg rsPSMA #7.

Figure 8 shows the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase through measuring the rate of cleavage of glutamate from methotrexate di-gamma glutamate by folate hydrolase present in 0.0002 µg rsPSMA #8.

Figure 9 shows the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the enzymatic activity of folate hydrolase through measuring the rate of cleavage of glutamate from methotrexate di-gamma glutamate by folate hydrolase present in lysates of C4-2 cells.

Figure 10 depicts the cloning protocol for IgG1 antibody cloning into pcDNA.

Figure 11 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-006.

Figure 12 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-026.

Figure 13 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-051.

Figure 14 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-069.

Figure 15 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody AB-PG1-XG1-077.

Figure 16 provides the plasmid map of a nucleic acid molecule encoding the heavy chain of antibody PSMA 10.3.

Figure 17 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-006.

Figure 18 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-026.

Figure 19 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-051.

Figure 20 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-069.

Figure 21 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody AB-PG1-XG1-077.

Figure 22 provides the plasmid map of a nucleic acid molecule encoding the light chain of antibody PSMA 10.3.

Figure 23 depicts the cytotoxicity of ^{225}Ac-3.9 on LNCaP target cells.

Figure 24 illustrates the reactivity of anti-PSMA monoclonal antibodies XG-006, XG-051, 4.40.1, 4.49.1, 4.292.1 and 4.304.1 incubated with either parent 3T3 cells (black histogram) or 3T3 cells enigineered to express cell-surface human PSMA (grey histogram) and analyzed by flow cytometry.

Figure 25 illustrates the binding of the anti-PSMA Abs. Figure 25A shows that anti-PSMA mAbs bind to 3T3-PSMA cells and not 3T3 cells. One representative experiment from at least ten determinations is shown. Figure 25B illustrates that binding to cell-surface PSMA using serial dilutions of anti-PSMA mAb-containing culture supernatants occurred. One representative experiment from five is shown. Figure 25C shows binding to cell-surface PSMA using serial dilutions of purified anti-PSMA mAbs, XG-006 and 10.3 One representative experiment is shown.

Figure 26 illustrates the immunotoxin cytotoxicity of murine anti-PSMA antibodies on C4-2 prostate cancer cells. SJ25C-1 as a control antibody is a murine anti-CD19 IgG.

- 20 -

The LD 50s (M) for 5.4, 3.9, and mJ591 antibodies were 2.27×10^{-11}, 2.29×10^{-11} and 8.82×10^{-11}, respectively.

Figure 27 illustrates the immunotoxin cytotoxicity of murine anti-PSMA antibodies on PSMA-3T3 cells. SJ25C-1 as a control antibody is a murine anti-CD19 IgG. The LD 50s (M) for 5.4, 3.9, and mJ591 antibodies were 1.64×10^{-11}, 1.96×10^{-11} and 8.90×10^{-11}, respectively.

Figure 28 provides the cytotoxicity of direct conjugated human 4.304 anti-PSMA antibodies with saporin on PSMA-3T3. The LD50 was 1.48×10^{-11} M for direct conjugated 4.304 anti-PSMA antibodies with saporin.

Figure 29 illustrates the results of the competition assay of unmodified 4.304, 4.40, mJ591 anti-PSMA antibodies used to compete with In-111 radiolabeled 4.40 and 4.304 anti-PSMA antibodies.

Figure 30 illustrates the results of the competition assay of unmodified 4.304, mJ591 anti-PSMA antibodies used to compete with In-111 radiolabeled mJ591 anti-PSMA antibodies.

Figure 31 shows an analysis of antibody PRGX1-XG-006 in association phase and dissociation phase at different concentrations of rsPSMA from 100 nM to 6.25 nM.

Figure 32 shows the results of the comparison of the fully human anti-PSMA antibodies 4.40.1, 4.49.1, 051 and 006 and the murine anti-PSMA antibody 3.9 performed using Biacore analysis.

Figure 33 provides results from the Scatchard analysis using In-111 labeled anti-PSMA antibody 3.9 of the PSMA-3T3, LNCaP and C4-2 cell lines.

Figure 34 shows *in vitro* cytotoxicity of Ac-225 labeled human anti-PSMA antibody 4.40 on prostate cancer cells.

Figure 35 shows the results of *in vivo* radioimmunotherapy with Lu-177 labeled human anti-PSMA antibodies.

Figure 36 is a series of graphs that show flow cytometry data for the binding of anti-PSMA antisera to PSMA-3T3 cells. Antisera from mice immunized with a rsPSMA dimer preparation (ABIM151, ABIM152, ABIM153, ABIM154 and ABIM155) exhibited strong binding to PSMA-expressing cells. Antisera from mice immunized with a rsPSMA monomer preparation (ABIM156, ABIM157, ABIM158, ABIM159 and ABIM160) exhibited little or no binding to PSMA-expressing cells.

Detailed Description of the Invention

The present invention provides antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA,

5   compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment.

Prostate specific membrane antigen (PSMA) is a 100 kD Type II membrane glycoprotein expressed in prostate tissues and was originally identified by reactivity with a

10   monoclonal antibody designated 7E11-C5 (Horoszewicz et al., 1987, *Anticancer Res.* 7:927-935; U.S. Pat. No. 5,162,504). PSMA was obtained in purified form (Wright et al., 1990, Antibody Immunoconjugates and Radio Pharmaceuticals 3:Abstract 193) and characterized as a type II transmembrane protein having sequence identity with the transferrin receptor (Israeli et al., 1994, *Cancer Res.* 54:1807-1811) and with NAALADase activity (Carter et al.,

15   1996, *Proc. Natl. Acad. Sci. U.S.A.* 93:749-753). More importantly, PSMA is expressed in increased amounts in prostate cancer, and elevated levels of PSMA are also detectable in the sera of these patients (Horoszewicz et al., 1987; Rochon et al., 1994, *Prostate* 25:219-223; Murphy et al., 1995, *Prostate* 26:164-168; and Murphy et al., 1995, *Anticancer Res.* 15:1473-1479). PSMA expression increases with disease progression, becoming highest in metastatic,

20   hormone-refractory disease for which there is no present therapy. Provocative recent data indicates that PSMA is also abundantly expressed on the neovasculature of a variety of other important tumors, including bladder, pancreas, sarcoma, melanoma, lung, and kidney tumor cells, but not on normal vasculature.

One aspect of the invention provides an isolated antibody or an antigen-binding

25   fragment thereof which specifically binds to an extracellular domain of PSMA wherein the antibody or the antigen-binding fragment thereof competitively inhibits the specific binding of a second antibody to its target epitope on PSMA, and wherein the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, 4.248.2,

30   4.360.3, 4.7.1, 4.4.1, 4.177.3, 4.16.1, 4.22.3, 4.28.3, 4.40.2, 4.48.3, 4.49.1, 4.209.3, 4.219.3, 4.288.1, 4.333.1, 4.54.1, 4.153.1, 4.232.3, 4.292.3, 4.304.1, 4.78.1, and 4.152.1.

- 22 -

Another aspect of the invention provides an isolated antibody or an antigen-binding fragment thereof that specifically binds to an epitope on PSMA defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, 4.248.2, 4.360.3, 4.7.1, 4.4.1, 4.177.3, 4.16.1, 4.22.3, 4.28.3, 4.40.2, 4.48.3, 4.49.1, 4.209.3, 4.219.3, 4.288.1, 4.333.1, 4.54.1, 4.153.1, 4.232.3, 4.292.3, 4.304.1, 4.78.1, and 4.152.1.

In particular embodiments, these antibodies are produced by hybridomas referred to herein as PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, and Abgenix 4.152.1, respectively. These hybridomas were deposited with ATCC as an International Depository Authority and given the following Patent Deposit Designations (Table 1):

Table 1.

Antibody	Hybridoma/Plasmid	Patent Deposit Designation	Date of Deposit
PSMA 3.7	PSMA 3.7	PTA-3257	April 5, 2001
PSMA 3.9	PSMA 3.9	PTA-3258	April 5, 2001
PSMA 3.11	PSMA 3.11	PTA-3269	April 10, 2001
PSMA 5.4	PSMA 5.4	PTA-3268	April 10, 2001
PSMA 7.1	PSMA 7.1	PTA-3292	April 18, 2001
PSMA 7.3	PSMA 7.3	PTA-3293	April 18, 2001
PSMA 10.3	PSMA 10.3	PTA-3347	May 1, 2001
	PSMA 10.3 HC in pcDNA (SEQ ID NO: 7)	PTA-4413	May 29, 2002
	PSMA 10.3 Kappa in pcDNA (SEQ ID NO: 13)	PTA-4414	May 29, 2002
PSMA 1.8.3	PSMA 1.8.3	PTA-3906	Dec. 5, 2001
PSMA A3.1.3	PSMA A3.1.3	PTA-3904	Dec. 5, 2001

PSMA A3.3.1	PSMA A3.3.1	PTA-3905	Dec. 5, 2001
Abgenix 4.248.2	Abgenix 4.248.2	PTA-4427	June 4, 2002
Abgenix 4.360.3	Abgenix 4.360.3	PTA-4428	June 4, 2002
Abgenix 4.7.1	Abgenix 4.7.1	PTA-4429	June 4, 2002
Abgenix 4.4.1	Abgenix 4.4.1	PTA-4556	July 18, 2002
Abgenix 4.177.3	Abgenix 4.177.3	PTA-4557	July 18, 2002
Abgenix 4.16.1	Abgenix 4.16.1	PTA-4357	May 16, 2002
Abgenix 4.22.3	Abgenix 4.22.3	PTA-4358	May 16, 2002
Abgenix 4.28.3	Abgenix 4.28.3	PTA-4359	May 16, 2002
Abgenix 4.40.2	Abgenix 4.40.2	PTA-4360	May 16, 2002
Abgenix 4.48.3	Abgenix 4.48.3	PTA-4361	May 16, 2002
Abgenix 4.49.1	Abgenix 4.49.1	PTA-4362	May 16, 2002
Abgenix 4.209.3	Abgenix 4.209.3	PTA-4365	May 16, 2002
Abgenix 4.219.3	Abgenix 4.219.3	PTA-4366	May 16, 2002
Abgenix 4.288.1	Abgenix 4.288.1	PTA-4367	May 16, 2002
Abgenix 4.333.1	Abgenix 4.333.1	PTA-4368	May 16, 2002
Abgenix 4.54.1	Abgenix 4.54.1	PTA-4363	May 16, 2002
Abgenix 4.153.1	Abgenix 4.153.1	PTA-4388	May 23, 2002
Abgenix 4.232.3	Abgenix 4.232.3	PTA-4389	May 23, 2002
Abgenix 4.292.3	Abgenix 4.292.3	PTA-4390	May 23, 2002
Abgenix 4.304.1	Abgenix 4.304.1	PTA-4391	May 23, 2002
AB-PG1-XG1-006	AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2) AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8)	PTA-4403 PTA-4404	May 29, 2002
AB-PG1-XG1-026	AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3) AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9)	PTA-4405 PTA-4406	May 29, 2002
AB-PG1-XG1-051	AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4) AB-PG1-XG1-051 Light	PTA-4407 PTA-4408	May 29, 2002

	Chain (SEQ ID NO: 10)		
AB-PG1-XG1-069	AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5) AB-PG1-XG1-069 Light Chain (SEQ ID NO: 11)	PTA-4409 PTA-4410	May 29, 2002
AB-PG1-XG1-077	AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6) AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12)	PTA-4411 PTA-4412	May 29, 2002

In another aspect of the invention, antibodies having particular sequences are provided. Specifically, the antibodies are selected from the group consisting of antibodies comprising: a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13. Also provided are antigen-binding fragments of the foregoing antibodies.

The plasmids encoding the heavy and light chains of antibodies PSMA 10.3, AB-PG1-XG1-006, AB-PG1-XG1-026, AB-PG1-XG1-051, AB-PG1-XG1-069, AB-PG1-XG1-077 were also deposited with ATCC and are shown in Table 1 above. As used herein, the names of the deposited hybridomas or plasmids may be used interchangeably with the names of the antibodies. It would be clear to one of skill in the art when the name is intended to refer to the antibody or when it refers to the plasmids or hybridomas that encode or produce the antibodies, respectively. Additionally, the antibody names may be an abbreviated form of the name shown in Table 1. For instance antibody AB-PG1-XG1-006 may be referred to as AB-PG1-XG1-006, PG1-XG1-006, XG1-006, 006, etc. In another example, the antibody name PSMA 4.232.3 may be referred to as PSMA 4.232.1, 4.232.3, 4.232.1, 4.232, etc. It is intended that all of the variations in the name of the antibody refer to the same antibody and not a different one.

Antibodies are also provided that are encoded by particular sets of heavy and light chain sequences. In one embodiment an antibody (AB-PG1-XG1-006) encoded by a nucleic

- 25 -

acid molecule which comprises the coding region or regions of the nucleic acid sequences set forth as :SEQ ID NOs: 2 and 8 is provided. In another embodiment the antibody (AB-PG1-XG1-026) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 3 and 9. In still another embodiment the antibody (AB-PG1-XG1-051) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 4 and 10. In yet another embodiment the antibody (AB-PG1-XG1-069) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 5 and 11. In another embodiment the antibody (AB-PG1-XG1-077) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 6 and 12. In yet another embodiment the antibody (PSMA 10.3) is encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 7 and 13.

In particularly preferred embodiments, the antibodies include a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32. As used herein, a "coding region" refers to a region of a nucleotide sequence that encodes a polypeptide sequence; the coding region can include a region coding for a portion of a protein that is later cleaved off, such as a signal peptide.

Those of skill in the art will appreciate that the invention includes nucleic acids and polypeptides that include nucleotide and amino acid sequences presented herein. In some instances, the nucleotide and amino acid sequences may include sequences that encode or that are signal peptides. The invention embraces each of these sequences with, or without, the portion of the sequence that encodes or is a signal peptide.

Antibodies also are provided that include particular sets of heavy and light chain variable sequences. In one embodiment an antibody (AB-PG1-XG1-006) includes an immunoglobulin variable sequence encoded by nucleic acid molecules which included the coding region or regions of the nucleic acid sequences set forth as :SEQ ID NOs: 14 and 16 is provided. Likewise the antibody may include an immunoglobulin variable sequence which

- 26 -

comprises the amino acid sequences set forth as SEQ ID NOs: 15 and 17. In another embodiment the antibody (AB-PG1-XG1-026) includes an immunoglobulin variable sequence encoded by nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 18 and 20 or includes an immunoglobulin

5   variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 19 and 21. In still another embodiment the antibody (AB-PG1-XG1-051) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 22 and 24 or includes an immunoglobulin variable sequence which comprises the amino acid sequences

10   set forth as SEQ ID NOs: 23 and 25. In yet another embodiment the antibody (AB-PG1-XG1-069) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 26 and 28 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 27 and 29. In another embodiment the

15   antibody (AB-PG1-XG1-077) includes an immunoglobulin variable sequence encoded by the nucleic acid molecules comprising the coding region or regions of nucleotide sequences set forth as: SEQ ID NOs: 30 and 32 or includes an immunoglobulin variable sequence which comprises the amino acid sequences set forth as SEQ ID NOs: 31 and 33.

In certain embodiments, the antibody is encoded by a nucleic acid molecule that is

20   highly homologous to the foregoing nucleic acid molecules. Preferably the homologous nucleic acid molecule comprises a nucleotide sequence that is at least about 90% identical to the nucleotide sequence provided herein. More preferably, the nucleotide sequence is at least about 95% identical, at least about 97% identical, at least about 98% identical, or at least about 99% identical to the nucleotide sequence provided herein. The homology can be

25   calculated using various, publicly available software tools well known to one of ordinary skill in the art. Exemplary tools include the BLAST system available from the website of the National Center for Biotechnology Information (NCBI) at the National Institutes of Health.

One method of identifying highly homologous nucleotide sequences is via nucleic acid hybridization. Thus the invention also includes antibodies having the PSMA-binding

30   properties and other functional properties described herein, which are encoded by nucleic acid molecules that hybridize under high stringency conditions to the foregoing nucleic acid molecules. Identification of related sequences can also be achieved using polymerase chain

reaction (PCR) and other amplification techniques suitable for cloning related nucleic acid sequences. Preferably, PCR primers are selected to amplify portions of a nucleic acid sequence of interest, such as a CDR.

The term "high stringency conditions" as used herein refers to parameters with which the art is familiar. Nucleic acid hybridization parameters may be found in references that compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. One example of high-stringency conditions is hybridization at 65°C in hybridization buffer (3.5X SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 2.5mM NaH_2PO_4(pH7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.015M sodium citrate, pH7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, a membrane upon which the nucleic acid is transferred is washed, for example, in 2X SSC at room temperature and then at 0.1 - 0.5X SSC/0.1X SDS at temperatures up to 68°C.

In other preferred embodiments, the antibodies include a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33. Antigen-binding fragments of the foregoing also are provided, as described elsewhere herein.

As used herein, the term "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds. Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or V_H) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, C_H1 , C_H2 and C_H3. Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or V_L) and a light chain constant region. The light chain constant region is comprised of one domain, CL. The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The

variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.

The term "antigen-binding fragment" of an antibody as used herein, refers to one or more portions of an antibody that retain the ability to specifically bind to an antigen (e.g., PSMA). It has been shown that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. Examples of binding fragments encompassed within the term "antigen-binding fragment" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the V_L, V_H, C_L and C_H1 domains; (ii) a F(ab')$_2$ fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the V_H and CH1 domains; (iv) a Fv fragment consisting of the V_L and V_H domains of a single arm of an antibody, (v) a dAb fragment (Ward *et al.*, (1989) *Nature* 341:544-546) which consists of a V_H domain; and (vi) an isolated complementarity determining region (CDR). Furthermore, although the two domains of the Fv fragment, V and V_H, are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the V_L and V_H regions pair to form monovalent molecules (known as single chain Fv (scFv); see e.g., Bird *et al.* (1988) *Science* 242:423-426; and Huston *et al.* (1988) *Proc. Natl. Acad. Sci. USA* 85:5879-5883). Such single chain antibodies are also intended to be encompassed within the term "antigen-binding portion" of an antibody. These antibody fragments are obtained using conventional procedures, such as proteolytic fragmentation procedures, as described in J. Goding, Monoclonal Antibodies: Principles and Practice, pp 98-118 (N.Y. Academic Press 1983), which is hereby incorporated by reference as well as by other techniques known to those with skill in the art. The fragments are screened for utility in the same manner as are intact antibodies.

An "isolated antibody", as used herein, is intended to refer to an antibody which is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to PSMA is substantially free of antibodies that specifically bind antigens other than PSMA). An isolated antibody that specifically binds to an epitope, isoform or variant of PSMA may, however, have cross-reactivity to other related antigens, e.g., from other species (e.g., PSMA species homologs). Moreover, an isolated antibody may

be substantially free of other cellular material and/or chemicals. As used herein, "specific binding" refers to antibody binding to a predetermined antigen. Typically, the antibody binds with an affinity that is at least two-fold greater than its affinity for binding to a non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or a closely-related antigen.

The isolated antibodies of the invention encompass various antibody isotypes, such as IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE. As used herein, "isotype" refers to the antibody class (e.g. IgM or IgG1) that is encoded by heavy chain constant region genes. The antibodies can be full length or can include only an antigen-binding fragment such as the antibody constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD or IgE or could consist of a Fab fragment, a F(ab')$_2$ fragment, and a Fv fragment.

The antibodies of the present invention can be polyclonal, monoclonal, or a mixture of polyclonal and monoclonal antibodies. The antibodies can be produced by a variety of techniques well known in the art. Procedures for raising polyclonal antibodies are well known. For example anti-PSMA polyclonal antibodies are raised by administering PSMA protein subcutaneously to New Zealand white rabbits which have first been bled to obtain pre-immune serum. The PSMA can be injected at a total volume of 100 μl per site at six different sites, typically with one or more adjustments. The rabbits are then bled two weeks after the first injection and periodically boosted with the same antigen three times every six weeks. A sample of serum is collected 10 days after each boost. Polyclonal antibodies are recovered from the serum, preferably by affinity chromatography using PSMA to capture the antibody. This and other procedures for raising polyclonal antibodies are disclosed in E. Harlow, et. al., editors, Antibodies: A Laboratory Manual (1988), which is hereby incorporated by reference.

Monoclonal antibody production may be effected by techniques which are also well known in the art. The term "monoclonal antibody," as used herein, refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. The process of monoclonal antibody production involves obtaining immune somatic cells with the potential for producing antibody, in particular B lymphocytes, which have been previously immunized with the antigen of interest either *in vivo* or *in vitro* and that are suitable for fusion with a B-cell myeloma line.

- 30 -

Mammalian lymphocytes typically are immunized by *in vivo* immunization of the animal (e.g., a mouse) with the desired protein or polypeptide, e.g., with PSMA in the present invention. Such immunizations are repeated as necessary at intervals of up to several weeks to obtain a sufficient titer of antibodies. Once immunized, animals can be used as a source of antibody-producing lymphocytes. Following the last antigen boost, the animals are sacrificed and spleen cells removed. Mouse lymphocytes give a higher percentage of stable fusions with the mouse myeloma lines described herein. Of these, the BALB/c mouse is preferred. However, other mouse strains, rabbit, hamster, sheep and frog may also be used as hosts for preparing antibody-producing cells. See; Goding (in Monoclonal Antibodies: Principles and Practice, 2d ed., pp. 60-61, Orlando, Fla., Academic Press, 1986). In particular, mouse strains that have human immunoglobulin genes inserted in the genome (and which cannot produce mouse immunoglobulins) are preferred. Examples include the HuMAb mouse strains produced by Medarex/GenPharm International, and the XenoMouse strains produced by Abgenix. Such mice produce fully human immunoglobulin molecules in response to immunization.

Those antibody-producing cells that are in the dividing plasmablast stage fuse preferentially. Somatic cells may be obtained from the lymph nodes, spleens and peripheral blood of antigen-primed animals, and the lymphatic cells of choice depend to a large extent on their empirical usefulness in the particular fusion system. The antibody-secreting lymphocytes are then fused with (mouse) B cell myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either *in vivo* or *in vitro* to produce large quantities of antibody. A description of the theoretical basis and practical methodology of fusing such cells is set forth in Kohler and Milstein, *Nature* 256:495 (1975), which is hereby incorporated by reference.

Alternatively, human somatic cells capable of producing antibody, specifically B lymphocytes, are suitable for fusion with myeloma cell lines. While B lymphocytes from biopsied spleens, tonsils or lymph nodes of an individual may be used, the more easily accessible peripheral blood B lymphocytes are preferred. The lymphocytes may be derived from patients with diagnosed prostate carcinomas or another PSMA-expressing cancer. In

addition, human B cells may be directly immortalized by the Epstein-Barr virus (Cole et al., 1995, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Although somatic cell hybridization procedures are preferred, in principle, other techniques for producing monoclonal antibodies can be employed such as viral or oncogenic transformation of B lymphocytes.

Myeloma cell lines suited for use in hybridoma-producing fusion procedures preferably are non-antibody-producing, have high fusion efficiency, and enzyme deficiencies that render them incapable of growing in certain selective media which support the growth of the desired hybridomas. Examples of such myeloma cell lines that may be used for the production of fused cell lines include P3-X63/Ag8, X63-Ag8.653, NS1/1.Ag 4.1, Sp2/0-Ag14, FO, NSO/U, MPC-11, MPC11-X45-GTG 1.7, S194/5XX0 Bul, all derived from mice; R210.RCY3, Y3-Ag 1.2.3, IR983F and 4B210 derived from rats and U-266, GM1500-GRG2, LICR-LON-HMy2, UC729-6, all derived from humans (Goding, in Monoclonal Antibodies: Principles and Practice, 2d ed., pp. 65-66, Orlando, Fla., Academic Press, 1986; Campbell, in Monoclonal Antibody Technology, Laboratory Techniques in Biochemistry and Molecular Biology Vol. 13, Burden and Von Knippenberg, eds. pp. 75-83, Amsterdam, Elseview, 1984).

Fusion with mammalian myeloma cells or other fusion partners capable of replicating indefinitely in cell culture is effected by standard and well-known techniques, for example, by using polyethylene glycol ("PEG") or other fusing agents (See Milstein and Kohler, *Eur. J. Immunol.* 6:511 (1976), which is hereby incorporated by reference).

In other embodiments, the antibodies can be recombinant antibodies. The term "recombinant antibody", as used herein, is intended to include antibodies that are prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from an animal (e.g., a mouse) that is transgenic for another species' immunoglobulin genes, antibodies expressed using a recombinant expression vector transfected into a host cell, antibodies isolated from a recombinant, combinatorial antibody library, or antibodies prepared, expressed, created or isolated by any other means that involves splicing of immunoglobulin gene sequences to other DNA sequences.

In yet other embodiments, the antibodies can be chimeric or humanized antibodies. As used herein, the term "chimeric antibody" refers to an antibody, that combines the murine variable or hypervariable regions with the human constant region or constant and variable

- 32 -

framework regions. As used herein, the term "humanized antibody" refers to an antibody that retains only the antigen-binding CDRs from the parent antibody in association with human framework regions (see, Waldmann, 1991, *Science* 252:1657). Such chimeric or humanized antibodies retaining binding specificity of the murine antibody are expected to have reduced

5   immunogenicity when administered *in vivo* for diagnostic, prophylactic or therapeutic applications according to the invention.

According to an alternative embodiment, the monoclonal antibodies of the present invention can be modified to be in the form of a bispecific antibody, or a multispecific antibody. The term "bispecific antibody" is intended to include any agent, e.g., a protein,

10   peptide, or protein or peptide complex, which has two different binding specificities which bind to, or interact with (a) a cell surface antigen and (b) an Fc receptor on the surface of an effector cell. The term "multispecific antibody" is intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has more than two different binding specificities which bind to, or interact with (a) a cell surface antigen, (b) an Fc receptor on the

15   surface of an effector cell, and (c) at least one other component. Accordingly, the invention includes, but is not limited to, bispecific, trispecific, tetraspecific, and other multispecific antibodies which are directed to cell surface antigens, such as PSMA, and to Fc receptors on effector cells. The term "bispecific antibodies" further includes diabodies. Diabodies are bivalent, bispecific antibodies in which the V_H and V_L domains are expressed on a single

20   polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen-binding sites (see e.g., Holliger, P., *et al.* (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448; Poijak, R.J., *et al.* (1994) *Structure* 2:1121-1123).

A bispecific antibody can be formed of an antigen-binding region specific for the

25   extracellular domain of PSMA and an antigen-binding region specific for an effector cell which has tumoricidal or tumor inhibitory activity. The two antigen-binding regions of the bispecific antibody are either chemically linked or can be expressed by a cell genetically engineered to produce the bispecific antibody. (See generally, Fanger et al., 1995 *Drug News & Perspec.* 8(3):133-137). Suitable effector cells having tumoricidal activity include but are

30   not limited to cytotoxic T-cells (primarily $CD8^+$ cells), natural killer cells, etc. An effective amount of a bispecific antibody according to the invention is administered to a prostrate

- 33 -

cancer patient and the bispecific antibody kills and/or inhibits proliferation of the malignant cells after localization at sites of primary or metastatic tumors bearing PSMA.

In certain embodiments, the antibodies are human antibodies. The term "human antibody", as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis *in vitro* or by somatic mutation *in vivo*). However, the term "human antibody", as used herein, is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse have been grafted onto human framework sequences (referred to herein as "humanized antibodies"). Human antibodies directed against PSMA are generated using transgenic mice carrying parts of the human immune system rather than the mouse system.

Fully human monoclonal antibodies also can be prepared by immunizing mice transgenic for large portions of human immunoglobulin heavy and light chain loci. See, e.g., U.S. patents 5,591,669, 5,598,369, 5,545,806, 5,545,807, 6,150,584, and references cited therein, the contents of which are incorporated herein by reference. These animals have been genetically modified such that there is a functional deletion in the production of endogenous (e.g., murine) antibodies. The animals are further modified to contain all or a portion of the human germ-line immunoglobulin gene locus such that immunization of these animals results in the production of fully human antibodies to the antigen of interest. Following immunization of these mice (e.g., XenoMouse (Abgenix), HuMAb mice (Medarex/GenPharm)), monoclonal antibodies are prepared according to standard hybridoma technology. These monoclonal antibodies have human immunoglobulin amino acid sequences and therefore will not provoke human anti-mouse antibody (HAMA) responses when administered to humans.

Preferably, the mice are 6-16 weeks of age upon the first immunization. For example, a purified or enriched preparation of PSMA antigen (e.g., recombinant PSMA or PSMA-expressing cells) is used to immunize the mice intraperitoneally (IP), although other routes of immunization known to one of ordinary skill in the art are also possible. PSMA antigen is injected in combination with an adjuvant, such as complete Freund's adjuvant, and preferably the initial injection is followed by booster immunizations with antigen in an adjuvant, such as

incomplete Freund's adjuvant. The immune response is monitored over the course of the
immunization protocol with plasma samples obtained by, for example, retroorbital bleeds.
The plasma is screened by ELISA (as described below), and mice with sufficient titers of
anti-PSMA human immunoglobulin are used for fusions. Mice are boosted intravenously
5   with antigen 3 days before sacrifice and removal of the spleen.

In particular embodiments, the antibodies are produced by hybridomas referred to
herein as PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-
3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3
(PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-
10   3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-
4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-
4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-
4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-
4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-
15   4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-
4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-
4652), and Abgenix 4.152.1 (PTA-4653). These hybridomas were deposited pursuant to, and
in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of
the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type
20   Culture Collection ("ATCC") as an International Depository Authority and given the Patent
Deposit Designations shown above and in Table 1.

The present invention further provides nucleic acid molecules encoding anti-PSMA
antibodies and vectors comprising the nucleic acid molecules as described herein. The
vectors provided can be used to transform or transfect host cells for producing anti-PSMA
25   antibodies with the specificity of antibodies described herein. In a preferred embodiment the
antibodies produced will have the specificity of the antibodies AB-PG1-XG1-006, AB-PG1-
XG1-026, AB-PG1-XG1-051, AB-PG1, XG1-069, AB-PG1-XG1-077 and PSMA 10.3. In
one embodiment the vectors can comprise an isolated nucleic acid molecule encoding the
heavy chain of the antibodies listed above encoded by a nucleic acid molecules comprising
30   the coding region or regions of the nucleic acid sequences set forth as SEQ ID NO: 2-7. In
another embodiment, the vectors can comprise the nucleic acid sequences encoding the light
chain of the antibodies set forth as SEQ ID NOs: 8-13. In a further embodiment the vectors

- 35 -

of the invention may comprise a heavy chain and a light chain sequence. In a further
embodiment, plasmids are given which produce the antibodies or antigen binding fragments
described herein. Plasmids of the invention include plasmids selected from the group
consisting of: AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2), AB-PG1-XG1-006 Light

5   Chain (SEQ ID NO: 8), AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3), AB-PG1-XG1-
026 Light Chain (SEQ ID NO: 9), AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4), AB-
PG1-XG1-051 Light Chain (SEQ ID NO: 10), AB-PG1-XG1-069 Heavy Chain (SEQ ID
NO: 5), AB-PG1-XG1-069 Light Chain (SEQ ID NO: 11), AB-PG1-XG1-077 Heavy Chain
(SEQ ID NO: 6), AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12), PSMA 10.3 Heavy

10   Chain (SEQ ID NO: 7), and PSMA 10.3 Kappa (SEQ ID NO: 13).

         The isolated antibody or antigen-binding fragment thereof preferably is selected for
its ability to bind live cells expressing PSMA. In order to demonstrate binding of monoclonal
antibodies to live cells expressing the PSMA, flow cytometry can be used. For example, cell
lines expressing PSMA (grown under standard growth conditions) or prostate cancer cells

15   that express PSMA are mixed with various concentrations of monoclonal antibodies in PBS
containing 0.1% Tween 80 and 20% mouse serum, and incubated at 37°C for 1 hour. After
washing, the cells are reacted with fluorescein-labeled anti-human IgG secondary antibody (if
human anti-PSMA antibodies were used) under the same conditions as the primary antibody
staining. The samples can be analyzed by a fluorescence activated cell sorter (FACS)

20   instrument using light and side scatter properties to gate on single cells. An alternative assay
using fluorescence microscopy may be used (in addition to or instead of) the flow cytometry
assay. Cells can be stained exactly as described above and examined by fluorescence
microscopy. This method allows visualization of individual cells, but may have diminished
sensitivity depending on the density of the antigen.

25   Binding of the antibody or antigen-binding fragment thereof to live cells expressing
PSMA can inhibit the growth of the cells or mediate cytolysis of the cells. Cytolysis can be
complement mediated or can be mediated by effector cells. In a preferred embodiment, the
cytolysis is carried out in a living organism, preferably a mammal, and the live cell is a tumor
cell. Examples of tumors which can be targeted by the antibodies of the invention include,

30   any tumor that expresses PSMA, such as, prostate, bladder, pancreas, lung, colon, kidney,
melanomas and sarcomas. In a preferred embodiment the tumor cell is a prostate cancer cell.

- 36 -

The testing of antibody cytolytic activity *in vitro* by chromium release assay can provide an initial screening prior to testing *in vivo* models. This testing can be carried out using standard chromium release assays. Briefly, polymorphonuclear cells (PMN), or other effector cells, from healthy donors can be purified by Ficoll Hypaque density centrifugation,

5   followed by lysis of contaminating erythrocytes. Washed PMNs can be suspended in RPMI supplemented with 10% heat-inactivated fetal calf serum and mixed with ^{51}Cr labeled cells expressing PSMA, at various ratios of effector cells to tumor cells (effector cells:tumor cells). Purified anti-PSMA IgGs can then be added at various concentrations. Irrelevant IgG can be used as negative control. Assays can be carried out for 0-120 minutes at 37°C. Samples can

10 be assayed for cytolysis by measuring ^{51}Cr release into the culture supernatant. Anti-PSMA monoclonal antibodies can also be tested in combinations with each other to determine whether cytolysis is enhanced with multiple monoclonal antibodies.

Antibodies which bind to PSMA also can be tested in an *in vivo* model (e.g., in mice) to determine their efficacy in mediating cytolysis and killing of cells expressing PSMA, e.g.,

15 tumor cells. These antibodies can be selected, for example, based on the following criteria, which are not intended to be exclusive:

1) binding to live cells expressing PSMA;

2) high affinity of binding to PSMA;

3) binding to a unique epitope on PSMA (to eliminate the possibility that

20   antibodies with complimentary activities when used in

combination would compete for binding to the same epitope);

4) opsonization of cells expressing PSMA;

5) mediation of growth inhibition, phagocytosis and/or killing of cells

expressing PSMA in the presence of effector cells;

25 6) modulation (inhibition or enhancement) of NAALADase, folate

hydrolase, dipeptidyl peptidase IV and/or γ-glutamyl hydrolase

activities;

7) growth inhibition, cell cycle arrest and/or cytotoxicity in the absence of

effector cells;

30 8) internalization of PSMA;

9) binding to a conformational epitope on PSMA;

10) minimal cross-reactivity with cells or tissues that do not express

PSMA; and

11) preferential binding to dimeric forms of PSMA rather than monomeric

forms of PSMA.

Preferred antibodies of the invention meet one or more, and preferably all, of these criteria. In a particular embodiment, the antibodies are used in combination, e.g., as a pharmaceutical composition comprising two or more different anti-PSMA antibodies or binding fragments thereof. For example, anti-PSMA antibodies having different, but complementary activities can be combined in a single therapy to achieve a desired therapeutic or diagnostic effect. An illustration of this would be a composition containing an anti-PSMA antibody that mediates highly effective killing of target cells in the presence of effector cells, combined with another anti-PSMA antibody that inhibits the growth of cells expressing PSMA.

In a preferred aspect of the invention, the antibody or antigen-binding fragment thereof binds to a conformational epitope within the extracellular domain of the PSMA molecule. To determine if the selected human anti-PSMA antibodies bind to conformational epitopes, each antibody can be tested in assays using native protein (e.g., non-denaturing immunoprecipitation, flow cytometric analysis of cell surface binding) and denatured protein (e.g., Western blot, immunoprecipitation of denatured proteins). A comparison of the results will indicate whether the antibodies bind conformational epitopes. Antibodies that bind to native protein but not denatured protein are those antibodies that bind conformational epitopes, and are preferred antibodies.

To determine if the selected human anti-PSMA antibodies bind preferentially (i.e., selectively and/or specifically) to a PSMA dimer, each antibody can be tested in assays (e.g., immunoprecipitation followed by Western blotting) using native dimeric PSMA protein and dissociated monomeric PSMA protein. A comparison of the results will indicate whether the antibodies bind preferentially to the dimer or to the monomer. Antibodies that bind to the PSMA dimer but not to the monomeric PSMA protein are preferred antibodies.

Preferred antibodies include antibodies that competitively inhibit the specific binding of a second antibody to its target epitope on PSMA. To determine competitive inhibition, a variety of assays known to one of ordinary skill in the art can be employed. For example, the cross-competition assays set forth in Examples 4 and 21 can be used to determine if an

antibody competitively inhibits binding to PSMA by another antibody. These examples
provide cell-based methods employing flow cytometry or solid phase binding analysis. Other
assays that evaluate the ability of antibodies to cross-compete for PSMA molecules that are
not expressed on the surface of cells, in solid phase or in solution phase, also can be used.

5   These assays preferably use the PSMA multimers described herein.

Certain preferred antibodies competitively inhibit the specific binding of a second
antibody to its target epitope on PSMA by at least about 10%, 20%, 30%, 40%, 50%, 60%,
70%, 80%, 90%, 95%, or 99%. Inhibition can be assessed at various molar ratios or mass
ratios; for example competitive binding experiments can be conducted with a 2-fold, 3-fold,

10   4-fold, 5-fold, 7-fold, 10-fold or more molar excess of the first antibody over the second
antibody.

Other preferred antibodies include antibodies that specifically (i.e., selectively) bind
to an epitope on PSMA defined by a second antibody. To determine the epitope, one can use
standard epitope mapping methods known in the art. For example, fragments (peptides) of

15   PSMA antigen (preferably synthetic peptides) that bind the second antibody can be used to
determine whether a candidate antibody binds the same epitope. For linear epitopes,
overlapping peptides of a defined length (e.g., 8 or more amino acids) are synthesized. The
peptides preferably are offset by 1 amino acid, such that a series of peptides covering every 8
amino acid fragment of the PSMA protein sequence are prepared. Fewer peptides can be

20   prepared by using larger offsets, e.g., 2 or 3 amino acids. In addition, longer peptides (e.g.,
9-, 10- or 11-mers) can be synthesized. Binding of peptides to antibodies can be determined
using standard methodologies including surface plasmon resonance (BIACORE; see Example
22) and ELISA assays. For examination of conformational epitopes, larger PSMA fragments
can be used. Other methods that use mass spectrometry to define conformational epitopes

25   have been described and can be used (see, e.g., Baerga-Ortiz et al., *Protein Science* 11:1300-
1308, 2002 and references cited therein). Still other methods for epitope determination are
provided in standard laboratory reference works, such as Unit 6.8 ("Phage Display Selection
and Analysis of B-cell Epitopes") and Unit 9.8 ("Identification of Antigenic Determinants
Using Synthetic Peptide Combinatorial Libraries") of *Current Protocols in Immunology*,

30   Coligan et al., eds., John Wiley & Sons. Epitopes can be confirmed by introducing point
mutations or deletions into a known epitope, and then testing binding with one or more
antibodies to determine which mutations reduce binding of the antibodies.

In one embodiment of the invention the antibody or antigen-binding fragment thereof binds to and is internalized with PSMA expressed on cells. The mechanism by which the antibody or antigen-binding fragment thereof is internalized with the prostate specific membrane antigen is not critical to the practice of the present invention. For example, the

5   antibody or antigen-binding fragment thereof can induce internalization of PSMA. Alternatively, internalization of the antibody or antigen-binding fragment thereof can be the result of routine internalization of PSMA. The antibody or antigen-binding fragment thereof can be used in an unmodified form, alone or in combination with other compositions. Alternatively, the antibody or antigen-binding fragment thereof can be bound to a substance

10   effective to kill the cells upon binding of the antibody or antigen-binding fragment thereof to prostate specific membrane antigen and upon internalization of the biological agent with the prostate specific membrane antigen.

The human PSMA antibodies of the present invention specifically bind cell-surface PSMA and/or rsPSMA with sub-nanomolar affinity. The human PSMA antibodies of the

15   present invention have binding affinities of about 1×10^{-9}M or less, preferably about 1×10^{-10}M or less, more preferably 1×10^{-11}M or less. In a particular embodiment the binding affinity is less than about 5×10^{-10}M.

An antibody can be linked to a detectable marker, an antitumor agent or an immunomodulator. Antitumor agents can include cytotoxic agents and agents that act on

20   tumor neovasculature. Detectable markers include, for example, radioactive or fluorescent markers. Cytotoxic agents include cytotoxic radionuclides, chemical toxins and protein toxins.

The cytotoxic radionuclide or radiotherapeutic isotope preferably is an alpha-emitting isotope such as ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{212}Pb, ^{224}Ra or ^{223}Ra. Alternatively, the cytotoxic

25   radionuclide may a beta-emitting isotope such as ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{64}Cu, ^{153}Sm or ^{166}Ho. Further, the cytotoxic radionuclide may emit Auger and low energy electrons and include the isotopes ^{125}I, ^{123}I or ^{77}Br.

Suitable chemical toxins or chemotherapeutic agents include members of the enediyne family of molecules, such as calicheamicin and esperamicin. Chemical toxins can also be

30   taken from the group consisting of methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin and 5-fluorouracil. Other antineoplastic agents that may be conjugated to the anti-PSMA antibodies of the

present invention include dolastatins (U.S. Patent Nos. 6,034,065 and 6,239,104) and derivatives thereof. Of particular interest is dolastatin 10 (dolavaline-valine-dolaisoleuine-dolaproine-dolaphenine) and the derivatives auristatin PHE (dolavaline-valine-dolaisoleuine-dolaproine-phenylalanine-methyl ester) (Pettit, G.R. et al., *Anticancer Drug Des.* 13(4):243-277, 1998; Woyke, T. et al., *Antimicrob. Agents Chemother.* 45(12):3580-3584, 2001), and aurastatin E and the like. Toxins that are less preferred in the compositions and methods of the invention include poisonous lectins, plant toxins such as ricin, abrin, modeccin, botulina and diphtheria toxins. Of course, combinations of the various toxins could also be coupled to one antibody molecule thereby accommodating variable cytotoxicity. Other chemotherapeutic agents are known to those skilled in the art.

Toxin-conjugated forms of the PSMA antibodies of the present invention mediate specific cell killing of PSMA-expressing cells at picomolar concentrations. The toxin-conjugated PSMA antibodies of the present invention exhibit IC_{50}s at concentrations of less than about 1×10^{-10}M, preferably less than about 1×10^{-11}M, more preferably less than about 1×10^{-12}M. In a particular embodiment an IC_{50} is achieved at a concetration of less than about 1.5×10^{-11}M.

Agents that act on the tumor vasculature can include tubulin-binding agents such as combrestatin A4 (Griggs et al., *Lancet Oncol.* 2:82, 2001), angiostatin and endostatin (reviewed in Rosen, *Oncologist* 5:20, 2000, incorporated by reference herein) and interferon inducible protein 10 (U.S. Patent No. 5,994,292). A number of antiangiogenic agents currently in clinical trials are also contemplated. Agents currently in clinical trials include: 2ME2, Angiostatin, Angiozyme, Anti-VEGF RhuMAb, Apra (CT-2584), Avicine, Benefin, BMS275291, Carboxyamidotriazole, CC4047, CC5013, CC7085, CDC801, CGP-41251 (PKC 412), CM101, Combretastatin A-4 Prodrug, EMD 121974, Endostatin, Flavopiridol, Genistein (GCP), Green Tea Extract, IM-862, ImmTher, Interferon alpha, Interleukin-12, Iressa (ZD1839), Marimastat, Metastat (Col-3), Neovastat , Octreotide, Paclitaxel, Penicillamine, Photofrin, Photopoint, PI-88, Prinomastat (AG-3340), PTK787 (ZK22584), RO317453, Solimastat, Squalamine, SU 101, SU 5416, SU-6668, Suradista (FCE 26644), Suramin (Metaret), Tetrathiomolybdate, Thalidomide, TNP-470 and Vitaxin. additional antiangiogenic agents are described by Kerbel, J. Clin. Oncol. 19(18s):45s-51s, 2001, which is incorporated by reference herein. Immunomodulators suitable for conjugation to anti-PSMA antibodies include α-interferon, γ-interferon, and tumor necrosis factor alpha (TNFα).

The coupling of one or more toxin molecules to the anti-PSMA antibody is envisioned to include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding, and complexation. The toxic compounds used to prepare the anti-PSMA immunotoxins are attached to the antibodies or PSMA-binding

5   fragments thereof by standard protocols known in the art.

The covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent agents are useful in coupling protein molecules to other proteins, peptides or amine functions, etc. For example, the literature is replete with coupling agents such as carbodiimides,

10   diisocyanates, glutaraldehyde, diazobenzenes, and hexamethylene diamines. This list is not intended to be exhaustive of the various coupling agents known in the art but, rather, is exemplary of the more common coupling agents.

In preferred embodiments, it is contemplated that one may wish to first derivatize the antibody, and then attach the toxin component to the derivatized product. Suitable cross-

15   linking agents for use in this manner include, for example, SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), and SMPT, 4-succinimidyl-oxycarbonyl-methyl-(2-pyridyldithio)toluene.

In addition, protein toxins can be fused to the anti-PSMA antibody or PSMA binding fragment by genetic methods to form a hybrid immunotoxin fusion protein. To make a fusion

20   immunotoxin protein in accordance with the invention, a nucleic acid molecule is generated that encodes an anti-PSMA antibody, a fragment of an anti-PSMA antibody, a single chain anti-PSMA antibody, or a subunit of an anti-PSMA antibody linked to a protein toxin. Such fusion proteins contain at least a targeting agent (e.g., anti-PSMA antibody subunit) and a toxin of the invention, operatively attached. The fusion proteins may also include additional

25   peptide sequences, such as peptide spacers which operatively attach the targeting agent and toxin compound, as long as such additional sequences do not appreciably affect the targeting or toxin activities of the fusion protein. The two proteins can be attached by a peptide linker or spacer, such as a glycine-serine spacer peptide, or a peptide hinge, as is well known in the art. Thus, for example, the C-terminus of an anti-PSMA antibody or fragment thereof can be

30   fused to the N-terminus of the protein toxin molecule to form an immunotoxin that retains the binding properties of the anti-PSMA antibody. Other fusion arrangements will be known to one of ordinary skill in the art.

To express the fusion immunotoxin, the nucleic acid encoding the fusion protein is inserted into an expression vector in accordance with standard methods, for stable expression of the fusion protein, preferably in mammalian cells, such as CHO cells. The fusion protein can be isolated and purified from the cells or culture supernatant using standard methodology, such as a PSMA affinity column.

Radionuclides typically are coupled to an antibody by chelation. For example, in the case of metallic radionuclides, a bifunctional chelator is commonly used to link the isotope to the antibody or other protein of interest. Typically, the chelator is first attached to the antibody, and the chelator-antibody conjugate is contacted with the metallic radioisotope. A number of bifunctional chelators have been developed for this purpose, including the diethylenetriamine pentaacetic acid (DTPA) series of amino acids described in U.S. patents 5,124,471, 5,286,850 and 5,434,287, which are incorporated herein by reference. As another example, hydroxamic acid-based bifunctional chelating agents are described in U.S. patent 5,756,825, the contents of which are incorporated herein. Another example is the chelating agent termed p-SCN-Bz-HEHA (1,4,7,10,13,16-hexaazacyclo-octadecane-N,N',N'',N''',N'''',N'''''-hexaacetic acid) (Deal et al., *J. Med. Chem.* 42:2988, 1999), which is an effective chelator of radiometals such as ^{225}Ac. Yet another example is DOTA (1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid), which is a bifunctional chelating agent (see McDevitt et al., Science 294:1537-1540, 2001) that can be used in a two-step method for labeling followed by conjugation.

In another aspect, the invention provides compositions comprising an isolated antibody, an antibody derivatized or linked to other functional moieties, or an antigen-binding fragment thereof or a combination of one or more of the aforementioned antibodies or antigen-binding fragments thereof. The compositions include a physiologically or pharmaceutically acceptable carrier, excipient, or stabilizer mixed with the isolated antibody or antigen-binding fragment thereof. In a preferred embodiment, the compositions include a combination of multiple (e.g., two or more) isolated antibodies or antigen-binding portions thereof of the invention. Preferably, each of the antibodies or antigen-binding portions thereof of the composition binds to a distinct conformational epitope of PSMA. In one embodiment, anti-PSMA antibodies having complementary activities are used in combination, e.g., as a pharmaceutical composition, comprising two or more anti-PSMA antibodies. For example, an antibody that mediates highly effective cytolysis of target cells

- 43 -

in the presence of effector cells can be combined with another antibody that inhibits the growth of cells expressing PSMA. As used herein, "target cell" shall mean any undesirable cell in a subject (e.g., a human or animal) that can be targeted by a composition of the invention. In preferred embodiments, the target cell is a cell expressing or overexpressing

5 PSMA. Cells expressing PSMA typically include tumor cells, such as prostate, bladder, pancreas, lung, kidney, colon tumor cells, melanomas, and sarcomas.

Pharmaceutical compositions of the invention also can be administered in combination therapy, i.e., combined with other agents. For example, the combination therapy can include a composition of the present invention with at least one anti-tumor agent,

10 immunomodulator, immunostimulatory agent, or other conventional therapy. The agent may be bound or conjugated to or formed as a recombinant fusion molecule with the PSMA antibodies of the present invention for directed targeting of the agent to PSMA-expressing cells.

The PSMA antibodies of the present invention may be used as a targeting moiety for

15 delivery of replication-selective virus to PSMA-expressing cells for tumor therapy. Replication-competent virus such as the p53 pathway targeting adenovirus mutant dl1520, ONYX-015, kill tumor cells selectively (Biederer, C. et al., J. Mol. Med. 80(3):163-175, 2002).

As used herein, "pharmaceutically acceptable carrier" or "physiologically acceptable

20 carrier" includes any and all salts, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. Preferably, the carrier is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., antibody may be coated

25 in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

When administered, the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with

30 the effectiveness of the biological activity of the active ingredients. Such preparations may routinely contain salts, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents, such as supplementary immune potentiating agents including

adjuvants, chemokines and cytokines. When used in medicine, the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.

5   A salt retains the desired biological activity of the parent compound and does not impart any undesired toxicological effects (see e.g., Berge, S.M., et al. (1977) *J. Pharm. Sci.* 66: 1-19). Examples of such salts include acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous and the like, as well as

10   from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids and the like. Base addition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium and the like, as well as from nontoxic organic amines, such as N,N'-dibenzylethylenediamine, N-methylglucamine,

15   chloroprocaine, choline, diethanolamine, ethylenediamine, procaine and the like.

      An anti-PSMA antibody composition may be combined, if desired, with a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances which are suitable for administration into a human. The term "carrier" denotes an

20   organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.

25   The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt.

      The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.

      The pharmaceutical compositions may conveniently be presented in unit dosage form

30   and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier which constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly

- 45 -

and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.

Compositions suitable for parenteral administration conveniently comprise a sterile aqueous or non-aqueous preparation of anti-PSMA antibodies, which is preferably isotonic

5   with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's

10   solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono-or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulations suitable for oral, subcutaneous, intravenous, intramuscular, etc. administration can be found in

15   *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA.

The active compounds can be prepared with carriers that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid,

20   collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., *Sustained and Controlled Release Drug Delivery Systems*, J.R. Robinson, ed., Marcel Dekker, Inc., New York, 1978.

The therapeutics of the invention can be administered by any conventional route,

25   including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, intratumor, or transdermal. When antibodies are used therapeutically, preferred routes of administration include intravenous and by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems

30   should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp. 1694-1712;

- 46 -

incorporated by reference). Those of skill in the art can readily determine the various
parameters and conditions for producing antibody aerosols without resorting to undue
experimentation.

The compositions of the invention are administered in effective amounts. An
5   "effective amount" is that amount of an anti-PSMA antibody composition that alone, or
together with further doses, produces the desired response, e.g. treats a malignancy in a
subject. This may involve only slowing the progression of the disease temporarily, although
more preferably, it involves halting the progression of the disease permanently. This can be
monitored by routine methods. The desired response to treatment of the disease or condition
10   also can be delaying the onset or even preventing the onset of the disease or condition.

Such amounts will depend, of course, on the particular condition being treated, the
severity of the condition, the individual patient parameters including age, physical condition,
size and weight, the duration of the treatment, the nature of concurrent therapy (if any), the
specific route of administration and like factors within the knowledge and expertise of the
15   health practitioner. These factors are well known to those of ordinary skill in the art and can
be addressed with no more than routine experimentation. It is generally preferred that a
maximum dose of the individual components or combinations thereof be used, that is, the
highest safe dose according to sound medical judgment. It will be understood by those of
ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose
20   for medical reasons, psychological reasons or for virtually any other reasons.

The pharmaceutical compositions used in the foregoing methods preferably are sterile
and contain an effective amount of anti-PSMA antibodies for producing the desired response
in a unit of weight or volume suitable for administration to a patient. The response can, for
example, be measured by determining the physiological effects of the anti-PSMA antibody
25   composition, such as regression of a tumor or decrease of disease symptoms. Other assays
will be known to one of ordinary skill in the art and can be employed for measuring the level
of the response.

The doses of anti-PSMA antibodies administered to a subject can be chosen in
accordance with different parameters, in particular in accordance with the mode of
30   administration used and the state of the subject. Other factors include the desired period of
treatment. In the event that a response in a subject is insufficient at the initial doses applied,

- 47 -

higher doses (or effectively higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits.

In general, doses can range from about 10 µg/kg to about 100,000 µg/kg. Based upon the composition, the dose can be delivered continuously, such as by continuous pump, or at periodic intervals. Desired time intervals of multiple doses of a particular composition can be determined without undue experimentation by one skilled in the art. Other protocols for the administration of anti-PSMA antibody compositions will be known to one of ordinary skill in the art, in which the dose amount, schedule of administration, sites of administration, mode of administration and the like vary from the foregoing.

In general, doses of radionuclide delivered by the anti-PSMA antibodies of the invention can range from about 0.01 mCi/Kg to about 10 mCi/kg. Preferably the dose of radionuclide ranges from about 0.1 mCi/Kg to about 1.0 mCi/kg. The optimal dose of a given isotope can be determined empirically by simple routine titration experiments well known to one of ordinary skill in the art.

Administration of anti-PSMA antibody compositions to mammals other than humans, e.g. for testing purposes or veterinary therapeutic purposes, is carried out under substantially the same conditions as described above.

The compositions (antibodies to PSMA and derivatives/conjugates thereof) of the present invention have *in vitro* and *in vivo* diagnostic and therapeutic utilities. For example, these molecules can be administered to cells in culture, e.g. *in vitro* or *ex vivo*, or in a subject, e.g., *in vivo*, to treat, prevent or diagnose a variety of disorders. As used herein, the term "subject" is intended to include humans and non-human animals. Preferred subjects include a human patient having a disorder characterized by expression, typically aberrant expression (e.g., overexpression) of PSMA.

One aspect of the present invention relates to a method of detecting cancerous cells or portions thereof in a biological sample (e.g., histological or cytological specimens, biopsies and the like), and, in particular, to distinguish malignant tumors from normal tissues and non-malignant tumors. This method involves providing an antibody or an antigen-binding binding fragment thereof, probe, or ligand, which binds to an extracellular domain of PSMA of such cells, e.g., an anti-PSMA antibody. The anti-PSMA antibody is bound to a label that permits the detection of the cells or portions thereof (e.g., PSMA or fragments thereof liberated from such cancerous cells) upon binding of the anti-PSMA antibody to the cells or

- 48 -

portions thereof. The biological sample is contacted with the labeled anti-PSMA antibody under conditions effective to permit binding of the anti-PSMA antibody to the extracellular domain of PSMA of any of the cells or portions thereof in the biological sample. The presence of any cells or portions thereof in the biological sample is detected by detection of

5   the label. In one preferred form, the contact between the anti-PSMA antibody and the biological sample is carried out in a living mammal and involves administering the anti-PSMA antibody to the mammal under conditions that permit binding of the anti-PSMA antibody to PSMA of any of the cells or portions thereof in the biological sample. Again, such administration can be carried out by any suitable method known to one of ordinary skill

10   in the art.

In addition, the anti-PSMA antibodies of the present invention can be used in immunofluorescence techniques to examine human tissue, cell and bodily fluid specimens. In a typical protocol, slides containing cryostat sections of frozen, unfixed tissue biopsy samples or cytological smears are air dried, formalin or acetone fixed, and incubated with the

15   monoclonal antibody preparation in a humidified chamber at room temperature. The slides are then washed and further incubated with a preparation of a secondary antibody directed against the monoclonal antibody, usually some type of anti-mouse immunoglobulin if the monoclonal antibodies used are derived from the fusion of a mouse spleen lymphocyte and a mouse myeloma cell line. This secondary antibody is tagged with a compound, for instance

20   rhodamine or fluorescein isothiocyanate, that fluoresces at a particular wavelength. The staining pattern and intensities within the sample are then determined by fluorescent light microscopy and optionally photographically recorded.

As yet another alternative, computer enhanced fluorescence image analysis or flow cytometry can be used to examine tissue specimens or exfoliated cells, i.e., single cell

25   preparations from aspiration biopsies of tumors using the anti-PSMA antibodies of this invention. The anti-PSMA antibodies of the invention are particularly useful in quantitation of live tumor cells, i.e., single cell preparations from aspiration biopsies of prostate tumors by computer enhanced fluorescence image analyzer or with a flow cytometer. The antibodies of the invention are particularly useful in such assays to differentiate benign from malignant

30   prostate tumors since the PSMA protein to which the anti-PSMA antibodies bind is expressed in increased amounts by malignant tumors as compared to benign prostate tumors. The percent PSMA positive cell population, alone or in conjunction with determination of other

attributes of the cells (e.g., DNA ploidy of these cells), may, additionally, provide very useful prognostic information by providing an early indicator of disease progression.

In yet another alternative embodiment, the antibodies of the present invention can be used in combination with other known antibodies to provide additional information regarding the malignant phenotype of a cancer.

The method of the present invention can be used to screen patients for diseases associated with the presence of cancerous cells or portions thereof. Alternatively, it can be used to identify the recurrence of such diseases, particularly when the disease is localized in a particular biological material of the patient. For example, recurrence of prostatic disease in the prostatic fossa may be encountered following radical prostatectomy. Using the method of the present invention, this recurrence can be detected by administering a short range radiolabeled antibody to the mammal and then detecting the label rectally, such as with a transrectal detector probe.

Alternatively, the contacting step can be carried out in a sample of serum or urine or other body fluids, including but not limited to seminal fluid, prostatic fluid, ejaculate, and the like, such as to detect the presence of PSMA in the body fluid. When the contacting is carried out in a serum or urine sample, it is preferred that the biological agent recognize substantially no antigens circulating in the blood other than PSMA. Since intact cells do not excrete or secrete PSMA into the extracellular environment, detecting PSMA in serum, urine, or other body fluids generally indicates that cells are being lysed or shed. Thus, the biological agents and methods of the present invention can be used to determine the effectiveness of a cancer treatment protocol by monitoring the level of PSMA in serum, urine or other body fluids.

In a particularly preferred embodiment of the method of detecting cancerous cells in accordance with the present invention, the anti-PSMA antibodies or an antigen-binding fragment thereof, binds to and is internalized with the prostate specific membrane antigen of such cells. Again, the biological agent is bound to a label effective to permit detection of the cells or portions thereof upon binding of the biological agent to and internalization of the biological agent with the prostate specific membrane antigen.

Biological agents suitable for detecting cancerous cells include anti-PSMA antibodies, such as monoclonal or polyclonal antibodies. In addition, antibody fragments, half-antibodies, hybrid derivatives, probes, and other molecular constructs may be utilized. These

biological agents, such as antibodies, antigen-binding fragments thereof, probes, or ligands, bind to extracellular domains of prostate specific membrane antigens or portions thereof in cancerous cells. As a result, the biological agents bind not only to cells which are fixed or cells whose intracellular antigenic domains are otherwise exposed to the extracellular

5   environment. Consequently, binding of the biological agents is concentrated in areas where there are prostate cells, irrespective of whether these cells are fixed or unfixed, viable or necrotic. Additionally or alternatively, these biological agents bind to and are internalized with prostate specific membrane antigens or portions thereof in normal, benign hyperplastic, and to a greater degree in cancerous cells.

10   The antibodies or antigen-binding fragments thereof can also be utilized in *in vivo* therapy of cancer. The antibodies can be used alone or covalently attached, either directly or via linker, to a compound which kills and/or inhibits proliferation of the malignant cells or tissues following administration and localization of the conjugates. When the antibody is used by itself, it may mediate tumor destruction by complement fixation or antibody-

15   dependent cellular cytotoxicity. Alternatively, the antibody may be administered in combination with a chemotherapeutic drug to result in synergistic therapeutic effects (Baslya and Mendelsohn, 1994 *Breast Cancer Res. and Treatment* 29:127-138). A variety of different types of substances can be directly conjugated to the antibody for therapeutic uses, including radioactive metal and non-metal isotopes, chemotherapeutic drugs, toxins, etc. as

20   described above and known in the art (see, e.g., Vitetta and Uhr, 1985, *Annu. Rev. Immunol.* 3:197).

         The antibodies or antigen-binding fragments thereof of the invention can also be administered together with complement. Accordingly, within the scope of the invention are compositions comprising antibodies or antigen-binding fragments thereof and serum or

25   complement. These compositions are advantageous in that the complement is located in close proximity to the human antibodies or antigen-binding fragments thereof. Alternatively, the antibodies or antigen-binding fragments thereof of the invention and the complement or serum can be administered separately.

         The antibodies can be administered with one or more immunostimulatory agents to

30   induce or enhance an immune response, such as IL-2 and immunostimulatory oligonucleotides (e.g., those containing CpG motifs). Preferred immunostimulatory agents

stimulate specific arms of the immune system, such as natural killer (NK) cells that mediate antibody-dependent cell cytotoxicity (ADCC).

Antigens, such as the PSMA dimers described herein, can be administered with one or more adjuvants to induce or enhance an immune response. An adjuvant is a substance which potentiates the immune response. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham); saponins including QS21 (SmithKline Beecham); immunostimulatory oligonucleotides (e.g., CpG oligonucleotides described by Kreig et al., *Nature* 374:546-9, 1995);incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; vitamin E and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol, Quil A, Ribi Detox, CRL-1005, L-121, and combinations thereof.

Other agents which stimulate the immune response of the subject to PSMA multimer antigens can also be administered to the subject. For example, cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-2 (IL-2); IL-4; IL-5; IL-12, which has been shown to enhance the protective effects of vaccines (*see, e.g., Science* 268: 1432-1434, 1995); GM-CSF; IL-15; IL-18; combinations thereof, and the like. Thus cytokines can be administered in conjunction with antibodies, antigens, chemokines and/or adjuvants to increase an immune response.

Chemokines useful in increasing immune responses include but are not limited to SLC, ELC, MIP3α, MIP3β, IP-10, MIG, and combinations thereof.

The antibodies or antigen-binding fragments thereof of the present invention can be used in conjunction with other therapeutic treatment modalities. Such other treatments include surgery, radiation, cryosurgery, thermotherapy, hormone treatment, chemotherapy, vaccines, and other immunotherapies.

Also encompassed by the present invention is a method which involves using the antibodies or antigen-binding fragments thereof for prophylaxis. For example, these materials can be used to prevent or delay development or progression of cancer.

Use of the cancer therapy of the present invention has a number of benefits. Since the anti-PSMA antibodies or antigen-binding fragments thereof according to the present invention preferentially target prostate cancer cells, other tissue is spared. As a result, treatment with such biological agents is safer, particularly for elderly patients. Treatment

according to the present invention is expected to be particularly effective, because it directs high levels of anti-PSMA antibodies or antigen-binding fragments thereof to the bone marrow and lymph nodes where prostate cancer metastases predominate. Moreover, tumor sites for prostate cancer tend to be small in size and, therefore, easily destroyed by cytotoxic

5   agents. Treatment in accordance with the present invention can be effectively monitored with clinical parameters such as serum prostate specific antigen and/or pathological features of a patient's cancer, including stage, Gleason score, extracapsular, seminal, vesicle or perineural invasion, positive margins, involved lymph nodes, etc. Alternatively, these parameters can be used to indicate when such treatment should be employed.

10   Because the antibodies or antigen-binding fragments thereof of the present invention bind to living cells, therapeutic methods using these biological agents are much more effective than those which target lysed cells. For the same reasons, diagnostic and imaging methods which determine the location of living normal, benign hyperplastic, or cancerous cells are much improved by employing the antibodies or antigen-binding fragments thereof of

15   the present invention. In addition, the ability to differentiate between living and dead cells can be advantageous, especially to monitor the effectiveness of a particular treatment regimen.

Also within the scope of the invention are kits comprising the compositions of the invention and instructions for use. The kits can further contain at least one additional

20   reagent, such as complement, or one or more additional antibodies of the invention (e.g., an antibody having a complementary activity which binds to an epitope in PSMA antigen distinct from the first antibody). Other kits can include the PSMA multimers described hereinbelow.

Kits containing the antibodies or antigen-binding fragments thereof of the invention

25   can be prepared for *in vitro* diagnosis, prognosis and/or monitoring cancer by the immunohistological, immunocytological and immunoserological methods described above. The components of the kits can be packaged either in aqueous medium or in lyophilized form. When the antibodies or antigen-binding fragments thereof are used in the kits in the form of conjugates in which a label moiety is attached, such as an enzyme or a radioactive

30   metal ion, the components of such conjugates can be supplied either in fully conjugated form, in the form of intermediates or as separate moieties to be conjugated by the user or the kit.

- 53 -

A kit may comprise a carrier being compartmentalized to receive in close confinement therein one or more container means or series of container means such as test tubes, vials, flasks, bottles, syringes, or the like. A first of said container means or series of container means may contain one or more anti-PSMA antibodies or antigen-binding fragments thereof

5   or PSMA. A second container means or series of container means may contain a label or linker-label intermediate capable of binding to the primary anti-PSMA antibodies (or fragment thereof).

Kits for use in *in vivo* tumor localization and therapy method containing the anti-PSMA antibodies or antigen-binding fragments thereof conjugated to other compounds or

10   substances can be prepared. The components of the kits can be packaged either in aqueous medium or in lyophilized form. When the antibodies or antigen-binding fragments thereof are used in the kits in the form of conjugates in which a label or a therapeutic moiety is attached, such as a radioactive metal ion or a therapeutic drug moiety, the components of such conjugates can be supplied either in fully conjugated form, in the form of intermediates

15   or as separate moieties to be conjugated by the user of the kit.

In one aspect of the invention, a method for modulating at least one enzymatic activity of PSMA, the activity selected from the group consisting of N-acetylated α-linked acidic dipeptidase (NAALADase), folate hydrolase, dipeptidyl dipeptidase IV and γ-glutamyl hydrolase activity or combination thereof *in vitro* or *in vivo*. The modulation may be

20   enhancement or inhibition of at least one enzymatic activity of PSMA.

In a preferred embodiment, the invention provides methods for inhibiting at least one enzymatic activity of PSMA, the activity selected from the group consisting of N-acetylated α-linked acidic dipeptidase (NAALADase), folate hydrolase, dipeptidyl dipeptidase IV and γ-glutamyl hydrolase activity or combination thereof *in vitro* or *in vivo*. The method

25   comprises contacting a NAALADase, a folate hydrolase, a dipeptidyl dipeptidase IV and/or a γ-glutamyl hydrolase with an amount of an isolated antibody or antigen-binding fragment thereof of the invention under conditions wherein the isolated monoclonal antibody or antigen-binding fragment thereof inhibits NAALADase, folate hydrolase, dipeptidyl dipeptidase IV or γ-glutamyl hydrolase activity.

30   Tissue levels of NAALADase can be determined by detergent solubilizing homogenizing tissues, pelleting the insoluble material by centrifugation and measuring the NAALADase activity in the remaining supernatant. Likewise, the NAALADase activity in

- 54 -

bodily fluids can also be measured by first pelleting the cellular material by centrifugation and performing a typical enzyme assay for NAALADase activity on the supernatant. NAALADase enzyme assays have been described by Frieden, 1959, *J. Biol, Chem.*, 234:2891. In this assay, the reaction product of the NAALADase enzyme is glutamic acid.

5   This is derived from the enzyme catalyzed cleavage of N-acetylaspartylglutamate to yield N-acetylaspartic acid and glutamic acid. Glutamic acid, in a $NAD(P)^+$ requiring step, yields 2-oxoglutarate plus NAD(P)H in a reaction catalyzed by glutamate dehydrogenase. Progress of the reaction can easily and conveniently be measured by the change in absorbance at 340 nm due to the conversion of $NAD(P)^+$ to NAD(P)H.

10   Folate hydrolase activity of PSMA can be measured by performing enzyme assays as described by Heston and others (e.g., *Clin. Cancer Res.* 2(9):1445-51, 1996; *Urology* 49(3A Suppl):104-12,1997). Folate hydrolases such as PSMA remove the gamma-linked glutamates from polyglutamated folates. Folate hydrolase activity can be measured using substrates such as methotrexate tri-gamma glutamate (MTXGlu3), methotrexate di-gamma glutamate

15   (MTXGlu2) and pteroylpentaglutamate (PteGlu5), for example using capillary electrophoresis (see *Clin. Cancer Res.* 2(9):1445-51, 1996). Timed incubations of PSMA with polyglutamated substrates is followed by separation and detection of hydrolysis products.

       The invention also includes isolated antibodies and binding fragments thereof that

20   selectively bind PSMA multimers. As used herein, particularly with respect to the binding of PSMA multimers by the anti-PSMA antibodies and binding fragments, "selectively binds" means that an antibody preferentially binds to a PSMA protein multimer (e.g., with greater avidity, greater binding affinity) rather than to a PSMA protein monomer. In preferred embodiments, the antibodies of the invention bind to a PSMA protein multimer with an

25   avidity and/or binding affinity that is 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 3-fold, 4-fold, 5-fold, 7-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 70-fold, 100-fold, 200-fold, 300-fold, 500-fold, 1000-fold or more than that exhibited by the antibody for a PSMA protein monomer. Preferably, the antibody selectively binds a PSMA protein multimer, and not a PSMA protein monomer, i.e., substantially

30   exclusively binds to a PSMA protein multimer. Most preferably, the antibody selectively binds a PSMA protein dimer.

- 55 -

The isolated antibody or binding fragment that selectively binds a PSMA protein multimer can, in some embodiments, modulate enzymatic activity of the PSMA protein multimer. In one such embodiment, the antibody inhibits at least one enzymatic activity such as NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity,

5   γ-glutamyl hydrolase activity, or combinations thereof. In another embodiment, the antibody enhances at least one enzymatic activity such as NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity, or combinations thereof.

A PSMA protein multimer, as used herein, is a protein complex of at least two PSMA

10 proteins or fragments thereof. The PSMA protein multimers can be composed of various combinations of full-length PSMA proteins (e.g., SEQ ID NO:1), recombinant soluble PSMA (rsPSMA, e.g., amino acids 44-750 of SEQ ID NO:1) and fragments of the foregoing that form multimers (i.e., that retain the protein domain required for forming dimers and/or higher order multimers of PSMA). In preferred embodiments, at least one of the PSMA proteins

15 forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide. Preferred PSMA protein multimers are dimers, particularly those formed from recombinant soluble PSMA protein. A particularly preferred embodiment is a rsPSMA homodimer.

The PSMA protein multimers referred to herein are believed to assume a native conformation and preferably have such a conformation. The PSMA proteins in certain

20 embodiments are noncovalently bound together to form the PSMA protein multimer. For example, it has been discovered that PSMA protein noncovalently associates to form dimers under non-denaturing conditions, as described in the Examples below.

The PSMA protein multimers can, and preferably do, retain the activities of PSMA. The PSMA activity may be an enzymatic activity, such as folate hydrolase activity,

25 NAALADase activity, dipeptidyl peptidase IV activity and γ-glutamyl hydrolase activity. Methods for testing the PSMA activity of multimers are well known in the art (reviewed by O'Keefe et al. in: Prostate Cancer: Biology, Genetics, and the New Therapeutics, L.W.K. Chung, W.B. Isaacs and J.W. Simons (eds.) Humana Press, Totowa, NJ, 2000, pp. 307-326), some of which are described in the Examples herein below.

30 In certain aspects, the invention also includes compositions including one or more of the isolated PSMA protein multimers described herein, such as the PSMA protein dimer. In preferred embodiments, a PSMA protein multimer composition contains at least about 10%

- 56 -

PSMA protein multimer. In other embodiments, the PSMA protein multimer composition contains at least about 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 99.5% PSMA protein multimer. In a preferred embodiment, the PSMA protein multimer composition contains substantially pure PSMA protein multimer, with substantially no

5   PSMA protein monomer. It is understood that the list of specific percentages includes by inference all of the unnamed percentages between the recited percentages.

As used herein with respect to polypeptides, proteins or fragments thereof, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use. Isolated, when referring to a protein or polypeptide, means, for

10   example: (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may be, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure

15   polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

20   Fragments of a PSMA protein preferably are those fragments which retain a distinct functional capability of the PSMA protein. Functional capabilities which can be retained in a fragment include binding of other PSMA molecules to form dimers and higher order multimers, interaction with antibodies, interaction with other polypeptides or fragments thereof, and enzymatic activity. Other PSMA protein fragments, e.g., other recombinant

25   soluble fragments of SEQ ID NO:1, can be selected according to their functional properties. For example, one of ordinary skill in the art can prepare PSMA fragments recombinantly and test those fragments according to the methods exemplified below.

Modifications to a PSMA polypeptide are typically made to the nucleic acid which encodes the PSMA polypeptide, and can include deletions, point mutations, truncations,

30   amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a

- 57 -

fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the PSMA amino acid sequence.

In general, modified PSMA polypeptides include polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a PSMA polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Modifications conveniently are prepared by altering a nucleic acid molecule that encodes the PSMA polypeptide. Mutations of a nucleic acid which encode a PSMA polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such a hairpins or loops, which can be deleterious to expression of the modified polypeptide.

Modifications can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the PSMA polypeptide. Modified PSMA polypeptides then can be expressed and tested for one or more activities (e.g., antibody binding, enzymatic activity, multimeric stability) to determine which mutation provides a modified polypeptide with the desired properties. Further mutations can be made to modified PSMA polypeptides (or to non-modified PSMA polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a PSMA coding sequence or cDNA clone to enhance expression of the polypeptide. The activity of modified PSMA polypeptides can be tested by cloning the gene encoding the modified PSMA polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the modified PSMA polypeptide, and testing for a functional capability of the PSMA polypeptides as disclosed herein. The foregoing procedures are well known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in PSMA polypeptides to provide functionally equivalent PSMA polypeptides, i.e.,

- 58 -

modified PSMA polypeptides that retain the functional capabilities of PSMA polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Modified PSMA polypeptides can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. Exemplary functionally equivalent PSMA polypeptides include conservative amino acid substitutions of SEQ ID NO:1, or fragments thereof, such as the recombinant soluble PSMA polypeptide (amino acids 44-750 of SEQ ID NO:1). Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

Conservative amino-acid substitutions in PSMA polypeptides typically are made by alteration of a nucleic acid encoding a PSMA polypeptide. Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis, or by chemical synthesis of a gene encoding a PSMA polypeptide. Where amino acid substitutions are made to a small fragment of a PSMA polypeptide, the substitutions can be made by directly synthesizing the peptide. The activity of functionally equivalent fragments of PSMA polypeptides can be tested by cloning the gene encoding the altered PSMA polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered PSMA polypeptide, and testing for a functional capability of the PSMA polypeptides as disclosed herein.

The PSMA protein multimers as described herein have a number of uses, some of which are described elsewhere herein. The multimers are useful for testing of compounds that modulate PSMA enzymatic activity or PSMA multimerization. The multimers can be used to isolate antibodies that selectively bind PSMA, including those selective for conformational epitopes, those selective for binding PSMA multimers and not PSMA monomers, and those that selectively modulate an enzymatic activity of PSMA. The

multimers, particularly dimeric PSMA, also can be used to induce or increase immune responses to PSMA, as vaccine compositions.

Agents that selectively modulate an enzymatic activity of PSMA include agents that inhibit or enhance at least one enzymatic activity of PSMA, such as NAALADase activity, folate hydrolase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity, or combinations thereof.

Thus methods of screening for candidate agents that modulate at least one enzymatic activity of a PSMA enzyme are provided in accordance with the invention. The methods can include mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, thereby contacting the PSMA enzyme with the candidate agent. The methods also include adding a substrate for the PSMA enzyme to the reaction mixture, and determining the amount of a product formed from the substrate by the PSMA enzyme. Such methods are adaptable to automated, high-throughput screening of compounds. A decrease in the amount of product formed in comparison to a control is indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme. An increase in the amount of product formed in comparison to a control is indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme. The PSMA enzyme can be NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and/or γ-glutamyl hydrolase. The PSMA enzyme preferably is a PSMA multimer that includes recombinant soluble PSMA, most preferably a noncovalently associated dimer of PSMA in a native conformation.

The reaction mixture comprises a candidate agent. The candidate agent is preferably an antibody, a small organic compound, or a peptide, and accordingly can be selected from combinatorial antibody libraries, combinatorial protein libraries, or small organic molecule libraries. Typically, a plurality of reaction mixtures are run in parallel with different agent concentrations to obtain a different response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration of agent or at a concentration of agent below the limits of assay detection.

Candidate agents encompass numerous chemical classes, although typically they are organic compounds, proteins or antibodies (and fragments thereof that bind antigen). In some preferred embodiments, the candidate agents are small organic compounds, i.e., those having a molecular weight of more than 50 yet less than about 2500, preferably less than about 1000 and, more preferably, less than about 500. Candidate agents comprise functional

chemical groups necessary for structural interactions with polypeptides and/or nucleic acids, and typically include at least an amine, carbonyl, hydroxyl, or carboxyl group, preferably at least two of the functional chemical groups and more preferably at least three of the functional chemical groups. The candidate agents can comprise cyclic carbon or heterocyclic

5   structure and/or aromatic or polyaromatic structures substituted with one or more of the above-identified functional groups. Candidate agents also can be biomolecules such as peptides, saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like.

        Candidate agents are obtained from a wide variety of sources including libraries of

10   synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides, synthetic organic combinatorial libraries, phage display libraries of random or non-random peptides, combinatorial libraries of proteins or antibodies, and the like. Alternatively, libraries of natural compounds in the form of

15   bacterial, fungal, plant, and animal extracts are available or readily produced. Additionally, natural and synthetically produced libraries and compounds can be readily be modified through conventional chemical, physical, and biochemical means. Further, known agents may be subjected to directed or random chemical modifications such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs of the agents.

20   A variety of other reagents also can be included in the mixture. These include reagents such as salts, buffers, neutral proteins (e.g., albumin), detergents, etc. which may be used to facilitate optimal protein-protein and/or protein-agent binding. Such a reagent may also reduce non-specific or background interactions of the reaction components. Other reagents that improve the efficiency of the assay such as protease inhibitors, nuclease

25   inhibitors, antimicrobial agents, and the like may also be used.

        The mixture of the foregoing reaction materials is incubated under conditions whereby, the candidate agent interacts with the PSMA enzyme. The order of addition of components, incubation temperature, time of incubation, and other parameters of the assay may be readily determined. Such experimentation merely involves optimization of the assay

30   parameters, not the fundamental composition of the assay. Incubation temperatures typically are between 4°C and 40°C. Incubation times preferably are minimized to facilitate rapid, high throughput screening, and typically are between 0.1 and 10 hours.

After incubation, the presence or absence of PSMA enzyme activity is detected by any convenient method available to the user. For example, the reaction mixture can contain a substrate for the PSMA enzyme. Preferably the substrate and/or the product formed by the action of the PSMA enzyme are detectable. The substrate usually comprises, or is coupled to,

5   a detectable label. A wide variety of labels can be used, such as those that provide direct detection (e.g., radioactivity, luminescence, optical, or electron density, etc) or indirect detection (e.g., epitope tag such as the FLAG epitope, enzyme tag such as horseradish peroxidase, etc.). The label may be bound to the substrate, or incorporated into the structure of the substrate.

10   A variety of methods may be used to detect the label, depending on the nature of the label and other assay components. For example, the label may be detected while bound to the substrate or subsequent to separation from the substrate. Labels may be directly detected through optical or electron density, radioactive emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, strepavidin-biotin conjugates, etc. Methods

15   for detecting a variety of labels are well known in the art.

Examples

Materials and Methods

20   *DNA constructs.* All secreted PSMA constructs were derived from the original human PSMA clone p55A provided by Dr. W.D.W. Heston (Israeli et al., *Cancer Res.* 53: 227-230, 1993). The constructs were subcloned into expression vector PPI4 (Trkola et al., *Nature* 384: 184-187, 1996) for high-level expression and secretion in mammalian cells. Recombinant soluble PSMA (rsPSMA) corresponds to the entire extracellular domain of PSMA (amino acids 44-

25   750 of SEQ ID NO:1 (GenBank Protein Accession number AAA60209)).

pcDNA Plasmid Constructs: Nucleic acid molecules encoding the anti-PSMA antibodies 10.3, 006, 026, 051, 069 and 077 were cloned into plasmid pcDNA. The cloning protocol is given in Figure 10. Primers (SEQ ID NOs: 33-36, sense and anti-sense) used for the variable

30   region amplifications are also shown. The plasmids constructed for anti-PSMA antibodies 006, 026, 051, 069, 077 and 10.3 contain nucleotide sequences encoding the heavy chain of the antibodies (SEQ ID NOs: 2-7; PTA-4403, PTA-4405, PTA-4407, PTA-4409, PTA-4411,

- 62 -

PTA-4413, respectively) or contain nucleotide sequences encoding light chain of the antibodies (SEQ ID NOs: 8-13; PTA-4404, PTA-4406, PTA-4408, PTA-4410, PTA-4412 and PTA-4414, respectively). Plasmid maps are given in Figures 11-22.

5   *Western blots.* Cells were lysed in PBS containing 1mM EDTA, 1% NP-40, 1% Triton X-100, and 5mg/ml aprotinin and cell debris was removed by centrifugation at 3000g for 30 min at 4°C. Lysates were separated on a 5-20% gradient gel before transfer to nitrocellulose membranes. The resulting blots were blocked in PBS containing 5% milk, 0.02% SDS and 0.1% Triton X-100 before incubation with MAB544 primary antibody (Maine

10   Biotechnologies) at a concentration of 2mg/ml. After three washes, blots were incubated with a goat anti-mouse HRP-conjugated secondary antibody at a concentration of 0.2mg/ml. Blots are visualized using the Renaissance chemiluminescence system (Perkin-Elmer Life Sciences, Boston, MA).

15   *ELISA.* Cells were lysed in PBS containing 1mM EDTA, 1% NP-40, 1% Triton X-100, and 5mg/ml aprotinin. The resulting cell membranes were plated onto 96-well plates and dried in a sterile hood overnight. The plates were then blocked with PBS containing casein and Tween-20 before addition of mouse sera or hybridoma supernatants, using purified MAB544 (Maine Biotechnologies) or 7E11 (Cytogen) as a standard. After washing in PBS, an alkaline

20   phosphatase conjugated secondary antibody (subclass specific) was incubated and subsequently washed in PBS. The pNPP substrate was then added for colorimetric detection at a wavelength of 405 nm.

Flow cytometry. Wild-type 3T3 or PSMA-expressing 3T3 cells (10^6 cells per condition) were

25   washed in PBS containing 0.1% NaN$_3$. Antibodies or sera were then added (1:100 dilution in PBS) and incubated on ice for 30 minutes. After washing in PBS+0.1% NaN$_3$, the cells were incubated with anti-mouse IgG+IgM (Calbiotech) for 30 minutes on ice. Cells were washed again in PBS+0.1% NaN$_3$ and analyzed by flow cytometry.

30   <u>Example 1: Generation of a panel of monoclonal antibodies (mAbs) to conformational epitopes on PSMA</u>

- 63 -

A panel of anti-PSMA mAbs that represent promising candidates for therapy was created. Briefly, the mAbs were generated as follows: BALB/c mice were immunized subcutaneously with recombinant PSMA at approximately three-week intervals. After a total of 4 injections, mice were sacrificed and their splenocytes fused with a myeloma cell line

5   using standard techniques in order to create hybridomas. Individual hybridoma supernatants were screened by ELISA for reactivity with PSMA derived from either LNCaP human prostate tumor cells or from 3T3 cells engineered to express full-length human PSMA (3T3-PSMA cells). Positive clones were secondarily screened by flow cytometry for specific reactivity with intact 3T3-PSMA and LNCaP cells so as to select antibodies that recognize

10 native, cell-surface PSMA and thus have the greatest therapeutic potential.

Mice having the ability to produce human antibodies (XenoMouse, Abgenix; Mendez et al., *Nature Genetics* 15:146, 1997) were immunized subcutaneously once or twice weekly with 5 X 10^6 LNCaP cells adjuvanted with alum or Titermax Gold (Sigma Chemical Co., St. Louis, MO). Animals were boosted twice with 10 μg of recombinant PSMA protein

15 immunoaffinity captured onto protein G magnetic microbeads (Miltenyi Biotec, Auburn, CA). PSMA mAb 3.11 was used for capture. Splenocytes were fused with NSO myeloma cells and the hybridomas that resulted were screened as above by flow cytometry to detect clones producing antibodies reactive with the extracellular portion of PSMA. One clone, 10.3 (PTA-3347), produced such antibodies.

20 These methods have yielded a high proportion of mAbs that react exclusively with conformation-specific epitopes on cell-surface PSMA. As shown in Fig. 1, several (mAbs 3.7, 3.9, 3.11, 5.4, and 10.3) but not all (mAb 3.12) mAbs specifically bind viable PSMA-expressing cells. Using recombinant soluble PSMA proteins expressed in Chinese hamster ovary (CHO) cell lines, it further was demonstrated that the mAbs bind epitopes in the

25 extracellular region of PSMA. The mAbs were also tested for their ability to immunoprecipitate native PSMA from 3T3-PSMA cell lysates. The mAbs positive in flow cytometry (Fig. 1) were also effective in immunoprecipitation (Fig. 2), whereas mAb 3.12 was unreactive. Fig. 3 shows the recognition of non-denatured full-length PSMA and recombinant soluble PSMA by several PSMA antibodies that recognize PSMA conformation.

30 This further confirms that these methods yield a preponderance of mAbs that efficiently recognize native PSMA.

The mAbs were tested for reactivity with denatured PSMA by Western blot analysis (Fig. 4). Lysates from the indicated cells and samples (controls: 3T3 cells, PSMA-negative human prostate cell lines PC-3 and DU145, mock supernatant; PSMA-positive samples: PSMA-expressing 3T3 cells, PSMA-positive human prostate cell line LNCaP, rsPSMA-positive supernatant) were resolved by SDS-PAGE, electroblotted, and probed with anti-PSMA mAbs 3.1 and 3.12 (ATCC Patent Deposit Designations PTA-3639 and PTA-3640, respectively). Four mAbs tested in parallel (3.7, 3.8, 3.9, 3.11) showed no reactivity to either full-length or secreted rsPSMA proteins. 7E11 mAb immunoprecipitated full-length but not secreted rsPSMA.

The mAbs reactive in flow cytometry and immunoprecipitation (mAbs 3.7, 3.9, 3.11, 5.4, and 10.3) were all unreactive in Western blot analysis, indicating that the mAbs do not recognize linear epitopes. Taken together, the data strongly suggest that these 5 mAbs recognize conformation-specific epitopes located in the extracellular domain of PSMA. Since mAbs to conformational epitopes typically possess the greatest affinity and specificity for antigen, they represent preferred candidates for therapy.

The reactivities of certain anti-PSMA antibodies are described in Table 2:

Table 2: anti-PSMA antibody properties

mAb	Reactivity				Epitope
	ELISA	Flow Cytometry	IP	Western	
3.1	+	+	+	+	Linear, Extracellular, exposed on native PSMA
3.7	+	+	+	-	Conformational, extracellular
3.8	+	+	+	-	Conformational, extracellular
3.9	+	+	+	-	Conformational, extracellular
3.11	+	+	+	-	Conformational, extracellular
3.12	+	-	-	+	Linear, Extracellular, not exposed on native PSMA
5.4	+	+	+	-	Conformational, extracellular
7.1	+	-	-	+	Linear, Extracellular, not exposed on

					native PSMA
7.3	+	+	+	-	Conformational, extracellular
10.3	+	+	+	-	Conformational, extracellular
1.8.3	+	+		-	Extracellular
A3.1.3	+	+		-	Extracellular
A3.3.1	+	+		-	Extracellular

The mAbs were determined by ELISA to be primarily of the mouse IgG2a, mouse IgG2b and human IgG1 isotypes, which mediate potent effector functions. Although a number of anti-PSMA mAbs have been described over the years and evaluated for

5   therapeutic potential (see, e.g., Liu, H. *et al. Cancer Res.* 57: 3629-3634, 1997; Chang, S.S. *et al. Cancer Res.* 59: 3192-3198, 1999; Murphy, G.P. *et al. J Urology* 160: 2396-2401, 1998), none inhibit the enzymatic activity of PSMA and few recognize conformational determinants on PSMA.

10 Example 2: Production of anti-PSMA mAbs

To accurately and quantitatively assess the therapeutic potential of these mAbs, the mAbs are produced in a quantity and quality suitable for extensive *in vitro* and *in vivo* characterization. Briefly, the mAb-secreting hybridomas are cultured in roller bottles in DMEM/F12 medium supplemented with 10% FBS that has been depleted of bovine IgG

15 (Life Technologies). During the production phase of the culture, cells are maintained at $\sim$5 x 10^6 cells/mL via twice-weekly exchanges of media. Collected media are clarified by filtration through a 0.22 micron filter and stored at -95 °C prior to purification. Given an average antibody expression levels of $\sim$25 mg/L, approximately 3L of roller bottle supernatants are required for each antibody to allow for losses in purification.

20 Culture supernatants from a given hybridoma are pooled and loaded onto a Protein A Sepharose affinity column. Mouse IgG2a, mouse IgG2b and human IgG1 antibodies are loaded directly, but supernatants containing mouse IgG1 antibodies are adjusted to pH 8.5 and 1M NaCl prior to loading in order to promote binding. After washing the column, the mAb is eluted with low pH buffer into fractions using 1M Tris, pH 8.0. Elution peak

25 fractions are pooled, dialyzed against PBS buffer, concentrated to 5 mg/mL and stored in sterile aliquots at -95 °C. All purification procedures are carried out using endotoxin-free

buffers and sanitized chromatography columns. Purified mAbs are tested for purity by
reducing and nonreducing SDS-PAGE, for PSMA binding affinity by ELISA, and for
endotoxin levels by the *limulus* amebocyte lysate assay. These procedures routinely yield
"animal-grade" antibody at >95% purity and <0.5 endotoxin units per milligram of protein.

Example 3: Evaluation of the therapeutic potential of the unlabeled mAbs *in vitro*

Purified mAbs are tested in a battery of assays for therapeutically relevant properties,
including affinity, specificity, enzyme inhibitory activity and effector functions. The ideal
product candidate binds and inhibits PSMA activity at subnanomolar concentrations and
mediates potent cell-killing through Fc-related effector functions.

First, the mAbs' affinity for cell-surface and secreted forms of PSMA is measured by
flow cytometry and ELISA, respectively. In the flow cytometry assay, varying amounts of
mAbs are incubated with 5×10^5 3T3-PSMA cells in FACS buffer (PBS containing 1% FBS
and 0.1% NaN_3) for 2 hr to allow for saturation binding. Cells are washed and incubated
with a phycoerythrin-coupled goat antibody to mouse IgG (ICN/Cappel) for detection of
bound mAb by flow cytometry. Specific binding is calculated by subtracting the
fluorescence intensity observed with parental 3T3 cells.

For ELISA, CHO cell-derived recombinant soluble PSMA protein (rsPSMA,
Progenics, Tarrytown, NY) is diluted to 1 µg/ml in 50 mM carbonate buffer, pH 9.4, and
coated overnight at 4 °C onto 96-well Immulon II microtiter plates at 100 µl/well. The plates
are then blocked for 2 hr with PBS buffer containing 5% BSA. mAbs are added in a range of
concentrations in ELISA buffer (PBS buffer containing 2% BSA, 1% FBS and 0.5%
Tween 20) for 2 hours at room temperature. The plates are washed, and horseradish
peroxidase conjugated goat antibody to mouse IgG is added for 1 hr at room temperature.
The plates are washed again and 3,3',5,5'-tetramethylbenzidine dihydrochloride (TMB)
substrate (Pierce, Rockford, IL) is added for colorimetric readout at 450 nm using an ELISA
plate reader (Molecular Devices, Sunnyvale, CA).

Example 4: mAb cross-competition binding assay

To identify whether a given group of mAbs recognize distinct or overlapping epitopes
on PSMA, cross-competition binding assays are performed (Liu, H. *et al. Cancer Res* 57:
3629-3634, 1997). In this flow cytometry assay, a biotinylated test mAb is incubated with

3T3-PSMA cells in the presence or absence of varying concentrations of unlabeled competitor mAbs as described above. Following washing, phycoerythrin-conjugated streptavidin is added to determine the amount of bound biotinylated mAb. The percent inhibition is defined relative to that observed in the presence of an isotype-matched mAb of

5   irrelevant specificity (0% inhibition) and to that observed using excess unlabeled test mAb (100% inhibition).

Example 5: Effects of mAbs on PSMA enzymatic activity

PSMA has been shown to possess both folate hydrolase and N-acetylated α-linked

10   acidic dipeptidase (NAALADase) enzymatic activities, which may influence the proliferation and malignancies of the tumor cell (Heston, W.D.W. *Prostate: Basic and Clinical Aspects* (R.K. Naz, ed.). CRC Press, New York: 219-243, 1997). Several of the mAbs described above (mAb 3.9, mAb 5.4 and mAb 7.3) and mAb J591 (ATCC #HB-12126) were tested for folate hydrolase modulating activity using previously described assays for measuring PSMA

15   enzymatic activity (Pinto, J.T. *et al. Clinical Cancer Res* 2: 1445-1451, 1996).

Briefly, folate hydrolase activity was measured as follows. Fifty μM methotrexate di-gamma glutamate and 10 μg/ml rsPSMA (premixed with anti-PSMA or irrelevant mAb) was incubated in pH 4.5 acetate buffer in a volume of 100μl for 2 hr at 37°C. Reactions were terminated by boiling for 5 minutes prior to separation of free, mono- and di-gamma

20   glutamate forms of methotrexate by capillary electrophoresis on a Spectra Phoresis 1000 (Thermo Separation, San Jose, CA). The various methotrexate derivatives were quantified based on their retention times and absorbance at 300 nm.

The data show that mAb 5.4 potently blocks the enzymatic activity of purified rsPSMA protein and in lysates of C4-2 cells. C4-2 is an androgen independent derivative of

25   the LNaCP cell line (human prostate cancer line) which expresses endogenous PSMA. More details regarding the C4-2 cell line may be found in O'Keefe D.S. et al. *Prostate* 45: 149-157, 2000). Figures 7 and 8 provide the results for two production lots of rsPSMA (rsPSMA #7 and rsPSMA #8). The results for the C4-2 cell lysates are shown in Figure 9. The figures illustrate the effect of four antibodies (mAb 3.9, mAb 5.4, mAb 7.3 and mAb J591) on the

30   enzymatic activity of folate hydrolase by way of the rate of cleavage of glutamate from methotrexate di-gamma glutamate (MTXGlu2) by folate hydrolase present in the two

- 68 -

production lots of rsPSMA and in the C4-2 cell lysates. In addition to the inhibitory effects of mAb 5.4, mAb 3.9 was also found to inhibit folate hydrolase activity.

For NAALADase activity assays, rsPSMA protein is incubated with varying amounts of anti-PSMA or control mAbs in 50mM Tris pH 7.4, 1mM $CoCl_2$ for 10 minutes at 37°C before adding 50µl of 0.6µM N-acetylaspartyl-[^{3}H]glutamate. After 15 minutes, the reaction is stopped by adding 1 ml of 100mM $NaPO_4$. Cleaved glutamate is separated from the substrate by ion exchange chromatography and detected by scintillation counting. Each measurement is performed in triplicate.

Example 6: Reactivity with normal and malignant human tissues by immunohistochemistry

Anti-PSMA mAbs are tested by immunohistochemistry for reactivity with both normal and malignant human tissues using an avidin-biotin peroxidase method (Silver, D.A. et al. Clin Cancer Res 3: 81-85,1997). Frozen or paraffin-embedded tissues can be used. Paraffin-embedded tissue sections are deparaffinized and endogenous peroxidase activity is blocked by incubation with 1% H_2O_2 for 15 minutes. Sections are blocked in a 1:10 dilution of horse serum in 2% PBS-BSA (Sigma Chemical, St Louis, MO) for 30 minutes before overnight incubation with 2µg/ml anti-PSMA mAb in 2% PBS-BSA. After washing, sections are incubated with biotinylated secondary antibody, washed, and incubated with avidin:biotin peroxidase complexes (Vector Laboratories, Burlingame, CA) diluted 1:25 in PBS for 30 minutes. After washing, sections are visualized by immersion in PBS containing 0.05% diaminobenzidine tetrachloride, 0.01% H_2O_2, and 0.5% Triton X-100. Negative control sections are incubated with isotype-matched mAbs of irrelevant specificity. As a positive control, 7E11 (Cytogen, Princeton, NJ), a well-characterized anti-PSMA mAb, is used.

Example 7: Antibody-dependent cellular cytotoxicity (ADCC)

In the ADCC assay, mAbs are serially diluted and combined with ^{51}Cr-labeled 3T3-PSMA cells or human prostate PC-3 cells that have been engineered to express human PSMA (PC-3-PSMA cells). NK effector cells are purified from lymph nodes or spleens using anti-NK microbeads (Miltenyi Biotec). Sera, NK effector cells, and ^{51}Cr-loaded target cells are co-incubated at effector:target cell ratios of 10:1, 20:1, and 40:1, with each condition performed in triplicate. Cells are incubated 4-5 hours at 37°C before supernatants are

collected for measurement of ^{51}Cr release by gamma counting. The percent specific lysis is determined relative to that observed in the presence of isotype-matched non-specific mAb (0% lysis) to that obtained using 10% sodium dodecyl sulfate (100% lysis).

5   ## Example 8: Complement-mediated lysis (CML)

For CML, ^{51}Cr-loaded 3T3-PSMA or PC-3-PSMA cells serve as target cells. Serial dilutions of mAbs are co-incubated with rabbit complement and target cells for 4-5 hours at 37°C, with each condition being performed in triplicate. Supernatants are then collected and counted with a gamma counter. Specific lysis is computed as previously done with the
10   ADCC assay data.

Example 9: Anti-proliferative effects

To test anti-proliferative effects of these antibodies, anti-PSMA mAbs are serially diluted and incubated with LNCaP, PC-3-PSMA and parental PC-3 cells in log-phase growth.
15   At 4 hr, 24 hr, and 72 hr intervals, cells are removed and analyzed for density and viability by trypan blue staining and WST-1 assay (Roche Biochemicals).

Example 10: Optimization of chelation and radiolabeling procedures

The most promising mAbs identified using the procedures described in the foregoing
20   examples will be optimized for biochemical and biological stability and activity after labeling prior to evaluation in animals. Success in *in vitro* experiments is defined as identification of a radiolabeled mAb that specifically kills PSMA-expressing tumor cells at >10-fold lower concentrations than unlabeled or similarly labeled isotype control mAb.

Because the preferred α- and β-emitting isotopes are all radiometals, each of the
25   mAbs is first conjugated with an appropriate metal chelating agent. Based on the favorable *in vivo* stability data and its proven use in human clinical trials, the bifunctional chelating agent C-functionalized trans cyclohexyldiethylenetriaminepentaacetic acid (*p*-SCN-CHX-A''- DTPA) is the preferred agent for attaching either ^{90}Y or ^{213}Bi to the antibody (Brechbiel, M.W. *et al. J. Chem. Soc. Chem. Commun.* 1169-1170, 1991). A form of this chelate has
30   previously been tested in more than 70 doses in humans in ongoing trials at Memorial-Sloan Kettering Cancer Center (McDevitt, M.R. *et al. J. Nucl. Med.* 40:1722-1727, 1999). For ^{225}Ac, our initial studies will examine a novel bifunctional chelating agent termed *p*-SCN-Bz-

HEHA (1,4,7,10,13,16-hexaazacyclooctadecane-N,N',N'',N''',N'''',N'''''-hexaacetic acid) (Deal, K.A. *et al. J. Med. Chem.* 42:2988-2992, 1999). The objective is to optimize the antibody conjugation and chelation ratios to maximize labeling yield and activity while maintaining suitable stability for *in vivo* utilization. Additional chelating agents also are used
5   as they become available from the N.I.H. and other sources.

Initially, the antibody is rendered metal-free by incubation with a large molar excess of EDTA at pH=5. The EDTA and any metals scavenged from the antibody preparation are removed via continuous buffer exchange/dialysis so as to replace the pH=5 buffer with the conjugation buffer (Nikula, T.K. *et al. Nucl. Med. Biol.* 22:387-390, 1995). Conditions that
10   yield optimal chelator to antibody ratio but still remain immunoreactive are identified by systematically varying the chelator:antibody ratio, reaction time, temperature, and/or buffer systems about initial conditions that employ a 40-fold molar excess of chelator to antibody in HEPES buffer, pH 8.5. The number of chelates bound per antibody is determined using an established spectrophotometric method (Pippin, C.G. *et al. Bioconjugate Chemistry* 3: 342-
15   345, 1992).

For ^{90}Y and [225]Ac constructs, labeling efficiency is measured directly. For [213]Bi, initial antibody constructs are tested for chelation efficiency using ^{111}In, which has similar chelation chemistry as [213]Bi but possesses the advantages of a longer half life ($t_{1/2}$=3 days), ready availability, and traceable γ-emission. Once optimized using ^{111}In, labeling efficiency
20   is determined for [213]Bi.

Radiolabeled mAb is purified over a BioRad 10DG desalting column using 1% HSA as the mobile phase and evaluated by instant thin layer liquid chromatography (ITLC) and/or high performance liquid chromatography (HPLC) to determine the percent incorporation of radionuclide (Zamora, P.O. *et al. Biotechniques* 16: 306-311, 1994). ITLC and HPLC
25   provide a means of establishing purity and identifying the percent of low molecular weight radiochemical impurities (*i.e.*, metal chelates, colloids, and free metal). Duplicate ITLC strips for each mobile phase are developed, dried, and cut at the R_f of 0.5 mark and counted in a gamma counter. The HPLC system is equipped with both an online UV absorption detector and radioactivity detector. The HPLC elution profile directly correlates radioactivity
30   with protein and low molecular weight species as a function of the elution time. A TSK SW3000$_{XL}$ column (TosoHaas, Montgomeryville, PA) is used and calibrated using a range of protein molecular weight standards.

Example 11: Affinity and immunoreactivity of radiolabeled mAbs

Once radiolabeled constructs are obtained, purified, and assessed for biochemical and radiochemical purity, biological activity is determined. Binding activity of the radioconstruct

5   is performed by Scatchard analysis of binding data obtained using whole LNCaP and 3T3-PSMA cells and/or membrane fractions as previously described (Scheinberg, D.A. *et al.* *Leukemia* 3: 440-445 (1991).

The immunoreactivity of the synthetic constructs is evaluated in order to correlate the chelate:antibody molar ratio with the biological activity. Briefly, 2 ng of labeled mAb is

10   incubated with a ~25-fold excess of PSMA as expressed on 3T3-PSMA cells. After a 30 min incubation at 0°C, the cells are collected by centrifugation and the supernatant containing unbound mAb is added to fresh 3T3-PSMA cells for an additional 30 min at 0°C. Both sets of cells are centrifuged and washed twice with cold PBS. The cell pellets, supernatant and wash fractions are counted for radioactivity. Immunoreactivity is defined as the amount of

15   radioactivity in the cell pellets divided by the total radioactivity in the cell pellets, supernatant and wash fractions.

Example 12: mAb internalization

The activity of radiolabeled mAbs can be significantly modulated by their

20   internalization rates. Internalization of the cell surface antibody-antigen complex is measured using ^{111}In radiolabeled antibody constructs (Caron, P.C. *et al.* *Cancer Res* 52: 6761-6767, 1992). Briefly, $5x10^5$ 3T3-PSMA cells are incubated at 37°C with ^{111}In radiolabeled antibody for varying time periods. Cells are washed with PBS and cell-surface bound radiolabeled constructs are stripped with 1ml of 50mM glycine/150mM NaCl, pH=2.8. Total

25   cell-associated radioactivity and acid-resistant (internalized) radioactivity are determined by γ-counting to ascertain the rate of internalization. Parental 3T3 cells that do not express PSMA are used as a control to determine non-specific binding. Based upon previous results by other groups (Smith-Jones P.M. *et al.* *Cancer Res* 60: 5237-5243, 2000), significant internalization of PSMA after binding with one or more of the mAb constructs is expected.

30

Example 13: *In vitro* cytotoxicity studies

- 72 -

Assessment of *in vitro* cytotoxicity of α-labeled mAbs was undertaken once the immunoreactivity of the radioimmunoconjugate was established. Approximately 50,000 target cells (either LNCaP or 3T3-PSMA cells) were treated in 96 well plates and analyzed 24-96 hours later. Quantification of cell death due to ^{225}Ac-labeled constructs (or ^{213}Bi) was accomplished by determining the uptake of ^{3}H-thymidine by surviving cells (Nikula, T.K. *et al. J. Nucl. Med.* 40: 166-176, 1999). Specificity was determined by use of control cells (PSMA-negative human prostate cell lines PC-3 and DU-145, as well as control 3T3 cells), blocking with excess unlabeled antibody, and control radioconjugates.

The cytotoxic effects of antibody conjugate concentration, specific activity, and time of exposure were then assessed. Cytotoxicity was expressed relative to that seen with 1M HCl (100% cell death) and media (background cell death). LD_{50} values were calculated by plotting cell viability as a function of the number of ^{225}Ac atoms bound on the cells (McDevitt, M.R. *et al.* (1998) *Eur. J. Nucl. Med.* 25: 1341-1351 (1998).

Multicellular spheroids of LNCaP-FGC cells had been established and were used to investigate the potential of radioimmunotherapy (RIT) to eradicate minimal disease *in vitro*. These three-dimensional spheroids mimic tissue structures more accurately than monolayer cultures and thus provide a more relevant model of solid tumors (O'Connor, K.C. *Pharm. Res.* 16: 486-493, 1999). LNCaP-FGC is a fast growing clone of the original LNCaP cell line, and the cells were grown using a liquid overlay technique to a size of 200-600μm (Ballangrud, A.M. *et al. Clin. Cancer Res.* 5: 3171s-3176s, 1999). In larger spheroids, the inner mass of cells becomes necrotic, while the outer rim consists of proliferating tumor cells. Antibody penetration was measured by confocal microscopy, and prior results suggested that an anti-PSMA antibody should penetrate to a depth of 40-50μm (Ballangrud, A.M. *et al.* 7th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton NJ, 1998). The *in vitro* cytotoxicity of ^{225}Ac-3.9 on LNCaP target cells is shown in Figure 23. The percentage of viable PSMA$^+$ LNCaP cells was plotted as a function of activity of the radioconjugate. Addition of a 100-fold excess of unlabeled antibody was used as a control for specificity.

Example 14: Evaluation of the *in vivo* efficacy of unlabeled and radiolabeled mAbs in mouse xenograft models of human prostate cancer

- 73 -

Antibodies that are successful in the foregoing assays demonstrate significant specificity and functional properties that suggest they will be useful for therapeutic use. The most promising of these radiolabeled and "naked" mAb constructs are evaluated in the best available mouse models of prostate cancer. The studies employ an established xenograft

5   model in which the LNCaP human prostate tumor cell line is injected into immunocompromised nude mice and allowed to form solid tumors (Ellis, W.J. *et al. Clin Cancer Res* 2: 1039-1048 (1996), which then are treated with both radiolabeled and unlabeled anti-PSMA mAb constructs. Follow-on studies also utilize a mouse xenograft model, CWR22, which reproduces many of the key biological features of human prostate cancer.

10

LNCaP tumor cell xenograft model

A construct showing high affinity and high specificity is taken into the LNCaP tumor cell xenograft *in vivo* model for biodistribution and pharmacokinetic analysis. ^{111}In-labeled anti-PSMA antibody is used for these studies due to its favorable chelation chemistry,

15   radioactive half-life and traceable gamma emission. Timepoints are evaluated as appropriate for the half-lives of ^{213}Bi, ^{225}Ac, ^{177}Lu and ^{90}Y, which are the nuclides of therapeutic interest. Labeled radioconstructs (1-5μg) are injected i.v. into nude mice (normal and tumor bearing) and the mice are sacrificed at 5 min, 15 min, 30 min, 60 min, 2 hrs, 4 hrs, 18hrs, and 24hrs post-injection. Blood and major organs are taken from animals, weighed, and the percent

20   radioactivity injected per gram of tissue is determined (Nikula, T.K. *et al. J. Nucl. Med.* 40: 166-176, 1999). Specificity is addressed by pre-injection with excess unlabeled construct. Macroscopic tumor volume and animal survival rates is recorded throughout the experiments.

A dose-ranging study is also conducted to determine the toxicity of the constructs when administered via i.v. or i.p. injection to normal and tumor-bearing mice. These animals

25   are routinely examined for toxic side effects during the course of the studies by blood chemistry and physical examination. Animals are sacrificed during and at the conclusion of the study in order to collect blood and body tissues for further evaluation. Previous data has demonstrated an approximate maximum tolerated dose of 250μCi/mouse, so total doses are kept below that level.

30   Once i.v. biodistribution and toxicity is documented, radiotherapy of tumors is assessed. Groups of five mice are injected with <1μg radiolabeled anti-PSMA mAb construct both pre- and post-tumor challenge to assess anti-tumor activity. Antigen negative

(RAJI or RAMOS) xenografted tumors are also used as a control. Other controls include (1) treatment with unlabeled anti-PSMA mAb only and (2) excess unlabeled anti-PSMA mAb pretreatment before ^{213}Bi, ^{225}Ac, ^{177}Lu and/or ^{90}Y-labeled anti-PSMA to block specific targeting.

5   Groups of tumor bearing mice are injected with unlabeled anti-PSMA mAbs (at equimolar concentrations) and several dose levels of radiolabeled anti-PSMA or a similarly labeled isotype control antibody. The effect on tumor growth is assessed over time. Statistical differences between therapy groups is determined using an analysis of variance (ANOVA) method and animal survival is illustrated using Kaplan-Meier plots. The efficacy

10   of ^{213}Bi, ^{225}Ac, ^{177}Lu and/or ^{90}Y-labeled anti-PSMA constructs is correlated to the data obtained *in vitro*. Success in these experiments is defined as the ability to significantly (p <0.05) increase life-span and/or decrease tumor volume as compared to a radiolabeled isotype control mAb.

       Furthermore, the tumor models are used to test whether predosing with unlabeled

15   antibody prior to injection of radiolabeled antibody improves delivery of the radiolabeled antibody to the tumor. The tumor-bearing mice are injected with <1µg radiolabeled anti-PSMA antibody with or without a prior single injection of 5-100µg of unlabeled antibody. After several days, animals are sacrificed for evaluation of the distribution of radioactivity in the tumor, normal tissue, and blood. If predosing with unlabeled antibody improves delivery

20   and targeting of radiolabeled antibody to the tumors, this approach is applied and optimized in toxicity and therapeutic studies.

       In addition to overall survival, the role of timing of the injection after tumor transplantation (Day 1 vs 3 vs 7), the role of dosage (dose-response curves using 3-4 dose levels), the role of schedule (single vs multiple divided daily injections) and the specificity of

25   the treatment (pre-treatment with unlabeled anti-PSMA to block targeting) is examined.

       These *in vivo* studies are designed to address the maximum tolerated dose of radiolabeled antibody, the activity of the antibody, the optimal dosing schedule (single or multiple injections), and the effect on tumor size. Successful completion of this work enables determination of the feasibility of PSMA-targeted alpha particle radioimmunotherapy (RIT)

30   of prostate cancer and identifies the optimal ^{213}Bi and/or ^{225}Ac-labeled constructs to enter into clinical development.

- 75 -

CWR22 mouse xenograft model

The most promising anti-PSMA mAbs in unlabeled, toxin-labeled and/or radiolabeled form are tested in the CWR22 human prostate cancer xenograft mouse model, (Wainstein, M.A. *et al. Cancer Res* 54:6049-6052 (1994); Nagabhushan, M. *et al. Cancer Res* 56:3042-
5   3046 (1996); Pretlow, T.G. *et al. J Natl Cancer Inst* 85:394-398 (1993)). This model has many features of the human condition including a dependence on androgens, a correlation between measured levels of PSA in serum and tumor size, and high-level expression of PSMA. Following androgen withdrawal, PSA levels decrease to nearly undetectable levels and tumor volume decreases. Later, the tumor regrows as an androgen-independent
10   neoplasm, manifest initially by a rise in PSA and later, measurable tumor growth. After androgen withdrawal, tumors regrow at variable time periods.

Four to six week old nude athymic BALB/c male mice are obtained from the National Cancer Institute-Frederick Cancer Center and maintained in pressurized ventilated caging. While immunodeficient in many respects, these mice mediate wild-type levels of ADCC and
15   CML. The CWR22 tumor line is propagated in the animals by the injection of minced tumor tissue from an established tumor into the subcutaneous tissue of the flanks of athymic nude mice together with reconstituted basement membrane (Matrigel, Collaborative Research, Bedford, MA). To maintain serum androgen levels, the mice are administered 12.5-mg sustained-release testosterone pellets (Innovative Research of America, Sarasota, FL)
20   subcutaneously before receiving tumors. Three to four weeks after inoculation, tumors of approximately 1.5 x 1.0 x 1.0 cm are measured. Androgens are withdrawn by surgical castration under pentobarbital anesthesia and removal of the sustained-release testosterone pellets. Tumor size is determined by caliper measurements of height, width and depth. PSA values are performed on the serum of the mice after tail bleeding using a Tandem-R PSA
25   immuno-radiometric assay (Hybritech, San Diego, CA).

Groups of five mice are injected with anti-PSMA mAb or a similar isotype control mAb at dosages from 5-100μg to assess anti-tumor activity. The effect of scheduling single doses vs. multiple divided daily injections is also examined. Macroscopic tumor volume and animal survival rates are recorded throughout the experiments. Statistical differences
30   between therapy groups are determined using an analysis of variance (ANOVA) method and animal survival are illustrated using Kaplan-Meier plots, with success defined as a difference

- 76 -

of p<0.05. Similarly, the efficacy of "naked" mAbs is compared to that seen with ^{90}Y, ^{177}Lu, ^{213}Bi and/or ^{225}Ac-labeled anti-PSMA constructs.

These *in vivo* studies are designed to address the maximum tolerated dose of mAb, the activity of the antibody, the optimal dosage and dosing schedule (single or multiple divided injections), and the effect of treatment on tumor size. Successful completion of this work will enable determination of the feasibility of PSMA-targeted immunotherapy of prostate cancer and identification of the optimal constructs to enter into clinical development.

Example 15: Investigation Of Native PSMA Protein Conformation

Extraction of PSMA from the cell surface of LNCaP and 3T3 cells

LNCaP or 3T3 cells were grown to confluency in a T150 cell culture flask, detached using cell dissociation solution (Mediatech, Herndon, VA) and transferred to a 15ml conical tube. The cells were washed twice with PBS and resuspended with 2ml of M-Per™ Mammalian Protein Extraction Reagent (Pierce, Rockford, IL). Following incubation for 10 min at 4°C, cell debris and insoluble aggregates were removed by centrifugation at 15,000 rpm for 30 min at 4°C. The supernatant was transferred to a cryogenic vial and stored at - 80°C until further use.

Production and Purification of Recombinant, Soluble PSMA (rsPSMA)

The extracellular domain of PSMA (amino acids 44-750 of the full-length protein, SEQ ID NO:1) was obtained as a secreted protein from a DXB11 Chinese hamster ovary (CHO) cell line, stably transfected with an rsPSMA expression vector. The cells were grown in a Celligen Plus 2.2L Packed Bed Bioreactor (New Brunswick Scientific, Edison, NJ) in protein-free media. The Bioreactor was operated in perfusion mode, and supernatant was collected aseptically into collection bags maintained at 4°C. The protease inhibitor aprotinin was added to the harvest supernatant, which was concentrated 25-fold prior to storage at - 90°C. For purification, the concentrate was thawed and purified using subsequent steps of Concanavalin A lectin affinity chromatography and Butyl-Sepharose hydrophobic interaction chromatography. The purified protein was dialyzed against 10mM potassium phosphate, pH 7.0. The purified rsPSMA protein is dimeric, and possesses folate hydrolase enzymatic activity when tested according to published procedures (Pinto et al., *Clinical Cancer*

- 77 -

Research 2:1445, 1996) and reacts with each of a panel of conformation-specific monoclonal antibodies, indicating that rsPSMA adopts a native conformation.

Polyacrylamide Gel Electrophoresis (PAGE) and Western Blotting of the different PSMA
5 *proteins*

        For each individual PAGE analysis, 15µl of each cell lysate and 5µl of the purified rsPSMA were used.

        SDS-PAGE was performed using standard procedures. Samples were prepared by boiling for 5 minutes in the presence of Laemmli sample buffer (with or without the reducing
10 agent dithiothreitol [DTT]). Samples were then applied on a 4-15% Tris-Glycine gel (BioRad, Hercules, CA). After electrophoresis for 1h at 200V, the proteins were transferred onto nitrocellulose (BioRad) and analyzed by Western blotting.

        The oligomeric nature of the different PSMA proteins was analyzed using Blue Native PAGE (BN-PAGE). Each sample was diluted with an equal volume of 2x BN-PAGE
15 sample buffer (0.1M MOPS / 0.1M Tris / 40% glycerol / 0.1% Coomassie G-250) prior to loading onto the gel. BN-PAGE was performed using 4-12% BisTris gels (Invitrogen, Carlsbad, CA) and 50mM MOPS / 50mM Tris, pH 7.7 as running buffer. Coomassie Blue was omitted from the cathode buffer to avoid interference with protein binding during the transfer of the proteins onto nitrocellulose. Following electrophoresis for 2.5hrs at 125V, the
20 proteins were transferred onto a nitrocellulose membrane (BioRad) and analyzed by Western blotting.

        Western blotting was performed as follows: Subsequent to transfer, the nitrocellulose membrane was blocked with 5% milk in PBS / 0.1% Triton X-100 / 0.02% SDS, which was also used for the subsequent wash and antibody incubation steps. PSMA proteins were
25 detected using the anti-PSMA mAbs 3.1 or 3.9 (Progenics Pharmaceuticals) as primary antibody and HRP-labeled anti-mouse IgG as secondary antibody and 1h incubation at room temperature. The membranes were colorimetrically developed using chemiluminescence (NEN Plus, Perkin Elmer Life Sciences, Boston, MA).

30 *Results*

        Both full-length PSMA and recombinant, soluble PSMA (rsPSMA) migrate on reducing and non-reducing SDS-PAGE with a molecular weight of ~100 kDa (Fig. 5). The

result for full-length PSMA is in accordance with prior observations (Israeli et al., U.S. Patent 5,538,866; Murphy et al., U.S. Patent 6,158,508; Israeli, et al., *Cancer Research* 54:1807, 1994; Troyer et al. *Int. J. Cancer* 62:552, 1995; Troyer et al., *The Prostate* 30:233, 1997; Grauer et al., *Cancer Research* 58:4787, 1998). In each of these reports, full-length PSMA

5   migrated as a major band of 100-120 kDa, with a minor (typically <5% of the total PSMA protein) 180-200 kDa band observed in a subset of reports (U.S. Patent 6,158,508; Troyer et al., 1995; Troyer et al., 1997). Troyer et al. (1995) describe the 180-200 kDa species as being a noncovalently associated PSMA dimer that can be disrupted with increasing concentrations of SDS detergent.

10   rsPSMA contains 94% (707 of 750) of the amino acids present in full-length PSMA, and the two proteins are not clearly resolved in this analysis, as expected.

SDS-PAGE allows the analysis of denatured proteins only. In order to examine native proteins in their native state, other techniques have to be employed, such as Blue Native PAGE (BN-PAGE). BN-PAGE is used to determine the native molecular weight of

15   proteins and their noncovalent complexes (Schägger & v. Jagow, *Anal. Biochem.* 199:223-231, 1991; Schägger et al., *Anal. Biochem.* 217:220-230, 1994). The dye Coomassie Blue G-250 binds to the hydrophobic domains on the surface of most proteins, enhances solubility, and introduces a charge shift on the native proteins resulting in migration towards the anode at pH 7.5 irrespective of the isoelectric point of the protein. Although the migration velocity

20   of proteins in BN-PAGE varies somewhat, the molecular mass of proteins can be determined by their respective end points of migration due to the decreasing pore size of the acrylamide gradient present in the gels.

When analyzed by BN-PAGE, full-length PSMA (extracted from LNCaP or 3T3 cells) as well as purified rsPSMA migrate with a molecular weight of ~190kDa (Fig. 6). This

25   surprising observation for full-length PSMA indicates that the predominant form of cell-surface PSMA is a noncovalently associated dimer. This unexpected result can be contrasted with that of previous reports (U.S. Patent 6,158,508; Troyer et al. 1995; Troyer et al., 1997), where the PSMA dimer represents a minor species in SDS-PAGE analyses. Presumably, the noncovalent PSMA dimer is largely dissociated by boiling in the presence of the denaturing

30   detergent SDS.

Moreover, the result for the purified rsPSMA protein indicates that the dimer is stabilized via interactions between extracellular amino acids in addition to or exclusive of

amino acids in the transmembrane or intracellular segments, which are not present in rsPSMA.

Example 16: Dissociation of PSMA Multimers

5 · PSMA is a putative zinc metalloprotease, and site-directed mutagenesis of amino acids implicated in zinc binding results in a profound loss of enzymatic activity (Speno et al., *Molecular Pharmacology*, 55:179, 1999). These amino acids include His-377, Asp-387, Glu-425, Asp-453 and His-553. Ethylenediaminetetraacetic acid (EDTA) is a strong chelating agent for Zn^{2+} and other divalent cations, and thus has the potential to remove Zn^{2+}

10 or other coordinate divalent cations from PSMA. We have determined that EDTA treatment causes the PSMA homodimer to dissociate into monomeric subunits. Similar results can be expected for other agents that possess similar chelating properties, such as ethyleneglycol-bis(beta-aminoethyl ether) (EGTA).

The purified rsPSMA protein was incubated with or without 10mM EDTA for 16 hr

15 at 4°C and then analyzed by BN-PAGE. Under these conditions, the EDTA-treated protein was monomeric, whereas rsPSMA remained dimeric in the absence of EDTA. Although the dissociation of the PSMA dimer into monomer was essentially complete, any residual · dimeric protein can be removed if desired by gel filtration, ultracentrifugation or other size-based separation methods that are well-known to those skilled in the art.

20

Example 17: Methods for identifying promoters of PSMA dissociation

Compounds are screened for the ability to promote dissociation of PSMA dimers using a method that includes:

(a)   contacting a PSMA dimer with a compound under conditions that do not

25 promote dissociation of the PSMA dimer in the absence of the compound;

(b)   measuring the amount of PSMA monomer; and

(c)   comparing the amount of PSMA monomer measured in the presence of the compound with that observed in the absence of the compound.

An increase in the amount of PSMA monomer measured in the presence of the

30 compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

In a further embodiment, compounds are screened for the ability to promote dissociation of PSMA dimers using a method that includes:

(a)   contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

5   (b)   measuring the amount of PSMA dimer; and

(c)   comparing the amount of PSMA dimer measured in the presence of the compound with that observed in the absence of the compound.

A decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

10

In a further embodiment, compounds are screened for the ability to promote dissociation of PSMA dimers using a method that includes:

(a)   contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

15   (b)   measuring the amounts of PSMA monomer and PSMA dimer;

(c)   calculating a ratio of PSMA monomer to PSMA dimer; and

(d)   comparing the ratio obtained in (c) with that obtained in the absence of the compound.

An increase in the ratio measured in the presence of the compound indicates that the

20   compound is capable of promoting dissociation of the PSMA dimer.

Example 18: Cell surface PSMA binding studies

Flow cytometry

25   Parent 3T3 cells or PSMA-expressing 3T3 cells (2 x 10^5 cells per condition) were washed in PBS and incubated with PBS containing goat serum (10% v/v) for 20 minutes on ice to block non-specific binding sites. Anti-PSMA monoclonal antibodies (unpurified form in supernatants or purified mAbs) were added in serial dilutions to cells in 100μl PBS and incubated on ice for 30 minutes. Control anti-human IgG (Caltag, Burlingame, CA) was used

30   to establish background binding. After two washes in PBS, the cells were incubated with anti-human IgG (BD Pharmingen, San Diego, CA) for 30 minutes on ice. Cells were washed twice in PBS, resuspended in 250μl PBS and analyzed by flow cytometry using a FACScan machine (Becton Dickinson, Franklin Lakes, NJ) and CellQuest software. Viable cells were

gated by forward scatter and side scatter parameters, and binding was quantified using histogram plots of mean fluorescence intensity (MFI) levels.

Anti-PSMA mAbs XG-006 (PTA-4403 and PTA-4404, heavy and light chain

5   plasmids), XG-051 (PTA-4407 and PTA-4408), 4.40.1 (PTA-4360; 4.40, 4.40.1 and 4.40.2 are the same antibody that represent different stages of subcloning the hybridoma), 4.49.1, 4.292.1 (PTA-4390) and 4.304.1 were found to avidly bind to cell surface PSMA (Figure 24).

Maximal Binding

10   Flow cytometry data (mean fluorescence intensity v. antibody concentration) were transposed and plotted using Excel software (Microsoft, Redmond, WA). Results from representative experiments of at least three determinations are depicted in Figures 25A-25C. Binding was compared by calculation of 50% effective concentration (EC50) using the Forecast function in Excel. The EC50 value represents the concentration of antibody

15   required for half-maximal binding.

Anti-PSMA mAbs 10.3 (PSMA 10.3) and XG-006 were found to bind to 3T3-PSMA cells and not 3T3 cells (Figure 25A). Antibody (26nM) was added to cells, which were analyzed by flow cytometry. Binding to cell-surface PSMA using serial dilutions of anti-PSMA mAb-containing culture supernatants of XG-006, 4.304.1, XG-026 (PTA-4405 and

20   PTA-4406) and 4.49.1 also was demonstrated (Figure 25B). Binding to cell-surface PSMA using serial dilutions of purified anti-PSMA mAbs XG-006 and 10.3 is represented by Figure 25C.

Example 19: Cytotoxicity of toxin-labeled antibody

25   PSMA-3T3, LNCaP, and/or C4-2 cells (and control cell lines 3T3 and PC3 that do not express PSMA) were plated at 2,500 cells/100 μL/well in 96-well microplates (Falcon) and were incubated overnight at 37 °C in the presence of 5% CO_2. The media used for PSMA-3T3 (and 3T3) and LNCaP (and C4-2 and PC3) was DMEM or RMPI 1640, respectively, containing 2 mM L-glutamine, 10% FBS, and 1% penicillin-streptomycin. 50 ng (in 50 μL)

30   of Mab-Zap or Hum-ZAP (Advanced Targeting Systems, San Diego, CA) in medium was added in each well. Mab-Zap and Hum-Zap are goat anti-mouse IgG antibody or goat anti-human IgG antibody covalently linked to saporin, the most potent of the plant ribosome-

- 82 -

inactivating proteins (RIP) from the seeds of the plant *Saponaria officinalis*. Saporin induces
cell death by apoptosis (Bergamaschi, G., Perfetti, V., Tonon, L., Novella, A., Lucotti, C.,
Danova, M., Glennie, M.J., Merlini, G.,Cazzola, M. Saporin, a ribosome-inactivating protein
used to prepare immunotoxins, induces cell death via apoptosis. *Br J Haematol* 93, 789-94.
5   (1996)). The Mab-Zap did not bind to or internalize in cells in the absence of an appropriate
primary antibody.

Murine 3.9, 5.4, mJ591 (ATCC# HB-12126) and human 006, 4.40, 4.304 anti-PSMA
antibodies (and control IgG antibodies) were added into plates at different concentrations to
bring the total volume to 200 µL in triplicate. The plates were kept cold on ice for at least 30
10   min to maximize Map-Zap or Hum-Zap binding to PSMA antibodies before internalization.
The plates were incubated for 2 days and then the medium was changed and incubated for
another 2 days. After 4 days incubation, the medium was withdrawn and fresh medium
containing 10 % Alamar Blue (20 µL, Bioscience, Camarillo, CA) was added into each well
and incubated for 2 hrs. A CytoFlour plate reader was used to measure fluorescence in 96-
15   well plates at wavelengths of 530 nm excitation and 590 nm emission. Internalization of
toxin was mediated by anti-PSMA antibodies. The cell kill is illustrated in Figure 26 on C4-2
cells and in Figure 27 on PSMA-3T3 cells.

Human 4.304 anti-PSMA antibody was directly conjugated with saporin (Wrenn et
al., *Brain Res.* 740:175-184, 1996), and its cytotoxicity was demonstrated using a similar
20   protocol as described above (see Figure 28).

Example 20: Immunoreactivity

PSMA-3T3, LNCaP and C4-2 were used as PSMA expressing cell lines and 3T3 was
used as a control cell line not expressing PSMA. The cells were blocked with 10% goat
25   serum on ice to reduce non-specific binding in this assay.

A small amount (1-5 ng) of labeled mAb was added into a cell pellet of 10 million
cells and incubated at 0°C (on ice) with gentle mixing. After a 1 hour incubation, the cells
were collected by centrifugation and the supernatant containing unbound mAb was
transferred to a fresh cell pellet for an additional 1 hour incubation at 0°C. Both sets of cells
30   were centrifuged and washed twice with cold PBS. The cell pellets, supernatant and wash
fractions were counted for radioactivity. Immunoreactivity is defined as the amount of

radioactivity in the cell pellets divided by the total radioactivity in the cell pellets, supernatant and wash fractions. These data are shown below in Table 3.

Table 3. Immunoreactivity of In-111 radiolabeled antibody on PSMA expressing cells

Radiolabeled mAb	Immunoreactivity (%)	Cell line
In-111 4.304	92.6 (1.4)	PSMA-3T3 (3T3)
	92.6	PSMA-3T3
	91.4 (1.7)	PSMA-3T3 (3T3)
	89.1	LNCaP
	92.4	C4-2
Average=	91.6 ± 1.5	
In-111 4.40	87.7 (0.5)	PSMA-3T3 (3T3)
	86.8	PSMA-3T3
	89.4 (1.5)	PSMA-3T3 (3T3)
Average=	88.0 ± 1.3	
In-111 mJ591	58.5	PSMA-3T3
	54.9 (1.1)	PSMA-3T3 (3T3)
Average=	56.7 ± 2.5	
In-111 3.9	88	LNCaP
	87	C4-2
	89 (2)	PSMA-3T3 (3T3)
	95.3 (0.5)	PSMA-3T3 (3T3)
	88.6	PSMA-3T3
	84.8	C4-2
	89.3	PSMA-3T3
Average=	88.6 ± 3.2	

5

Antibodies 4.40, 4.304 and mJ591 were conjugated to the bifunctional chelate CHX-A"-DTPA and antibody 3.9 was conjugated to C-DOTA.

- 84 -

Example 21: Competitive binding assay to identify binding epitopes

     To identify whether a given group of mAbs recognize distinct or overlapping epitopes on PSMA, competition binding assays were performed with In-111 radiolabeled antibodies. 2×10^5 cells (100 μL) of PSMA-3T3 were plated into 96-well microplates, and antibodies 4.40, 4.304 and mJ591 (100 μL) at different concentrations (series dilution) were added. The cells were incubated at 0°C for 30 min. 20 μL of In-111 radiolabeled CHX-A''-DTPA antibody constructs were added into each well. After a 2 hour incubation on ice for competition binding, the cells were washed 5 times using cold PBS. The cells containing bound In-111 antibodies were recovered from microplates into test tubes and counted in a gamma counter.

     Results detailed in Figures 29 show that mJ591 blocked In-111 4.40 binding to PSMA-3T3 cells and did not block In-111 4.304. In addition, 4.40 and 4.304 did not block each other. Unmodified antibodies 4.304 and mJ591 were also used to compete with In-111 radiolabeled mJ591. Human 4.304 did not compete with In-111 mJ591 for binding to PSMA-3T3 (Figure 30).

Example 22: Binding affinity using Biacore 3000

     To determine the kinetics and affinity of the antibodies, the antibodies in crude supernatants, in purified form and in bifunctional chelate modified forms were analyzed using a Biacore 3000 instrument (Biacore Inc., Piscataway, NJ). Biacore 3000 is a fully automated surface plasmon resonance (SPR)-based biosensor system that is designed to provide real-time kinetic data from assay formats that require no tags or labeling of compounds for biomolecular interactions. It is ideal for screening crude supernatants.

     The streptavidin-coated sensor chips (SA chips, Biacore) were used to capture biotinylated anti-human IgG antibody (Sigma, St. Louis, MO). The entire sensor chip surface was conditioned with five injections of conditioning solution (1 M NaCl, 50 mM NaOH) and equilibrated with PBS buffer containing 0.005% polysorbate 20. Two to three thousand resonance units (RU) of biotinylated anti-human IgG antibody (Sigma) were immobilized onto the SA chip followed by an injection of regeneration buffer (glycine-HCl, pH 2.2). Antibodies in supernatants were diluted to 2 μg/mL in PBS buffer and captured onto one anti-human IgG flow cell, while isotype-matched control human antibody (Sigma) was similarly captured on a second flow cell. rsPSMA at different concentrations in PBS buffer was

- 85 -

flowed over the cells at 30 µL/min for 3 min in an "association phase" followed by a "dissociation phase" for 10 min. SPR was monitored and displayed as a function of time. For each antibody at one concentration, the chip was regenerated and equilibrated. An example of the analysis of antibody PRGX1-XG-006 in association phase and dissociation

5   phase at different concentrations of rsPSMA from 100 nM to 6.25 nM is shown in Figure 31. Thermodynamic and kinetic rate constants of binding were calculated using the Biacore Evaluation software. For example, the affinity of XG-006 antibodies in a supernatant to rsPSMA was determined to be 4.92×10^{-10} M with a K_a of 1.3×10^5 M^{-1} s^{-1} and a K_d of 6.4×10^{-5} s^{-1}. Selective data for several human PSMA antibodies in crude supernatant, purified form,

10 and modified with bifunctional chelate is listed in Table 4 for comparison.

Binding activity of In-111 radiolabeled antibodies was determined by Scatchard analysis of binding data obtained using PSMA-expressing cells (LNCaP, C4.2, PSMA-3T3 and parental 3T3 as a control). The experimental procedures and methods of data analysis have been described previously (Scheinberg, D.A. *et al. Leukemia* 3: 440-445 (1991).

15

Table 4: Kinetic rate constants of antibodies in crude supernatant, purified, bifunctional chelate modified forms along with KD determined using In-111 radiolabeled Scatchard analysis.

Antibodies	Ka (M^{-1},s^{-1})	Kd (s^{-1})	KD (M^{-1})	Avg KD
006 Supernatant	1.30E+05	6.40E-05	4.92E-10	4.92E-10
Purified 006-1	2.94E+05	1.37E-04	4.66E-10	
Purified 006-2	2.26E+05	1.27E-04	5.62E-10	5.14E-10
4.40 Supernatant	2.10E+05	1.25E-04	5.95E-10	5.95E-10
Purified 4.40-1	2.54E+05	1.52E-04	5.98E-10	
Purified 4.40-2	2.43E+05	2.37E-04	9.75E-10	7.87E-10
CHX-4.40-1	2.57E+05	1.60E-04	6.23E-10	
CHX-4.40-2	2.47E+05	1.55E-04	6.28E-10	6.25E-10
IN-111CHX-4.40-1			4.44E-09	
IN-111CHX-4.40-2			4.95E-09	4.70E-09
4.304 Supernatant	1.40E+05	1.25E-04	8.93E-10	8.93E-10
Purified 4.304-1	8.31E+04	1.20E-04	1.44E-09	
Purified 4.304-2	1.06E+05	6.33E-05	5.97E-10	1.02E-09
CHX-4.304-1	6.19E+04	1.21E-04	1.95E-09	
CHX-4.304-2	6.79E+04	1.49E-04	2.19E-09	2.07E-09
IN-111CHX-4.304-1			9.63E-09	
IN-111CHX-4.304-2			5.97E-09	7.80E-09
10.3 Supernatant	1.90E+05	3.63E-04	1.91E-09	1.91E-09
Purified 10.3-1	3.28E+05	6.32E-05	1.93E-10	
Purified 10.3-2	2.96E+05	6.43E-05	2.17E-10	2.05E-10

A comparison of the fully human antibodies 4.40.1, 4.49.1, 051 and 006 and the murine antibody 3.9 was performed by Biacore. For each antibody for comparison, response was normalized to 100 RU. The graph of time vs. response difference for these antibodies is given in Figure 32. The binding affinities for these antibodies were determined to be 6.1 , 6.7, 5.8, 4.8 and 13.7x10^{-10}M, respectively.

Example 23: Characterization of cell lines for *in vitro* and *in vivo* studies

Results from a Scatchard analysis using In-111 labeled anti-PSMA antibody 3.9 are represented in Figure 33. Transfected murine 3T3 cells express >1 million copies of PSMA per cell, LNCAP cells (androgen dependent human prostate cancer cell line) express 0.64 million copies, while C4-2 cells (androgen independent) express 0.25 million copies per cell. The affinity of 3.9 for cell surface PSMA is 6.4 nM for PSMA-3T3, 4.0 nM for LNCAP and 3.3 nM for C4-2 (4.6 nM is the average of these data).

A summary of the analyses of crude supernatants for the human anti-PSMA antibodies is given in Table 5 below.

Table 5: Characterization of anti-PSMA monoclonal antibodies

Supernatant	Ab Conc (µg/mL)		Binding to 3T3-PSMA (FACS)					Biacore studies		
	PGNX	Lysate EIA	PGNX FACS	AVG Max binding	AVG EC50	C4.2 FACS	Anti-PSMA Western	KD, M-1 (x 10^{-10})	Ka, M-1s-1 (x 10^5)	Kd, s-1 (x 10-5)
PRGX1-XG1-026	4.7	ND[1]	ND	148	2.4	ND	Conf.[2]	2.0	1.5	2.9
4.4.1	4.7	0.08	7	8	ND	5.2	Conf.	4.2	2.3	9.7
PRGX1-XG1-006	1.8	0.39	114	183	3.4	9.5	Conf.	4.8	1.3	6.4
PRGX1-XG1-051	3.5	0.48	83	202	2.0	9.9	Conf.	5.8	1.4	8.2
4.40.1	4.3	0.33	53	163	2.3	10.8	Conf.	6.1	2.1	12.5
4.49.1	2.6	0.36	362	162	0.9	16.2	Conf.	6.7	3.1	20.7
4.292.1	2.7	0.18	75	195	6.0	9.2	Conf.	6.8	1.2	8.5
4.304.1	4.1	0.39	92	184	9.1	8.4	Conf.	8.7	1.4	12.5
4.232.1	2.4	0.49	97	138	2.7	6.0	Linear[3]	9.4	1.5	13.8
4.153.1	5.9	0.29	279	182	5.3	14.8	Conf.	9.5	1.2	11.8
4.333.1	2.9	0.18	82	168	3.1	6.6	Conf.	11	0.7	8.5
PRGX1-XG1-077	3.9	0.45	392	227	6.0	12.4	Conf.	16	0.6	10.4
10.3	8.5	1.06	ND	ND	ND	ND	ND	19	1.9	36.4
pure 10.3		0.44	130	181	7.5	ND	Conf.	ND		
						4.7				
4.22.1	2.8	0.08	7	ND	ND	4.7	ND	20	1.7	33
4.248.1	3.5	0.37	7	ND	ND	4.1	Conf.	27	1.0	28
4.54.1	10	0.14	267	162	3.9	13.6	ND	30	1.9	56·
4.7.1	5	0.23	156	141	1.6	10.2	Conf.	32	1.7	56
4.78.1	5.3	0.00	205	118	1.0	7.9	Conf.	53	2.4	125
4.48.1	4.9	0.06	14	ND	ND	7.7	ND	62	0.9	59
4.209.1	3.5	0.22	60	ND	ND	6.7	ND	142	0.9	125
4.177.1	1.1	0.15	236	174	2.4	10.6	ND	155	0.6	93
4.152.1	3.4	0.38	81	85	4.0	7.5	ND	163	0.8	126
4.28.1	4.2	0.04	112	155	4.2	11.3	ND	167	1.2	192
4.16.1	5.3	0.00	8	ND	ND	7.8	ND	177	1.8	313
4.360.1	1.5	0.02	112	130	2.2	7.9	ND	197	1.0	201
4.288.1	15.4	0.02	67	141	4.1	6.5	ND	198	1.3	257
4.219.2	0.5	0.34	69	ND	ND	5.9	ND	ND		
PRGX1-XG1-069	6.5	ND	ND	71	7.9	ND	ND	No Binding		
Murine 3.9								13.7	0.7	9.7
Control								6.34	2.24	14.2

[1] ND=not determined

[2] conf.=conformational epitope

[3] linear=linear epitope

5

- 88 -

Example 24: Cytotoxicity of radiolabeled antibody

The *in vitro* cytotoxicity of Ac-225 labeled anti-PSMA antibody was determined using methodology similar to that used in Example 19. Prostate cancer cells (100 μL of C4-2, LNCaP, and PC3 cells at a concentration of 2 x 10^4 cells/mL) were placed into separate well of a 96 well microplate. After overnight incubation, the cells were treated with Ac-225 labeled human anti-PSMA 4.40 antibody at different concentrations for over 4 days. Cell cytotoxicity was quantified using Alamar Blue (Biosource International, Camarillo, CA).

Figure 34 shows a plot of cell survival vs. Ac-225 activity concentration. The EC50 for PSMA expressing cells (C4-2 and LNCaP) was < 2 nCi/mL. However, the EC50 was 420 nCi/mL for PC3 cells, which do not express PSMA on the cell surface. Therefore, the Ac-225 labeled human anti-PSMA 4.40 antibody shows > 200-fold selectivity in killing PSMA expressing prostate cancer cells (C4-2 and LNCaP) vs. control cells (PC3).

Example 25: *In Vivo* Radioimmunotherapy with Lu-177 Labeled Antibodies

Athymic nude mice from the National Cancer Institute were implanted subcutaneously with 2 x 10^6 PSMA-3T3 cells. After measurable tumors appeared at day 7 post implantation, the mice were treated by injection with either a single 250 μCi dose human anti-PSMA antibody 4.40 or 4.304 labeled with Lu-177 (University of Missouri Research Reactor), or were injected with buffer only as control. The tumor size of individual animals was measured using an electronic caliper. Figure 35 shows a plot of the median tumor size in each group over time. Tumor growths were substantially reduced in Lu-177 antibody treated groups compared to the control group.

Example 26: Immunization with rsPSMA dimer preparations

Immunization

BALB/c mice were immunized by subcutaneous injection at days 0, 7, 14, and 42 with either 5 μg clinical rsPSMA lot # 4019-C001 (75 % dimer/25 % monomer) or 5 μg rsPSMA batch # TD045-003 run 1/peak 2 (100 % monomer) and adjuvanted with 50 μg alhydrogel per dose. Serum was drawn 10 days after the fourth immunization and analyzed by enzyme-linked immunoassay (EIA) and flow cytometry.

EIA

rsPSMA lot # 4019-C001 or rsPSMA batch # TD045-003 run 1/peak 2 was passively adsorbed to 96-well microtiter plates. Remaining binding sites on the plate were blocked with a PBS/Casein/Tween 20 buffer. Serially diluted mouse serum or controls were added

5 and bound antibody was detected using a goat anti-mouse IgG antibody conjugated to alkaline phosphatase. The EIA was developed with the substrate pNPP which produces a color change that is directly proportional to the amount of anti-PSMA antibody bound. Absorbance was read at 405 nm with a correction of 620 nm. Antibody titer was defined as the highest dilution of mouse serum yielding a blank corrected absorbance of 0.1. Immune

10 mouse serum with a known anti-PSMA titer or normal mouse serum with no anti-PSMA reactivity was used as controls.

Flow Cytometry Analysis

PSMA-3T3 cells were incubated with 200 µL of immune serum at a dilution of 1/50

15 in PBS with 0.1 % sodium azide on ice for 30 minutes. Immune mouse serum with known anti-PSMA titer or normal mouse serum with no anti-PSMA reactivity was used as controls. The cells were washed twice with PBS with 0.1 % sodium azide and incubated for 30 minutes on ice with FITC-conjugated goat anti-mouse IgG. Cells were washed once, resuspended in PBS with 0.1 % sodium azide and subjected to flow cytometric analysis on

20 FACScaliber (Becton Dickinson).

Results

5/5 mice immunized with rsPSMA lot # 4019-C001 showed an anti-PSMA antibody response by EIA. Antibody titer was similar for assay plates coated with rsPSMA lot # 4019-

25 C001 (75 % dimer/25 % monomer) and assay plates coated with rsPSMA batch # TD045-003 run 1/peak 2 (100 % monomer). Median response for the group was 1/6400.

4/5 mice immunized with rsPSMA batch # TD045-003 run 1/peak 2 showed an anti-PSMA antibody response by EIA. One mouse was negative. Antibody titer was similar for assay plates coated with rsPSMA lot # 4019-C001 (75 % dimer/25 % monomer) and assay

30 plates coated with rsPSMA batch # TD045-003 run 1/peak 2 (100 % monomer). Median response for the group was 1/6400.

The results of the EIA analysis are provided in Table 6.

Table 6: Specificity of the anti-PSMA antibody response in mice vaccinated 4 times with rsPSMA 5 µg/dose and 50 µg/dose Alhydrogel

Mouse ID #	Immunogen	EIA Titer vs. Lot 4019-C001	EIA Titer vs. Batch TD045-003 run1/peak 2	Median RFI vs. PSMA-3T3 cells
ABIM151	4019-C001 Dimer	1/3200	1/3200	84
ABIM152	4019-C001 Dimer	1/3200	1/3200	41
ABIM153	4019-C001 Dimer	1/25600	1/25600	76
ABIM154	4019-C001 Dimer	1/12800	1/12800	63
ABIM155	4019-C001 Dimer	1/6400	1/6400	74
ABIM156	Monomer	1/1600	1/1600	5
ABIM157	Monomer	1/6400	1/12800	8
ABIM158	Monomer	0	0	6
ABIM159	Monomer	1/6400	1/6400	6
ABIM160	Monomer	1/6400	1/6400	12

5

As shown in Fig. 36, anti-PSMA antibody in the serum of mice immunized with a dimer preparation of rsPSMA (lot # 4019-C001) showed strong binding to PSMA-3T3 cells. Anti-PSMA antibody in the serum of mice immunized with a 100% monomer preparation of rsPSMA (batch # TD045-003 run 1/peak 2) showed no binding to PSMA-3T3 cells.

10

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose and variations can be made by those skilled in the art without departing from the spirit and scope of the invention which is defined

15 by the following claims.

The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.

Claims

1. An isolated antibody or an antigen-binding fragment thereof which specifically binds to an epitope on prostate specific membrane antigen (PSMA), wherein the antibody or the antigen-binding fragment thereof competitively inhibits the specific binding of a second antibody to its target epitope on PSMA, wherein the second antibody is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising:

  (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

  (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

2. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

  (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and

  (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.

3. The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

  (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and

  (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9.

- 92 -

4.   The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 4, and

        (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 10.

5.   The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 5, and

        (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 11.

6.   The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 6, and

        (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 12.

7.   The isolated antibody or antigen-binding fragment of claim 1, wherein the second antibody comprises:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 7, and

        (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 13.

8.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA

`7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix

5   4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

9.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group

10   consisting of antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

(b) a light chain encoded by a nucleic acid molecule comprising the light chain coding

15   region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13,
and antigen-binding fragments thereof.

10.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second

20   antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 2, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 8.

25

11.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 3, and

30   (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 9.

12.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 4, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 10.

12.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 5, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 11.

13.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 6, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 12.

14.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 7, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 13.

15.   An isolated antibody which specifically binds to an extracellular domain of prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 9.

16.   The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

5   17.   The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

18.   The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

10

19.   The isolated antibody of claim 15, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

20.   An antigen-binding fragment of the isolated antibody of claim 9, comprising:

15   (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and
              (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of

20   nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

21.   An antigen-binding fragment of the isolated antibody of claim 20, comprising:
              (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 14, and

25   (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 16.

22.   An antigen-binding fragment of the isolated antibody of claim 20, comprising:
              (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the

30   coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 18, and
              (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 20.

23.   An antigen-binding fragment of the isolated antibody of claim 20, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 22, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 24.

24.   An antigen-binding fragment of the isolated antibody of claim 20, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 26, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 28.

25.   An antigen-binding fragment of the isolated antibody of claim 20, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 30, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 32.

26.   The antigen-binding fragment of the isolated antibody of claim 9, comprising:

(a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and

(b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

27.   An antigen-binding fragment of the isolated antibody of claim 26, comprising:

(a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 15, and

(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 17.

28.   An antigen-binding fragment of the isolated antibody of claim 26, comprising:

(a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 19, and

(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 21.

29.   An antigen-binding fragment of the isolated antibody of claim 26, comprising:

(a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 23, and

(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 25.

30.   An antigen-binding fragment of the isolated antibody of claim 26, comprising:

(a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 27, and

(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 29.

31.   An antigen-binding fragment of the isolated antibody of claim 26, comprising:

(a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 31, and

(b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 33.

32. An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 20 or claim 26.

33.   The isolated antigen-binding fragment of claim 32, wherein the CDR is CDR3.

34.   An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 1-33.

35.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 2.

5   36.   An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 8.

37.   An expression vector comprising an isolated nucleic acid molecule encoding the

10   heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 2 and 8.

38.   An expression vector comprising an isolated nucleic acid molecule encoding the

15   heavy chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 3.

39.   An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding

20   region or regions of the nucleotide sequence set forth as SEQ ID NO: 9.

40.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-026 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID

25   NOs: 3 and 9.

41.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 4.

30

42.   An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 10.

5   43.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-051 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 4 and 10.

10   44.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 5.

45.   An expression vector comprising an isolated nucleic acid molecule encoding the light

15   chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 11.

46.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-069 encoded by the nucleic acid molecules

20   comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 5 and 11.

47.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the

25   coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 6.

48.   An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 12.

30

49.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-077 encoded by the nucleic acid molecules

- 100 -

comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 6 and 12.

50.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 7.

51.   An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 13.

52.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 7 and 13.

53.   A host cell transformed or transfected by the expression vector of claim 34.

54.   A plasmid which produces the antibody or antigen binding fragments of any one of claims 1-33

55.   The plasmid of claim 54, wherein the plasmid is selected from the group consisting of: AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2), AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8), AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3), AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9), AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4), AB-PG1-XG1-051 Light Chain (SEQ ID NO: 10), AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5), AB-PG1-XG1-069 Light Chain (SEQ ID NO: 11), AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6), AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12), PSMA 10.3 Heavy Chain (SEQ ID NO: 7), and PSMA 10.3 Kappa (SEQ ID NO: 13).

56.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

5   57.   The isolated antibody or antigen-binding fragment thereof of claim 56 , wherein the cell is a tumor cell.

58.   The isolated antibody or antigen-binding fragment thereof of claim 57, wherein the tumor cell is a prostate tumor cell.

10

59.   The isolated antibody or antigen-binding fragment thereof of claim 58, wherein the tumor cell is a LNCaP cell.

60.   The isolated antibody or antigen-binding fragment thereof according to claim 1,
15   wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA.

61.   The isolated antibody or antigen-binding fragment thereof of claim 60 wherein cytolysis of cells expressing PSMA is mediated by effector cells.

20

62.   The isolated antibody or antigen-binding fragment thereof of claim 60 wherein cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

63.   The isolated antibody or antigen-binding fragment thereof according to claim 1,
25   wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA.

64.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind
30   to the epitope on PSMA.

65.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1,

5   IgA2, IgAsec, IgD or IgE.

66.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a recombinant antibody.

10   67.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a polyclonal antibody.

68.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a monoclonal antibody.

15

69.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a humanized antibody.

70.   The isolated antibody or antigen-binding fragment thereof according to claim 69,

20   wherein said antibody is a monoclonal antibody.

71.   The isolated antibody or antigen-binding fragment thereof according to claim 69, wherein said antibody is a polyclonal antibody.

25   72.   The isolated antibody or antigen-binding fragment thereof according to claim 69, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

73.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a chimeric antibody.

30

74.   The isolated antibody or antigen-binding fragment thereof according to claim 73, wherein said antibody is a monoclonal antibody.

75.   The isolated antibody or antigen-binding fragment thereof according to claim 73, wherein said antibody is a polyclonal antibody.

5   76.   The isolated antibody or antigen-binding fragment thereof according to claim 73, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

77.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a human antibody.

10

78.   The isolated antibody or antigen-binding fragment thereof according to claim 77, wherein said antibody is a monoclonal antibody.

79.   The isolated antibody or antigen-binding fragment thereof according to claim 77,
15   wherein said antibody is a polyclonal antibody.

80.   The isolated antibody or antigen-binding fragment thereof according to claim 77, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

20   81.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a bispecific or multispecific antibody.

82.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab
25   fragment, a F(ab')₂ fragment, and a Fv fragment CDR3.

83.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258),
30   PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),

Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),

Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),

Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),

Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),

5   Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),

Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),

Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

84.   The isolated antibody or antigen-binding fragment thereof according to claim 1,

10   wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

85.   The isolated monoclonal antibody or antigen-binding fragment thereof according to

claim 1, wherein the antibody or antigen-binding fragment thereof is internalized into a cell

with the prostate specific membrane antigen.

15

86.   A hybridoma cell line that produces an antibody selected from the group consisting of

PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA

10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3,

Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix

20   4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3,

Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3,

Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

87.   The hybridoma cell line of claim 86, wherein the hybridoma cell line is selected from

25   the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA

3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293),

PSMA 10.3 (PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA

A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix

4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1

30   (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2

(PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3

(PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1

(PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3
(PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1
(PTA-4652), and Abgenix 4.152.1(PTA-4653).

5   88.   A composition comprising:
            an antibody or antigen-binding fragment thereof according to any one of claims 1-33
     and a pharmaceutically acceptable carrier, excipient, or stabilizer.

     89.   The composition of claim 88, further comprising an antitumor agent, an
10   immunostimulatory agent, an immunomodulator, or a combination thereof.

     90.   The composition of claim 89, wherein the antitumor agent is a cytotoxic agent, an
     agent that acts on tumor neovasculature, or a combination thereof.

15   91.   The composition of claim 89, wherein the immunomodulator is α-interferon,
     γ-interferon, tumor necrosis factor-α or a combination thereof.

     92.   The composition of claim 89, wherein the immunostimulatory agent is interleukin-2,
     immunostimulatory oligonucleotides, or a combination thereof.
20

     93.   A composition comprising:
            a combination of two or more antibodies or antigen-binding fragments thereof
     according to any one of claims 1-33 and a pharmaceutically acceptable carrier, excipient, or
     stabilizer.
25

     94.   The composition of claim 93, further comprising an antitumor agent, an
     immunostimulatory agent, an immunomodulator, or a combination thereof.

     95.   The composition of claim 94, wherein the antitumor agent is a cytotoxic agent, an
30   agent that acts on tumor neovasculature, or a combination thereof.

96.   The composition of claim 94, wherein the immunomodulator is α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof.

97.   The composition of claim 94, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

98.   The isolated antibody or antigen-binding fragment thereof of claim 1, bound to a label.

99.   The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 98, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

100.   A composition comprising:
        an antibody or antigen-binding fragment thereof according to claim 98 and
a pharmaceutically acceptable carrier, excipient, or stabilizer.

101.   The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or rsPSMA with a binding affinity of about 1×10^{-9}M or less.

102.   The isolated antibody or antigen-binding fragment thereof of claim 101, wherein the binding affinity is about 1×10^{-10}M or less.

103.   The isolated antibody or antigen-binding fragment thereof of claim 102, wherein the binding affinity is about 1×10^{-11}M or less.

104.   The isolated antibody or antigen-binding fragment thereof of claim 101, wherein the binding affinity is less than about 5×10^{-10}M.

105.   The isolated antibody or antigen-binding fragment thereof of claim 1, bound to at least one therapeutic moiety .

106.   The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC$_{50}$s of less than about 1 X 10^{-10}M.

107.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the IC$_{50}$s is less than about 1 X 10^{-11}M.

108.   The isolated antibody or antigen-binding fragment thereof of claim 107, wherein the IC$_{50}$s is less than about 1 X 10^{-12}M.

109.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the IC$_{50}$s is less than about 1.5 X 10^{-11}M.

110.   The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is a drug.

111.   The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is a replication selective virus.

112.   The isolated antibody or antigen-binding fragment thereof of claim 110, wherein the drug is a cytotoxic drug.

113.   The isolated antibody or antigen-binding fragment thereof of claim 112, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

114.   The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is a toxin or a fragment thereof.

115.   The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is an enzyme or a fragment thereof.

116.   The isolated antibody or antigen-binding fragment thereof of claim 105, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

117.   The isolated antibody or antigen-binding fragment thereof of claim 116, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

118.   A composition comprising:
        the antibody or antigen-binding fragment of claim 105 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

119.   The isolated antibody or antigen-binding fragment thereof of 1, bound to a radioisotope.

120.   The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope emits α radiations.

121.   The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope emits β radiations.

122.   The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope emits γ radiations.

123.   The isolated antibody or antigen-binding fragment thereof according to claim 119, wherein the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

124.   A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 119 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

5   125.   A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising: the isolated labeled antibody or antigen-binding fragment thereof of claim 98, and one or more compounds for detecting the label.

126.   A kit according to claim 125, wherein the label is selected from the group consisting

10   of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

127.   The isolated antibody or antigen-binding fragment thereof of any of claims 1, 98, 105 or 119 packaged in lyophilized form.

15

128.   The isolated antibody or antigen-binding fragment thereof of any of claims 1, 98, 105 or 119 packaged in an aqueous medium.

129.   An isolated antibody or an antigen-binding fragment thereof which specifically binds

20   to an epitope on prostate specific membrane antigen (PSMA) defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix

25   4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences

30   set forth as SEQ ID NOs: 2-7, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

5   130.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3,

10   Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

15   131.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising:
          (a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of

20   nucleotide sequences set forth as SEQ ID NOs: 2-7, and
          (b) a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13,
          and antigen-binding fragments thereof.

25

132.   An isolated antibody which specifically binds to an epitope on prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 131.

30

133.   The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

134.   The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

5   135.   The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

136.   The isolated antibody of claim 132, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

10

137.   An antigen-binding fragment of the isolated antibody of claim 131, comprising:
        (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and
15   (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

138.   The antigen-binding fragment of the isolated antibody of claim 131, comprising:
20   (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and
        (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

25

139.   An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 137 or claim 138.

140.   The isolated antigen-binding fragment of claim 139, wherein the CDR is CDR3.

30

141.   An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 129-137.

142. A host cell transformed or transfected by the expression vector of claim 141.

143. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

144. The isolated antibody or antigen-binding fragment thereof of claim 143, wherein the cell is a tumor cell.

145. The isolated antibody or antigen-binding fragment thereof of claim 144, wherein the tumor cell is a prostate tumor cell.

146. The isolated antibody or antigen-binding fragment thereof of claim 145, wherein the tumor cell is a LNCaP cell.

147. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA.

148. The isolated antibody or antigen-binding fragment thereof of claim 147 wherein cytolysis of cells expressing PSMA is mediated by effector cells.

149. The isolated antibody or antigen-binding fragment thereof of claim 147 wherein cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

150. The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA.

151.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind to the epitope on PSMA.

5   152.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgA or IgE.

10

153.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a recombinant antibody.

154.   The isolated antibody or antigen-binding fragment thereof according to claim 129,
15   wherein said antibody is a polyclonal antibody.

155.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a monoclonal antibody.

20   156.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a humanized antibody.

157.   The isolated antibody or antigen-binding fragment thereof according to claim 156, wherein said antibody is a monoclonal antibody.

25

158.   The isolated antibody or antigen-binding fragment thereof according to claim 156, wherein said antibody is a polyclonal antibody.

159.   The isolated antibody or antigen-binding fragment thereof according to claim 156,
30   wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

160.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a chimeric antibody.

161.   The isolated antibody or antigen-binding fragment thereof according to claim 160,
5   wherein said antibody is a monoclonal antibody.

162.   The isolated antibody or antigen-binding fragment thereof according to claim 160, wherein said antibody is a polyclonal antibody.

10   163.   The isolated antibody or antigen-binding fragment thereof according to claim 160, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

164.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a human antibody.
15

165.   The isolated antibody or antigen-binding fragment thereof according to claim 164, wherein said antibody is a monoclonal antibody.

166.   The isolated antibody or antigen-binding fragment thereof according to claim 164,
20   wherein said antibody is a polyclonal antibody.

167.   The isolated antibody or antigen-binding fragment thereof according to claim 164, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

25   168.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein said antibody is a bispecific or multispecific antibody.

169.   The isolated antibody or antigen-binding fragment thereof according to claim 129, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab
30   fragment, a F(ab')2 fragment, and a Fv fragment CDR3.

170.   The isolated antibody or antigen-binding fragment thereof according to claim 129,
wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected
from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258),
PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-
3293), PSMA 10.3 (PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904),
PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),
Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),
Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),
Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),
Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),
Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),
Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),
Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

171.   The isolated antibody or antigen-binding fragment thereof according to claim 129,
wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

172.   The isolated monoclonal antibody or antigen-binding fragment thereof according to
claim 129, wherein the antibody or antigen-binding fragment thereof is internalized into a cell
with the prostate specific membrane antigen.

173.   A hybridoma cell line that produces an antibody selected from the group consisting of
PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA
10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3,
Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix
4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3,
Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3,
Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

174.   The hybridoma cell line of claim 173, wherein the hybridoma cell line is selected
from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258),
PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-

- 116 -

3293), PSMA 10.3 (PTA-3247) , PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904),

PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),

Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),

Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),

Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),

Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),

Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),

Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),

Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

175.   A composition comprising:

an antibody or antigen-binding fragment thereof according to any one of claims 129-140 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

176.   The composition of claim 175, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

177.   The composition of claim 176, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

178.   The composition of claim 176, wherein the immunomodulator is α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof.

179.   The composition of claim 176, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

180.   A composition comprising:

a combination of two or more antibodies or antigen-binding fragments thereof according to any one of claims 129-140 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

181.   The composition of claim 180, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

182.   The composition of claim 181, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

183.   The composition of claim 181, wherein the immunomodulator is α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof.

184.   The composition of claim 181, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

185.   The isolated antibody or antigen-binding fragment thereof of claim 129, bound to a label.

186.   The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 185, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

187.   A composition comprising:
        an antibody or antigen-binding fragment thereof according to claim 185 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

188.   The isolated antibody or antigen-binding fragment thereof of claim 129, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or rsPSMA with a binding affinity of about 1×10^{-9}M or less.

189.   The isolated antibody or antigen-binding fragment thereof of claim 188, wherein the binding affinity is about 1×10^{-10}M or less.

190.   The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is about 1×10^{-11}M or less.

191.   The isolated antibody or antigen-binding fragment thereof of claim 188, wherein the binding affinity is less than about 5×10^{-10}M.

192.   The isolated antibody or antigen-binding fragment thereof of claim 129, bound to at least one therapeutic moiety .

193.   The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC_{50}s of less than about 1×10^{-10}M.

194.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the IC_{50}s is less than about 1×10^{-11}M.

195.   The isolated antibody or antigen-binding fragment thereof of claim 194, wherein the IC_{50}s is less than about 1×10^{-12}M.

196.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the IC_{50}s is less than about 1.5×10^{-11}M.

197.   The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is a drug.

198   The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is a replication-selective virus.

199.   The isolated antibody or antigen-binding fragment thereof of claim 197, wherein the drug is a cytotoxic drug.

200.   The isolated antibody or antigen-binding fragment thereof of claim 199, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cisplatinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

201.   The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is a toxin or a fragment thereof.

202.   The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is an enzyme or a fragment thereof.

203.   The isolated antibody or antigen-binding fragment thereof of claim 192, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

204.   The isolated antibody or antigen-binding fragment thereof of claim 203, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

205.   A composition comprising:
        the antibody or antigen-binding fragment of claim 192 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

206.   The isolated antibody or antigen-binding fragment thereof of 129, bound to a radioisotope.

207.   The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope emits α radiations.

208.   The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope emits β radiations.

- 120 -

209. The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope emits γ radiations.

210. The isolated antibody or antigen-binding fragment thereof according to claim 206, wherein the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

211. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 206 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

212. A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising:
        the isolated labeled antibody or antigen-binding fragment thereof of claim 185, and
one or more compounds for detecting the label.

213. A kit according to claim 212, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

214. The isolated antibody or antigen-binding fragment thereof of any of claims 129, 185, 192 or 206 packaged in lyophilized form.

215. The isolated antibody or antigen-binding fragment thereof of any of claims 129, 185, 192 or 206 packaged in an aqueous medium.

216. A method for detecting the presence of PSMA, or a cell expressing PSMA, in a sample comprising:
        contacting the sample with an antibody or antigen-binding fragment thereof according to claim 1 or 129 for a time sufficient to allow the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and
        detecting the PSMA-antibody complex or PSMA-antigen-binding fragment complex, wherein the presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell expressing PSMA.

217.   A method for diagnosing a PSMA-mediated disease in a subject comprising:

administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an isolated amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129,

allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

detecting the formation of the PSMA-antibody complex or PSMA-antigen-binding fragment complex to the target epitope,

wherein the presence of a complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the presence of a PSMA-mediated disease.

218.   The method of claim 217 wherein the PSMA-mediated disease is prostate cancer.

219.   The method of claim 217 wherein the PSMA-mediated disease is a non-prostate cancer.

220.   The method of claim 219 wherein the non-prostate cancer is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

221.   The method of claim 216 or claim 217 wherein the antibody or antigen-binding fragment thereof is labeled.

222.   The method of claim 216 or claim 217 wherein a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

223.   A method for assessing the prognosis of a subject with a PSMA-mediated disease:

administering to a subject suspected of having or previously diagnosed with PSMA-

mediated disease an effective amount of an antibody or antigen-binding fragment thereof

5   according to claim 1 or 129,

allowing the formation of a complex between the antibody or antigen-binding

fragment thereof and PSMA,

detecting the formation of the complex to the target epitope,

wherein the amount of the complex in the subject suspected of having or previously

10   diagnosed with PSMA-mediated disease is indicative of the prognosis.

224.   A method for assessing the effectiveness of a treatment of a subject with a PSMA-

mediated disease:

administering to a subject suspected treated for a PSMA-mediated disease an effective

15   amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129,

allowing the formation of a complex between the antibody or antigen-binding

fragment thereof and PSMA,

detecting the formation of the complex to the target epitope,

wherein the amount of the complex in the subject suspected of having or previously

20   diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

225.   The method of claim 223 or 224 wherein the PSMA-mediated disease is prostate

cancer.

25   226.   The method of claim 223 or 224 wherein the PSMA-mediated disease is a non-

prostate cancer.

227.   The method of claim E4 wherein the non-prostate cancer is selected from the group

consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer

30   including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma;

kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue

sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma

- 123 -

multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

228.   The method of claim 223 or claim 224 wherein the antibody or antigen-binding fragment thereof is labeled.

229.   The method of claim 223 or claim 224 wherein a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

230.   A method for inhibiting the growth of a cell expressing PSMA comprising:
        contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 which specifically binds to an extracellular domain of PSMA effective to inhibit the growth of the cell expressing PSMA.

231.   A method for inducing cytolysis of a cell expressing PSMA comprising:
        contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 which specifically binds to an extracellular domain of PSMA effective to induce cytolysis of the cell expressing PSMA.

232.   The method of claim 231 wherein the cytolysis occurs in the presence of an effector cell.

233.   The method of claim 231 wherein the cytolysis is complement mediated.

234.   A method for treating or preventing a PSMA-mediated disease comprising: administering to a subject having a PSMA-mediated disease or at risk of having a PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 129 to treat or prevent the PSMA-mediated disease.

235.   The method of claim 234 wherein the PSMA-mediated disease is a cancer.

- 124 -

236. The method for claim 235 wherein the cancer is a prostate cancer.

237. The method for claim 235 wherein the cancer is a non-prostate cancer.

5   238. A method for treating or preventing a PSMA-mediated disease comprising:
        administering to a subject having a PSMA-mediated disease or at risk of having a
    PSMA-mediated disease an amount of an antibody or antigen-binding fragment thereof
    according to claim 1 or 129 effective to treat or prevent the PSMA-mediated disease.

10 239. The method of claim 238, wherein the PSMA-mediated disease is a cancer.

240. The method of claim 239, wherein the cancer is prostate cancer.

241. The method of claim 239 wherein the cancer is a non-prostate cancer.

15

242. The method of claim 241, wherein the non-prostate cancer is selected from the group
    consisting of: bladder cancer including transitional cell carcinoma; pancreatic cancer
    including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma;
    kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue
20 sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma
    multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular
    cancer including testicular embryonal carcinoma; and melanoma including malignant
    melanoma.

25 243. The method of claim 238, further comprising administering another therapeutic agent
    to treat or prevent the PSMA-mediated disease at any time before, during or after the
    administration of the antibody or antigen-binding fragment thereof.

244. The method of claim 243, wherein the therapeutic agent is a vaccine.

30

245. The method of claim 244, wherein the vaccine immunizes the subject against PSMA.

246. The method of claim 243, wherein the antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety.

247. The method of claim 246, wherein the therapeutic moiety is a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof.

248. The method of claim 247, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

249. The method of claim 246, wherein the antibody or antigen-binding fragment thereof is bound to a radioisotope, wherein the radiations emitted by the radioisotope is selected from the group consisting of α, β and γ radiations.

250. The method of claim 249, wherein the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

251. A method for inhibiting folate hydrolase activity comprising:
    contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits the folate hydrolase activity.

252. The method of claim 251 wherein the folate hydrolase polypeptide is isolated.

253. The method of claim 251 wherein the folate hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

254.   The method of claim 251 wherein the folate hydrolase polypeptide is contained in an organism.

255.   The method of claim 254 wherein the organism is an animal.

256.   The method of claim 255 wherein the animal is a mammal.

257.   A method for enhancing folate hydrolase activity comprising:

contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances the folate hydrolase activity.

258.   The method of claim 257 wherein the folate hydrolase polypeptide is isolated.

259.   The method of claim 257 wherein the folate hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

260.   The method of claim 257 wherein the folate hydrolase polypeptide is contained in an organism.

261.   The method of claim 260 wherein the organism is an animal.

262.   The method of claim 261 wherein the animal is a mammal.

263.   A method for inhibiting N-acetylated α-linked acidic dipeptidase (NAALADase) activity comprising:

contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits NAALADase activity.

264.   The method for claim 263 wherein the NAALADase polypeptide is isolated.

265.   The method for claim 263 wherein the NAALADase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

266.   The method for claim 263 wherein the NAALADase polypeptide is contained in an organism.

267.   The method for claim 266 wherein the organism is an animal.

268.   The method for claim 267 wherein the animal is a mammal.

269.   A method for enhancing N-acetylated α-linked acidic dipeptidase (NAALADase) activity comprising:

        contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances NAALADase activity.

270.   The method for claim 269 wherein the NAALADase polypeptide is isolated.

271.   The method for claim 269 wherein the NAALADase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

272.   The method for claim 269 wherein the NAALADase polypeptide is contained in an organism.

273.   The method for claim 272 wherein the organism is an animal.

274.   . The method for claim 273 wherein the animal is a mammal.

275.   A method for inhibiting dipeptidyl dipeptidase IV activity comprising:

contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits dipeptidyl dipeptidase IV activity.

276.   The method for claim 275 wherein the dipeptidyl dipeptidase IV polypeptide is isolated.

277.   The method for claim 275 wherein the dipeptidyl dipeptidase IV polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

278.   The method for claim 275 wherein the dipeptidyl dipeptidase IV polypeptide is contained in an organism.

279.   The method for claim 278 wherein the organism is an animal.

280.   The method for claim 279 wherein the animal is a mammal.

281.   A method for inhibiting dipeptidyl dipeptidase IV activity comprising:

contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits dipeptidyl dipeptidase IV activity.

282.   The method for claim 281 wherein the dipeptidyl dipeptidase IV polypeptide is isolated.

283.   The method for claim 281 wherein the dipeptidyl dipeptidase IV polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

284.   The method for claim 281 wherein the dipeptidyl dipeptidase IV polypeptide is contained in an organism.

5   285.   The method for claim 284 wherein the organism is an animal.

286.   The method for claim 285 wherein the animal is a mammal.

287.   A method for inhibiting γ–glutamyl hydrolase activity comprising:

10   contacting a γ–glutamyl hydrolase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ–glutamyl hydrolase activity.

15   288.   The method for claim 287 wherein the γ–glutamyl hydrolase polypeptide is isolated.

289.   The method for claim 287 wherein the γ–glutamyl hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

20
290.   The method for claim 287 wherein the γ–glutamyl hydrolase polypeptide is contained in an organism.

291.   The method for claim 290 wherein the organism is an animal.

25
292.   The method for claim 291 wherein the animal is a mammal.

293.   A method for inhibiting γ–glutamyl hydrolase activity comprising:

contacting a γ–glutamyl hydrolase polypeptide with an amount of an isolated antibody

30   or antigen-binding fragment thereof according to claim 1 or claim 129 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ–glutamyl hydrolase activity.

294.   The method for claim 293 wherein the γ–glutamyl hydrolase polypeptide is isolated.

295.   The method for claim 293 wherein the γ–glutamyl hydrolase polypeptide is contained
in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a
tissue homogenate.

296.   The method for claim 293 wherein the γ–glutamyl hydrolase polypeptide is contained
in an organism.

297.   The method for claim 296 wherein the organism is an animal.

298.   The method for claim 297 wherein the animal is a mammal.

299.   A method of specific delivery of at least one therapeutic agent to PSMA-expressing
cells, comprising:
        administering an effective amount of an antibody or antigen-binding fragment thereof
according to claim 1 or 129 conjugated to the at least one therapeutic agent.

300.   The method of claim 299, wherein the therapeutic agent is a nucleic acid molecule.

301.   The method of claim 299, wherein the therapeutic agent is an antitumor drug.

302.   The method of claim 301, wherein the antitumor drug is selected from the group
consisting of: a cytotoxic drug, a drug which acts on the tumor neovasculature and
combinations thereof.

303.   The method of claim 302, wherein the cytotoxic drug is selected from the group
consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan,
chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-
fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel,
dolastatin 10, auristatin E and auristatin PHE.

304.   The method of claim 299, wherein the therapeutic moiety is a toxin or a fragment
thereof.

5   305.   The method of claim 299, wherein the therapeutic moiety is an enzyme or a fragment
thereof.

306.   The method of claim 299, wherein the therapeutic moiety is a replication-selective
virus.

10

307.   The method of claim 299, wherein the therapeutic moiety is an immunostimulatory or
immunomodulating agent.

308.   The method of claim 307, wherein the immunostimulatory or immunomodulating
15   agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

309.   An isolated antibody or antigen-binding fragment thereof that selectively binds a
PSMA protein multimer.

20   310.   The isolated antibody or antigen-binding fragment thereof of claim 309, wherein the
PSMA protein multimer is a dimer.

311.   The isolated antibody or antigen-binding fragment thereof of claim 310, wherein at
least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA
25   (rsPSMA) polypeptide.

312.   The isolated antibody or antigen-binding fragment thereof of claim 311, wherein the
rsPSMA polypeptide consists essentially of amino acids 44-750 of SEQ ID NO:1.

30   313.   An isolated antibody or antigen-binding fragment thereof that selectively binds a
PSMA protein multimer, wherein the isolated antibody inhibits at least one enzymatic
activity of the PSMA protein multimer.

314. The isolated antibody or antigen-binding fragment thereof of claim 313, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

315. The isolated antibody or antigen-binding fragment thereof of claim 313, wherein the enzymatic activity is in the extracellular domain of the PSMA molecule.

316. The isolated antibody or antigen-binding fragment thereof of claim 313, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

317. An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody enhances at least one enzymatic activity of the PSMA protein multimer.

318. The isolated antibody or antigen-binding fragment thereof of claim 317, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

319. The isolated antibody or antigen-binding fragment thereof of claim 317, wherein the enzymatic activity is in the extracellular domain of the PSMA molecule.

320. The isolated antibody or antigen-binding fragment thereof of claim 317, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

321. A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 309 – 320, and an immunostimulatory oligonucleotide.

322.   A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 309 – 320, and a cytokine.

323.   The composition of claim 322, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

324.   The composition of any of claims 321 – 323, further comprising a pharmaceutically-acceptable carrier.

325.   A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the isolated antibody or composition of any of claims 309-324.

326.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and inhibits at least one enzymatic activity of PSMA.

327.   The isolated antibody or antigen-binding fragment thereof of claim 326, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

328.   The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ-glutamyl hydrolase.

329.   The isolated antibody or antigen-binding fragment thereof of claim 328, wherein the hydrolase is folate hydrolase and the antibody is mAb 5.4 or mAb 3.9.

330.   The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

331.   The isolated antibody or antigen-binding fragment thereof of claim 326, wherein the enzyme is active in cancer cells and has lesser activity in normal cells than in cancer cells or no activity in normal cells.

332.   The isolated antibody or antigen-binding fragment thereof of claim 331, wherein the cancer cells are prostate cancer cells.

5   333.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and enhances at least one enzymatic activity of PSMA.

334.   The isolated antibody or antigen-binding fragment thereof of claim 333, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

10

335.   The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ-glutamyl hydrolase.

336.   The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the

15   peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

337.   The isolated antibody or antigen-binding fragment thereof of claim 333, wherein the enzyme is active in normal cells and has lesser activity in cancer cells than in normal cells or

20   no activity in cancer cells.

338.   The isolated antibody or antigen-binding fragment thereof of claim 337, wherein the cancer cells are prostate cancer cells.

25   339.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody is raised by immunizing an animal with a preparation comprising a PSMA protein multimer.

340.   A composition comprising the isolated antibody or antigen-binding fragment thereof

30   of claims 326 – 339, and a pharmaceutically acceptable carrier.

341.   A composition comprising an isolated PSMA protein multimer.

342. The composition of claim 341, wherein the PSMA protein multimer is a dimer.

343. The composition of claim 341, wherein the composition comprises at least about 10% PSMA protein multimer.

344. The composition of claim 343, wherein the composition comprises at least about 20% PSMA protein multimer.

345. The composition of claim 344, wherein the composition comprises at least about 30% PSMA protein multimer.

346. The composition of claim 345, wherein the composition comprises at least about 40% PSMA protein multimer.

347. The composition of claim 346, wherein the composition comprises at least about 50% PSMA protein multimer.

348. The composition of claim 347, wherein the composition comprises at least about 75% PSMA protein multimer.

349. The composition of claim 348, wherein the composition comprises at least about 90% PSMA protein multimer.

350. The composition of claim 349, wherein the composition comprises at least about 95% PSMA protein multimer.

351. The composition of claim 341, wherein the PSMA protein multimer comprises noncovalently associated PSMA proteins.

352. The composition of claim 351, wherein the PSMA proteins are noncovalently associated under nondenaturing conditions.

353. The composition of any of claims 341-352, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide.

5   354. The composition of claim 341, wherein the PSMA protein multimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

355. The composition of claim 341, wherein the PSMA protein multimer comprises PSMA proteins in a native conformation.

10

356. The composition of claim 341, wherein the PSMA multimer is enzymatically active.

357. The composition of claim 356, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV

15   activity, γ-glutamyl hydrolase activity and combinations thereof.

358. The composition of any of claims 341-357, further comprising an adjuvant.

359. The composition of any of claims 341-357, further comprising a cytokine.

20

360. The composition of claim 359, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

361. The composition of any of claims 341-360, further comprising a pharmaceutically

25   acceptable carrier.

362. A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the composition of any of claims 341-361.

30   363. An isolated recombinant soluble PSMA (rsPSMA) protein multimer.

364. An isolated rsPSMA protein dimer.

365.   The isolated rsPSMA protein dimer of claim 364, wherein the dimer comprises noncovalently associated rsPSMA proteins.

5   366.   The isolated rsPSMA protein dimer of claim 365, wherein the rsPSMA proteins are noncovalently associated under nondenaturing conditions.

367.   The isolated rsPSMA protein dimer of claim 364, wherein the isolated rsPSMA dimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

10

368.   The isolated rsPSMA protein dimer of claim 364, wherein the isolated rsPSMA dimer is enzymatically active.

369.   The isolated rsPSMA protein dimer of claim 368, wherein the enzymatic activity is
15   selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

370.   A method of screening for a candidate agent that inhibits at least one enzymatic activity of a PSMA enzyme comprising
20   a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by
            b) adding a substrate for the PSMA enzyme to the reaction mixture, and
            c) determining the amount of a product formed from the substrate by the PSMA enzyme, wherein a decrease in the amount of product formed in comparison to a control is
25   indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme.

371.   The method of screening of claim 370, wherein the PSMA enzyme is selected from the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and
30   γ-glutamyl hydrolase.

- 138 -

372.   The method of screening of claim 370, wherein the PSMA multimer comprises recombinant soluble PSMA.

373.   The method of screening of claim 370, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

374.   A candidate agent that inhibits at least one enzymatic activity of PSMA identified according to the method of claim 370.

375.   The candidate agent according to claim 374, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

376.   A method of screening for a candidate agent that enhances at least one enzymatic activity of a PSMA enzyme comprising
        a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by
        b) adding a substrate for the PSMA enzyme to the reaction mixture, and
        c) determining the amount of a product formed from the substrate by the PSMA enzyme, wherein an increase in the amount of product formed in comparison to a control is indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme.

377.   The method of screening of claim 376, wherein the PSMA enzyme is selected from the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ-glutamyl hydrolase.

378.   The method of screening of claim 376, wherein the PSMA multimer comprises recombinant soluble PSMA.

379.   The method of screening of claim 376, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

380.   A candidate agent that enhances at least one enzymatic activity of PSMA identified according to the method of claim 376.

5   381.   The candidate agent according to claim 380, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

382.   A method for identifying a compound that promotes dissociation of PSMA dimers,
10   comprising
        contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;
        measuring the amount of PSMA monomer; and
        comparing the amount of PSMA monomer measured in the presence of the compound
15   with that observed in the absence of the compound;
        wherein an increase in the amount of PSMA monomer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

20   383.   A method for identifying a compound that promotes dissociation of PSMA dimers, comprising
        contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;
        measuring the amount of PSMA dimer; and
25   comparing the amount of PSMA dimer measured in the presence of the compound with that observed in the absence of the compound;
        wherein a decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

30
384.   A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

- 140 -

contacting a PSMA dimer with a compound under conditions that do not promote

dissociation of the PSMA dimer in the absence of the compound;

measuring the amounts of PSMA monomer and PSMA dimer;

calculating a ratio of PSMA monomer to PSMA dimer; and

5   comparing the ratio obtained in the presence of the compound with that obtained in

the absence of the compound;

wherein an increase in the ratio measured in the presence of the compound indicates

that the compound is capable of promoting dissociation of the PSMA dimer.

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY
FOLATE HYDROLASE ACTIVITY PRESENT IN 0.0002 ug rsPSMA #7

mAB 3.9
mAB 5.4
mAB 7.3
J591

ug ANTIBODY

(nmoles glu/mg PROTEIN)/hr

600000
500000
400000
300000
200000
100000
0

0   1   2   3   4   5   6   7

Fig. 7

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY
FOLATE HYDROLASE ACTIVITY PRESENT IN 0.0002 ug rsPSMA #8

Fig. 8

EFFECT OF VARIOUS ANTIBODIES ON THE RATE OF glu CLEAVED FROM MTXglu2 BY
FOLATE HYDROLASE ACTIVITY PRESENT IN C4-2 CELL MEMBRANE PREP, 8/15/01

Fig. 9

Human IgG1 cloning - into pcDNA

Construction of pcDNA-huCκ and pcDNA-huIgG1

		PCR product	Vector
Cκ	Sense	5' XbaI HindIII BamHI NheI 3'	5' NheI NotI 3'
	Anit-sense	EcoRI NotI	(pcDNA.neo)
Cγ1	Sense	5' XbaI KpnI HindIII BamHI NheI 3'	5' NheI/PmeI 3'
	Anti-sense	EcoRI XhoI PmeI	(pcDNA Hygro)

Construction of pcDNA-Ab (V-C cassette)

		PCR product	Vector
Vκ	Sense	BglII or BamHI (if necessary)*	5' BamHI NheI 3'
	Anti-sense	NheI	(pcDNA-huCκ)
Vγ1	Sense	BglII or BamHI (if necessary)*	5' BamHI NheI 3'
	Anti-sense	XbaI	(pcDNA-huIgG1)

*BamHI primer is used if the V region has an internal BglII site

Human IgG cloning- V-C cassette from pcDNA into "production" vector

	Insert from pcDNA
Igκ	5' HindIII or BanHI (if alternate sense primer used)
	3' EcoRI, NotI, XhoI, XbaI or PmeI
IgG1	5' KpnI, HindIII or BamHI (if alternate sense primer used)
	3' EcoRI*, XhoI or PmeI

* 2nd EcoRI site present in hygromycin resistance gene

Primers used for V region amplification
Vκ-sense:
5' GAAGATCT▨▨▨ ATG + 20-23 bp leader sequence 3'
      BglII Kozak
Vκ anti-sense(reverse/complementary):
5'AACTA GCT AGC AGT TCC AGA TTT CAA CTG CTC ATC AGA T 3'
       S   A   T   G   S   K   L   Q   E   D   S (aa. 23-13 Cκ)
          NheI

CLONING SITE OF NheI CODES FOR A S - THEREFORE NO AMINO ACID CHANGE DUE TO CLONING.

Vγ-SENSE:
5' GAAGATCT▨▨▨ ATG   + 17-29bp leader sequence 3'
      BglII KOZAK
Vγ anti-sense(reverse/complementary):
5' GC TCT AGA GGG TGC CAG GGG GAA GAC CGA T 3'
     (R) S   P   A   L   P   F   V   S (aa. 14-7 Cγ1)
      XbaI
Cloning into
5' CG GCT AGC
      S (A)

CLONING SITE JUNCTION OF XbaI/NheI (TCT AGC) CODES FOR S S - THEREFORE NO AMINO ACID
CHANGE DUE TO CLONING

Fig. 10

Fig. 11

AMPICILLIN RESISTANCE

VH DOMAIN

CH1 DOMAIN
(HINGE)

pcDNA-Ab-PG1-026-G1
7597 bp

CH2 DOMAIN

CH3 DOMAIN

HYGROMYCIN
RESISTANCE

Fig. 12

Fig. 13

Fig. 14

AMPICILLIN RESISTANCE

VH DOMAIN

CH1 DOMAIN
(HINGE)

pcDNA-Ab-PG1-077-G1
7576 bp

CH2 DOMAIN

CH3 DOMAIN

HYGROMYCIN
RESISTANCE

Fig. 15

Fig. 16

AMPICILLIN

006 Vk

HUMAN
Ck

pcDNA-Ab-PG1-006-k
6082 bp

NEOMYCIN

Fig. 17

Fig. 18

AMPICILLIN

Vk REGION

HUMAN
Ck

pcDNA-Ab-PG1-051-k
6082 bp

NEOMYCIN

Fig. 19

AMPICILLIN

Vk REGION

HUMAN Ck

pcDNA-Ab-PG1-069-k
6085 bp

NEOMYCIN

Fig. 20

Fig. 21

Fig. 22

Fig. 23

Fig. 24

ANTI-PSMA mAbs BIND SPECIFICALLY TO
CELL SURFACE PSMA

Fig. 25A

ANTI-PSMA mAb BINDING TO CELL SURFACE PSMA
(UNPURIFIED mAb IN CULTURE SUPERNATANT)

Fig. 25B

PURIFIED ANTI-PSMA Abs BINDING TO CELL SURFACE
PSMA

Fig. 25C

Fig. 26

Fig. 27

Fig. 28

Fig. 29

Fig. 30

Fig. 31

Fig. 32

Fig. 33

Fig. 34

Fig. 35

Fig. 36

SEQUENCE LISTING

<110>   PSMA DEVELOPMENT COMPANY, L.L.C.

        MADDON, Paul J.

        DONOVAN, Gerald P.

        OLSON, William C.

        SCHÜLKE, Norbert

        GARDNER, Jason

        MA, Dangshe

<120>   PSMA ANTIBODIES AND PROTEIN MULTIMERS

<130>   P00453.70005.WO

<150>   US 60/335,215

<151>   2001-10-23

<150>   US 60/362,747

<151>   2001-03-07

<150>   US 60/___,___

<151>   2002-09-20

<160>   33

<170>   PatentIn version 3.1

<210>   1

<211>   750

<212>   PRT

<213>   Homo sapiens

<400>   1

Met Trp Asn Leu Leu His Glu Thr Asp Ser Ala Val Ala Thr Ala Arg
1   5   10   15

Arg Pro Arg Trp Leu Cys Ala Gly Ala Leu Val Leu Ala Gly Gly Phe
        20   25   30

Phe Leu Leu Gly Phe Leu Phe Gly Trp Phe Ile Lys Ser Ser Asn Glu
        35   40   45

Ala Thr Asn Ile Thr Pro Lys His Asn Met Lys Ala Phe Leu Asp Glu
        50   55   60

Leu Lys Ala Glu Asn Ile Lys Lys Phe Leu Tyr Asn Phe Thr Gln Ile
65   70   75   80

Pro His Leu Ala Gly Thr Glu Gln Asn Phe Gln Leu Ala Lys Gln Ile
            85   90   95

Gln Ser Gln Trp Lys Glu Phe Gly Leu Asp Ser Val Glu Leu Ala His
            100   105   110

Tyr Asp Val Leu Leu Ser Tyr Pro Asn Lys Thr His Pro Asn Tyr Ile
        115   120   125

Ser Ile Ile Asn Glu Asp Gly Asn Glu Ile Phe Asn Thr Ser Leu Phe
        130   135   140

Glu Pro Pro Pro Gly Tyr Glu Asn Val Ser Asp Ile Val Pro Pro
145   150   155   160

Phe Ser Ala Phe Ser Pro Gln Gly Met Pro Glu Gly Asp Leu Val Tyr
            165   170   175

Val Asn Tyr Ala Arg Thr Glu Asp Phe Phe Lys Leu Glu Arg Asp Met
            180   185   190

Lys Ile Asn Cys Ser Gly Lys Ile Val Ile Ala Arg Tyr Gly Lys Val
        195   200   205

Phe Arg Gly Asn Lys Val Lys Asn Ala Gln Leu Ala Gly Ala Lys Gly
        210   215   220

Val Ile Leu Tyr Ser Asp Pro Ala Asp Tyr Phe Ala Pro Gly Val Lys
225   230   235   240

Ser Tyr Pro Asp Gly Trp Asn Leu Pro Gly Gly Gly Val Gln Arg Gly
            245   250   255

Asn Ile Leu Asn Leu Asn Gly Ala Gly Asp Pro Leu Thr Pro Gly Tyr
            260   265   270

Pro Ala Asn Glu Tyr Ala Tyr Arg Arg Gly Ile Ala Glu Ala Val Gly
        275   280   285

Leu Pro Ser Ile Pro Val His Pro Ile Gly Tyr Tyr Asp Ala Gln Lys
    290   295   300

Leu Leu Glu Lys Met Gly Gly Ser Ala Pro Pro Asp Ser Ser Trp Arg
305   310   315   320

Gly Ser Leu Lys Val Pro Tyr Asn Val Gly Pro Gly Phe Thr Gly Asn
            325   330   335

Phe Ser Thr Gln Lys Val Lys Met His Ile His Ser Thr Asn Glu Val
        340   345   350

Thr Arg Ile Tyr Asn Val Ile Gly Thr Leu Arg Gly Ala Val Glu Pro
        355   360   365

Asp Arg Tyr Val Ile Leu Gly Gly His Arg Asp Ser Trp Val Phe Gly
    370   375   380

Gly Ile Asp Pro Gln Ser Gly Ala Ala Val Val His Glu Ile Val Arg
385   390   395   400

Ser Phe Gly Thr Leu Lys Lys Glu Gly Trp Arg Pro Arg Arg Thr Ile
            405   410   415

Leu Phe Ala Ser Trp Asp Ala Glu Glu Phe Gly Leu Leu Gly Ser Thr
            420   425   430

Glu Trp Ala Glu Glu Asn Ser Arg Leu Leu Gln Glu Arg Gly Val Ala
        435   440   445

Tyr Ile Asn Ala Asp Ser Ser Ile Glu Gly Asn Tyr Thr Leu Arg Val
    450   455   460

Asp Cys Thr Pro Leu Met Tyr Ser Leu Val His Asn Leu Thr Lys Glu
465   470   475   480

Leu Lys Ser Pro Asp Glu Gly Phe Glu Gly Lys Ser Leu Tyr Glu Ser
                485   490   495

Trp Thr Lys Lys Ser Pro Ser Pro Glu Phe Ser Gly Met Pro Arg Ile
            500   505   510

```
Ser Lys Leu Gly Ser Gly Asn Asp Phe Glu Val Phe Phe Gln Arg Leu
        515             520                 525

Gly Ile Ala Ser Gly Arg Ala Arg Tyr Thr Lys Asn Trp Glu Thr Asn
        530             535                 540

Lys Phe Ser Gly Tyr Pro Leu Tyr His Ser Val Tyr Glu Thr Tyr Glu
545             550                 555                 560

Leu Val Glu Lys Phe Tyr Asp Pro Met Phe Lys Tyr His Leu Thr Val
                565                 570                 575

Ala Gln Val Arg Gly Gly Met Val Phe Glu Leu Ala Asn Ser Ile Val
                580                 585                 590

Leu Pro Phe Asp Cys Arg Asp Tyr Ala Val Val Leu Arg Lys Tyr Ala
        595                 600                 605

Asp Lys Ile Tyr Ser Ile Ser Met Lys His Pro Gln Glu Met Lys Thr
        610                 615                 620

Tyr Ser Val Ser Phe Asp Ser Leu Phe Ser Ala Val Lys Asn Phe Thr
625                 630                 635                 640

Glu Ile Ala Ser Lys Phe Ser Glu Arg Leu Gln Asp Phe Asp Lys Ser
                645                 650                 655

Asn Pro Ile Val Leu Arg Met Met Asn Asp Gln Leu Met Phe Leu Glu
                660                 665                 670

Arg Ala Phe Ile Asp Pro Leu Gly Leu Pro Asp Arg Pro Phe Tyr Arg
        675                 680                 685

His Val Ile Tyr Ala Pro Ser Ser His Asn Lys Tyr Ala Gly Glu Ser
690                 695                 700

Phe Pro Gly Ile Tyr Asp Ala Leu Phe Asp Ile Glu Ser Lys Val Asp
705                 710                 715                 720

Pro Ser Lys Ala Trp Gly Glu Val Lys Arg Gln Ile Tyr Val Ala Ala
                725                 730                 735

Phe Thr Val Gln Ala Ala Ala Glu Thr Leu Ser Glu Val Ala
                740                 745                 750
```

<210> 2

<211> 7570

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 2

```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg     60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg    120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc    180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt    240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata    300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc    360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc    420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt    480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg    780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga    900

ggtaccaagc ttggatctca ccatggagtt gggactgcgc tggggcttcc tcgttgctct    960

tttaagaggt gtccagtgtc aggtgcaatt ggtggagtct gggggaggcg tggtccagcc   1020

tgggaggtcc ctgagactct cctgtgcagc gtctggattc gccttcagta gatatggcat   1080

gcactgggtc cgccaggctc caggcaaggg gctggagtgg gtggcagtta tatggtatga   1140

tggaagtaat aaatactatg cagactccgt gaagggccga ttcaccatct ccagagacaa   1200

ttccaagaac acgcagtatc tgcaaatgaa cagcctgaga gccgaggaca cggctgtgta   1260

ttactgtgcg agaggcggtg acttcctcta ctactactat tacggtatgg acgtctgggg   1320

ccaagggacc acggtcaccg tctcctcagc ctccaccaag ggcccatcgg tcttccccct   1380

ggcaccctct agcaagagca cctctggggg cacagcggcc ctgggctgcc tggtcaagga   1440

ctacttcccc gaaccggtga cggtgtcgtg gaactcaggc gccctgacca gcggcgtgca   1500
```

```
caccttcccg gctgtcctac agtcctcagg actctactcc ctcagcagcg tggtgaccgt    1560

gccctccagc agcttgggca cccagaccta catctgcaac gtgaatcaca agcccagcaa    1620

caccaaggtg gacaagagag ttggtgagag gccagcacag ggagggaggg tgtctgctgg    1680

aagccaggct cagcgctcct gcctggacgc atcccggcta tgcagtccca gtccagggca    1740

gcaaggcagg ccccgtctgc ctcttcaccc ggaggcctct gcccgcccca ctcatgctca    1800

gggagagggt cttctggctt tttccccagg ctctgggcag gcacaggcta ggtgccccta    1860

acccaggccc tgcacacaaa ggggcaggtg ctgggctcag acctgccaag agccatatcc    1920

gggaggaccc tgcccctgac ctaagcccac cccaaaggcc aaactctcca ctccctcagc    1980

tcggacacct tctctcctcc cagattccag taactcccaa tcttctctct gcagagccca    2040

aatcttgtga caaaactcac acatgcccac cgtgcccagg taagccagcc caggcctcgc    2100

cctccagctc aaggcgggac aggtgcccta gagtagcctg catccaggga caggccccag    2160

ccgggtgctg acacgtccac ctccatctct tcctcagcac ctgaactcct ggggggaccg    2220

tcagtcttcc tcttcccccc aaaacccaag gacaccctca tgatctcccg gacccctgag    2280

gtcacatgcg tggtggtgga cgtgagccac gaagaccctg aggtcaagtt caactggtac    2340

gtggacggcg tggaggtgca taatgccaag acaaagccgc gggaggagca gtacaacagc    2400

acgtaccgtg tggtcagcgt cctcaccgtc ctgcaccagg actggctgaa tggcaaggag    2460

tacaagtgca aggtctccaa caaagccctc ccagccccca tcgagaaaac catctccaaa    2520

gccaaaggtg ggacccgtgg ggtgcgaggg ccacatggac agaggccggc tcggcccacc    2580

ctctgccctg agagtgaccg ctgtaccaac ctctgtccct acaggcagc cccgagaacc    2640

acaggtgtac accctgcccc catcccggga ggagatgacc aagaaccagg tcagcctgac    2700

ctgcctggtc aaaggcttct atcccagcga catcgccgtg gagtgggaga gcaatgggca    2760

gccggagaac aactacaaga ccacgcctcc cgtgctggac tccgacggct ccttcttcct    2820

ctatagcaag ctcaccgtgg acaagagcag gtggcagcag gggaacgtct tctcatgctc    2880

cgtgatgcat gaggctctgc acaaccacta cacgcagaag agcctctccc tgtctccggg    2940

taaatgagaa ttcctcgagt ctagagggcc cgtttaaacc cgctgatcag cctcgactgt    3000

gccttctagt tgccagccat ctgttgtttg cccctccccc gtgccttcct tgaccctgga    3060

aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc attgtctgag    3120

taggtgtcat tctattctgg ggggtggggt ggggcaggac agcaaggggg aggattggga    3180

agacaatagc aggcatgctg gggatgcggt gggctctatg gcttctgagg cggaaagaac    3240

cagctggggc tctagggggt atccccacgc gccctgtagc ggcgcattaa gcgcggcggg    3300

tgtggtggtt acgcgcagcg tgaccgctac acttgccagc gccctagcgc ccgctccttt    3360
```

```
cgctttcttc ccttcctttc tcgccacgtt cgccggcttt ccccgtcaag ctctaaatcg   3420

gggcatccct ttagggttcc gatttagtgc tttacggcac ctcgacccca aaaaacttga   3480

ttagggtgat ggttcacgta gtgggccatc gccctgatag acggtttttc gccctttgac   3540

gttggagtcc acgttcttta atagtggact cttgttccaa actggaacaa cactcaaccc   3600

tatctcggtc tattcttttg atttataagg gattttgggg atttcggcct attggttaaa   3660

aaatgagctg atttaacaaa aatttaacgc gaattaattc tgtggaatgt gtgtcagtta   3720

gggtgtggaa agtccccagg ctccccaggc aggcagaagt atgcaaagca tgcatctcaa   3780

ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa gtatgcaaag   3840

catgcatctc aattagtcag caaccatagt cccgcccta actccgccca tcccgcccct    3900

aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt ttatttatgc   3960

agaggccgag gccgcctctg cctctgagct attccagaag tagtgaggag gctttttttgg  4020

aggcctaggc ttttgcaaaa agctcccggg agcttgtata tccattttcg gatctgatca   4080

gcacgtgatg aaaaagcctg aactcaccgc gacgtctgtc gagaagtttc tgatcgaaaa   4140

gttcgacagc gtctccgacc tgatgcagct ctcggagggc gaagaatctc gtgctttcag   4200

cttcgatgta ggagggcgtg gatatgtcct gcgggtaaat agctgcgccg atggtttcta   4260

caaagatcgt tatgtttatc ggcactttgc atcggccgcg ctcccgattc cggaagtgct   4320

tgacattggg gaattcagcg agagcctgac ctattgcatc tcccgccgtg cacagggtgt   4380

cacgttgcaa gacctgcctg aaaccgaact gcccgctgtt ctgcagccgg tcgcggaggc   4440

catggatgcg atcgctgcgg ccgatcttag ccagacgagc gggttcggcc cattcggacc   4500

gcaaggaatc ggtcaataca ctacatggcg tgatttcata tgcgcgattg ctgatcccca   4560

tgtgtatcac tggcaaactg tgatggacga caccgtcagt gcgtccgtcg cgcaggctct   4620

cgatgagctg atgctttggg ccgaggactg ccccgaagtc cggcacctcg tgcacgcgga   4680

tttcggctcc aacaatgtcc tgacggacaa tggccgcata acagcggtca ttgactggag   4740

cgaggcgatg ttcggggatt cccaatacga ggtcgccaac atcttcttct ggaggccgtg   4800

gttggcttgt atggagcagc agacgcgcta cttcgagcgg aggcatccgg agcttgcagg   4860

atcgccgcgg ctccgggcgt atatgctccg cattggtctt gaccaactct atcagagctt   4920

ggttgacggc aatttcgatg atgcagcttg ggcgcagggt cgatgcgacg caatcgtccg   4980

atccggagcc gggactgtcg gcgtacaca aatcgcccgc agaagcgcgg ccgtctggac    5040

cgatggctgt gtagaagtac tcgccgatag tggaaaccga cgccccagca ctcgtccgag   5100

ggcaaaggaa tagcacgtgc tacgagattt cgattccacc gccgccttct atgaaaggtt   5160

gggcttcgga atcgttttcc gggacgccgg ctggatgatc ctccagcgcg gggatctcat   5220
```

```
gctggagttc ttcgcccacc ccaacttgtt tattgcagct tataatggtt acaaataaag    5280

caatagcatc acaaatttca caaataaagc attttttttca ctgcattcta gttgtggttt   5340

gtccaaactc atcaatgtat cttatcatgt ctgtataccg tcgacctcta gctagagctt    5400

ggcgtaatca tggtcatagc tgtttcctgt gtgaaattgt tatccgctca caattccaca    5460

caacatacga gccggaagca taaagtgtaa agcctggggt gcctaatgag tgagctaact    5520

cacattaatt gcgttgcgct cactgcccgc tttccagtcg ggaaacctgt cgtgccagct    5580

gcattaatga atcggccaac gcgcggggag aggcggtttg cgtattgggc gctcttccgc    5640

ttcctcgctc actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca    5700

ctcaaaggcg gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg    5760

agcaaaaggc cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca    5820

taggctccgc cccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa     5880

cccgacagga ctataaagat accaggcgtt ccccctggga agctccctcg tgcgctctcc    5940

tgttccgacc ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc    6000

gctttctcaa tgctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct    6060

gggctgtgtg cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg    6120

tcttgagtcc aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag    6180

gattagcaga gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta    6240

cggctacact agaaggacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg    6300

aaaaagagtt ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt    6360

tgtttgcaag cagcagatta cgcgcagaaa aaaggatct caagaagatc ctttgatctt     6420

ttctacgggg tctgacgctc agtggaacga aaactcacgt taagggattt tggtcatgag    6480

attatcaaaa aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat    6540

ctaaagtata tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc    6600

tatctcagcg atctgtctat ttcgttcatc catagttgcc tgactccccg tcgtgtagat    6660

aactacgata cgggagggct taccatctgg ccccagtgct gcaatgatac cgcgagaccc    6720

acgctcaccg gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgcag    6780

aagtggtcct gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaagctag    6840

agtaagtagt tcgccagtta atagtttgcg caacgttgtt gccattgcta caggcatcgt    6900

ggtgtcacgc tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg    6960

agttacatga tcccccatgt tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt    7020

tgtcagaagt aagttggccg cagtgttatc actcatggtt atggcagcac tgcataattc    7080
```

```
tcttactgtc atgccatccg taagatgctt ttctgtgact ggtgagtact caaccaagtc    7140

attctgagaa tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtcaa tacgggataa    7200

taccgcgcca catagcagaa ctttaaaagt gctcatcatt ggaaaacgtt cttcggggcg    7260

aaaactctca aggatcttac cgctgttgag atccagttcg atgtaaccca ctcgtgcacc    7320

caactgatct tcagcatctt ttactttcac cagcgtttct gggtgagcaa aaacaggaag    7380

gcaaaatgcc gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt    7440

cctttttcaa tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt    7500

tgaatgtatt tagaaaaata aacaaatagg ggttccgcgc acatttcccc gaaaagtgcc    7560

acctgacgtc                                                           7570
```

<210> 3

<211> 7597

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 3

```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg     60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg    120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc    180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt    240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata    300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc    360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc    420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt    480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg    780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga    900
```

```
ggtaccaagc ttggatctca ccatggggtc aaccgccatc ctcaccatgg agttggggct    960

gcgctgggtt ctcctcgttg ctcttttaag aggtgtccag tgtcaggtgc agctggtgga   1020

gtctggggga ggcgtggtcc agcctgggag gtccctgaga ctctcctgtg cagcgtctgg   1080

attcacctto agtaactatg tcatgcactg ggtccgccag gctccaggca aggggctgga   1140

gtgggtggca attatatggt atgatggaag taataaatac tatgcagact ccgtgaaggg   1200

ccgattcacc atctccagag acaattccaa gaacacgctg tatctgcaaa tgaacagcct   1260

gagagccgag gacacggctg tgtattactg tgcgggtgga tataactgga actacgagta   1320

ccactactac ggtatggacg tctggggcca agggaccacg gtcaccgtct cctcagcctc   1380

caccaagggc ccatcggtct tccccctggc accctctagc aagagcacct ctggggcac    1440

agcggccctg ggctgcctgg tcaaggacta cttccccgaa ccggtgacgg tgtcgtggaa   1500

ctcaggcgcc ctgaccagcg gcgtgcacac cttcccggct gtcctacagt cctcaggact   1560

ctactccctc agcagcgtgg tgaccgtgcc ctccagcagc ttgggcaccc agacctacat  ·1620

ctgcaacgtg aatcacaagc ccagcaacac caaggtggac aagagagttg gtgagaggcc   1680

agcacaggga gggagggtgt ctgctggaag ccaggctcag cgctcctgcc tggacgcatc   ·1740

ccggctatgc agtcccagtc cagggcagca aggcaggccc cgtctgcctc ttcacccgga   1800

ggcctctgcc cgccccactc atgctcaggg agagggtctt ctggcttttt ccccaggctc   1860

tgggcaggca caggctaggt gcccctaacc caggccctgc acacaaaggg gcaggtgctg   1920

ggctcagacc tgccaagagc catatccggg aggaccctgc ccctgaccta gcccaccccc   1980

aaaggccaaa ctctccactc cctcagctcg gacaccttct ctcctcccag attccagtaa   2040

ctcccaatct tctctctgca gagcccaaat cttgtgacaa aactcacaca tgcccaccgt   2100

gcccaggtaa gccagcccag gcctcgccct ccagctcaag gcgggacagg tgccctagag   2160

tagcctgcat ccagggacag gccccagccg ggtgctgaca cgtccacctc catctcttcc   2220

tcagcacctg aactcctggg gggaccgtca gtcttcctct ccccccaaa acccaaggac    2280

accctcatga tctcccggac ccctgaggtc acatgcgtgg tggtggacgt gagccacgaa   2340

gaccctgagg tcaagttcaa ctggtacgtg acggcgtgg  aggtgcataa tgccaagaca   2400

aagccgcggg aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg   2460

caccaggact ggctgaatgg caaggagtac aagtgcaagg tctccaacaa agccctccca   2520

gcccccatcg agaaaaccat ctccaaagcc aaaggtggga cccgtggggt gcgagggcca   2580

catggacaga ggccggctcg gcccaccctc tgccctgaga gtgaccgctg taccaacctc   2640

tgtccctaca gggcagcccc gagaaccaca ggtgtacacc ctgcccccat cccgggagga   2700

gatgaccaag aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat   2760
```

cgccgtggag tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt   2820

gctggactcc gacggctcct tcttcctcta tagcaagctc accgtggaca agagcaggtg   2880

gcagcagggg aacgtcttct catgctccgt gatgcatgag gctctgcaca accactacac   2940

gcagaagagc ctctccctgt ctccgggtaa atgagaattc ctcgagtcta gagggcccgt   3000

ttaaacccgc tgatcagcct cgactgtgcc ttctagttgc cagccatctg ttgtttgccc   3060

ctcccccgtg ccttccttga ccctggaagg tgccactccc actgtccttt cctaataaaa   3120

tgaggaaatt gcatcgcatt gtctgagtag gtgtcattct attctggggg gtggggtggg   3180

gcaggacagc aaggggagg attgggaaga caatagcagg catgctgggg atgcggtggg   3240

ctctatggct tctgaggcgg aaagaaccag ctggggctct aggggggtatc cccacgcgcc   3300

ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga ccgctacact   3360

tgccagcgcc ctagcgcccg ctcctttcgc tttcttccct tcctttctcg ccacgttcgc   3420

cggctttccc cgtcaagctc taaatcgggg catcccttta gggttccgat ttagtgcttt   3480

acggcacctc gaccccaaaa aacttgatta gggtgatggt tcacgtagtg ggccatcgcc   3540

ctgatagacg gtttttcgcc ctttgacgtt ggagtccacg ttctttaata gtggactctt   3600

gttccaaact ggaacaacac tcaaccctat ctcggtctat tcttttgatt tataagggat   3660

tttggggatt tcggcctatt ggttaaaaaa tgagctgatt taacaaaaat ttaacgcgaa   3720

ttaattctgt ggaatgtgtg tcagttaggg tgtggaaagt ccccaggctc cccaggcagg   3780

cagaagtatg caaagcatgc atctcaatta gtcagcaacc aggtgtggaa agtccccagg   3840

ctccccagca ggcagaagta tgcaaagcat gcatctcaat tagtcagcaa ccatagtccc   3900

gcccctaact ccgcccatcc cgcccctaac tccgcccagt tccgcccatt ctccgcccca   3960

tggctgacta attttttta tttatgcaga ggccgaggcc gcctctgcct ctgagctatt   4020

ccagaagtag tgaggaggct tttttggagg cctaggcttt tgcaaaaagc tcccgggagc   4080

ttgtatatcc attttcggat ctgatcagca cgtgatgaaa aagcctgaac tcaccgcgac   4140

gtctgtcgag aagtttctga tcgaaaagtt cgacagcgtc tccgacctga tgcagctctc   4200

ggagggcgaa gaatctcgtg ctttcagctt cgatgtagga gggcgtggat atgtcctgcg   4260

ggtaaatagc tgcgccgatg gtttctacaa agatcgttat gtttatcggc actttgcatc   4320

ggccgcgctc ccgattccgg aagtgcttga cattggggaa ttcagcgaga gcctgaccta   4380

ttgcatctcc cgccgtgcac agggtgtcac gttgcaagac ctgcctgaaa ccgaactgcc   4440

cgctgttctg cagccggtcg cggaggccat ggatgcgatc gctgcggccg atcttagcca   4500

gacgagcggg ttcggcccat tcggaccgca aggaatcggt caatacacta catggcgtga   4560

tttcatatgc gcgattgctg atccccatgt gtatcactgg caaactgtga tggacgacac   4620

```
cgtcagtgcg tccgtcgcgc aggctctcga tgagctgatg ctttgggccg aggactgccc    4680

cgaagtccgg cacctcgtgc acgcggattt cggctccaac aatgtcctga cggacaatgg    4740

ccgcataaca gcggtcattg actggagcga ggcgatgttc ggggattccc aatacgaggt    4800

cgccaacatc ttcttctgga ggccgtggtt ggcttgtatg gagcagcaga cgcgctactt    4860

cgagcggagg catccggagc ttgcaggatc gccgcggctc cgggcgtata tgctccgcat    4920

tggtcttgac caactctatc agagcttggt tgacggcaat ttcgatgatg cagcttgggc    4980

gcagggtcga tgcgacgcaa tcgtccgatc cggagccggg actgtcgggc gtacacaaat    5040

cgcccgcaga agcgcggccg tctggaccga tggctgtgta gaagtactcg ccgatagtgg    5100

aaaccgacgc cccagcactc gtccgagggc aaaggaatag cacgtgctac gagatttcga    5160

ttccaccgcc gccttctatg aaaggttggg cttcggaatc gttttccggg acgccggctg    5220

gatgatcctc cagcgcgggg atctcatgct ggagttcttc gcccacccca acttgtttat    5280

tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt    5340

tttttcactg cattctagtt gtggtttgtc caaactcatc aatgtatctt atcatgtctg    5400

tataccgtcg acctctagct agagcttggc gtaatcatgg tcatagctgt ttcctgtgtg    5460

aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc    5520

ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt    5580

ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg    5640

cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt    5700

tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc    5760

aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa    5820

aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa    5880

tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc    5940

ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc    6000

cgcctttctc ccttcgggaa gcgtggcgct ttctcaatgc tcacgctgta ggtatctcag    6060

ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga    6120

ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc    6180

gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac    6240

agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg    6300

cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca    6360

aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa    6420

aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa    6480
```

```
ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt      6540

aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaaactt ggtctgacag      6600

ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat      6660

agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc      6720

cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa      6780

ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca      6840

gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa      6900

cgttgttgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt      6960

cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc      7020

ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact      7080

catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc      7140

tgtgactggt gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg      7200

ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt taaaagtgct      7260

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc      7320

cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag      7380

cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac      7440

acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg      7500

ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt      7560

tccgcgcaca tttccccgaa aagtgccacc tgacgtc                              7597.
```

<210> 4

<211> 7579

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 4
```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg       60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg      120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc      180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt      240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata      300
```

```
tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc   360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc   420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt   480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt   540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca   600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg   660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc   720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg   780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca   840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga   900

ggtaccaagc ttggatctca ccatggagtt gggacttagc tgggttttcc tcgttgctct   960

tttaagaggt gtccagtgtc aggtccagct ggtggagtct ggggagggcg tggtccagcc  1020

tgggaggtcc ctgagactct cctgtgcagc gtctggattc accttcagta gctatggcat  1080

gcactgggtc cgccaggctc caggcaaggg gctggactgg gtggcaatta tttggcatga  1140

tggaagtaat aaatactatg cagactccgt gaagggccga ttcaccatct ccagagacaa  1200

ttccaagaag acgctgtacc tgcaaatgaa cagtttgaga gccgaggaca cggctgtgta  1260

ttactgtgcg agagcttggg cctatgacta cggtgactat gaatactact cggtatgga  1320

cgtctggggc caagggacca cggtcaccgt ctcctcagcc tccaccaagg gcccatcggt  1380

cttccccctg gcaccctcta gcaagagcac ctctgggggc acagcggccc tgggctgcct  1440

ggtcaaggac tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag  1500

cggcgtgcac accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt  1560

ggtgaccgtg ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa  1620

gcccagcaac accaaggtgg acaagagagt tggtgagagg ccagcacagg agggagggt  1680

gtctgctgga gccaggctc agcgctcctg cctggacgca tcccggctat gcagtcccag  1740

tccagggcag caaggcaggc cccgtctgcc tcttcacccg gaggcctctg cccgccccac  1800

tcatgctcag ggagagggtc ttctggcttt ttccccaggc tctgggcagg cacaggctag  1860

gtgcccctaa cccaggccct gcacacaaag gggcaggtgc tgggctcaga cctgccaaga  1920

gccatatccg ggaggaccct gcccctgacc taagcccacc ccaaaggcca aactctccac  1980

tccctcagct cggacacctt ctctcctccc agattccagt aactcccaat cttctctctg  2040

cagagcccaa atcttgtgac aaaactcaca catgcccacc gtgcccaggt aagccagccc  2100

aggcctcgcc ctccagctca aggcgggaca ggtgccctag agtagcctgc atccagggac  2160
```

```
aggccccagc cgggtgctga cacgtccacc tccatctctt cctcagcacc tgaactcctg   2220

gggggaccgt cagtcttcct cttccccca aaacccaagg acaccctcat gatctcccgg    2280

acccctgagg tcacatgcgt ggtggtggac gtgagccacg aagaccctga ggtcaagttc   2340

aactggtacg tggacggcgt ggaggtgcat aatgccaaga caaagccgcg ggaggagcag   2400

tacaacagca cgtaccgtgt ggtcagcgtc ctcaccgtcc tgcaccagga ctggctgaat   2460

ggcaaggagt acaagtgcaa ggtctccaac aaagccctcc agcccccat cgagaaaacc    2520

atctccaaag ccaaaggtgg gacccgtggg gtgcgagggc cacatggaca gaggccggct   2580

cggcccaccc tctgccctga gagtgaccgc tgtaccaacc tctgtcccta cagggcagcc   2640

ccgagaacca caggtgtaca ccctgccccc atcccgggag gagatgacca gaaccaggt    2700

cagcctgacc tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag   2760

caatgggcag ccggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc   2820

cttcttcctc tatagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt   2880

ctcatgctcc gtgatgcatg aggctctgca caaccactac acgcagaaga gcctctccct   2940

gtctccgggt aaatgagaat tcctcgagtc tagagggccc gtttaaaccc gctgatcagc   3000

ctcgactgtg ccttctagtt gccagccatc tgttgtttgc ccctcccccg tgccttcctt   3060

gaccctggaa ggtgccactc ccactgtcct ttcctaataa aatgaggaaa ttgcatcgca   3120

ttgtctgagt aggtgtcatt ctattctggg gggtggggtg gggcaggaca gcaagggga    3180

ggattgggaa gacaatagca ggcatgctgg ggatgcggtg ggctctatgg cttctgaggc   3240

ggaaagaacc agctggggct ctaggggta tccccacgcg ccctgtagcg cgcattaag    3300

cgcggcgggt gtggtggtta cgcgcagcgt gaccgctaca cttgccagcg ccctagcgcc   3360

cgctcctttc gctttcttcc cttcctttct cgccacgttc gccggctttc cccgtcaagc   3420

tctaaatcgg ggcatccctt tagggttccg atttagtgct ttacggcacc tcgaccccaa   3480

aaaacttgat tagggtgatg gttcacgtag tgggccatcg ccctgataga cggttttcg    3540

ccctttgacg ttggagtcca cgttctttaa tagtggactc ttgttccaaa ctggaacaac   3600

actcaaccct atctcggtct attcttttga tttataaggg attttgggga tttcggccta   3660

ttggttaaaa aatgagctga tttaacaaaa atttaacgcg aattaattct gtggaatgtg   3720

tgtcagttag ggtgtggaaa gtccccaggc tccccaggca ggcagaagta tgcaaagcat   3780

gcatctcaat tagtcagcaa ccaggtgtgg aaagtcccca ggctccccag caggcagaag   3840

tatgcaaagc atgcatctca attagtcagc aaccatagtc cgcccctaa ctccgcccat    3900

ccgcccta actccgccca gttccgccca ttctccgccc catggctgac taatttttt    3960

tatttatgca gaggccgagg ccgcctctgc ctctgagcta ttccagaagt agtgaggagg   4020
```

```
ctttttttgga ggcctaggct tttgcaaaaa gctcccggga gcttgtatat ccattttcgg   4080

atctgatcag cacgtgatga aaaagcctga actcaccgcg acgtctgtcg agaagtttct   4140

gatcgaaaag ttcgacagcg tctccgacct gatgcagctc tcggagggcg aagaatctcg   4200

tgctttcagc ttcgatgtag gagggcgtgg atatgtcctg cgggtaaata gctgcgccga   4260

tggtttctac aaagatcgtt atgtttatcg gcactttgca tcggccgcgc tcccgattcc   4320

ggaagtgctt gacattgggg aattcagcga gagcctgacc tattgcatct cccgccgtgc   4380

acagggtgtc acgttgcaag acctgcctga aaccgaactg cccgctgttc tgcagccggt   4440

cgcggaggcc atggatgcga tcgctgcggc cgatcttagc cagacgagcg ggttcggccc   4500

attcggaccg caaggaatcg gtcaatacac tacatggcgt gatttcatat gcgcgattgc   4560

tgatccccat gtgtatcact ggcaaactgt gatggacgac accgtcagtg cgtccgtcgc   4620

gcaggctctc gatgagctga tgctttgggc cgaggactgc cccgaagtcc ggcacctcgt   4680

gcacgcggat ttcggctcca acaatgtcct gacggacaat ggccgcataa·cagcggtcat   4740

tgactggagc gaggcgatgt tcggggattc ccaatacgag gtcgccaaca tcttcttctg   4800

gaggccgtgg ttggcttgta tggagcagca gacgcgctac ttcgagcgga ggcatccgga .  4860

gcttgcagga tcgccgcggc tccgggcgta tatgctccgc attggtcttg accaactcta   4920

tcagagcttg gttgacggca atttcgatga tgcagcttgg gcgcagggtc gatgcgacgc   4980

aatcgtccga tccggagccg ggactgtcgg gcgtacacaa atcgcccgca gaagcgcggc   5040

cgtctggacc gatggctgtg tagaagtact cgccgatagt ggaaaccgac gccccagcac   5100

tcgtccgagg gcaaaggaat agcacgtgct acgagatttc gattccaccg ccgccttcta   5160

tgaaaggttg ggcttcggaa tcgttttccg ggacgccggc tggatgatcc tccagcgcgg   5220

ggatctcatg ctggagttct tcgcccaccc caacttgttt attgcagctt ataatggtta   5280

caaataaagc aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag   5340

ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc tgtataccgt cgacctctag   5400

ctagagcttg gcgtaatcat ggtcatagct gtttcctgtg tgaaattgtt atccgctcac   5460

aattccacac aacatacgag ccggaagcat aaagtgtaaa gcctggggtg cctaatgagt   5520

gagctaactc acattaattg cgttgcgctc actgcccgct ttccagtcgg gaaacctgtc   5580

gtgccagctg cattaatgaa tcggccaacg cgcggggaga ggcggtttgc gtattgggcg   5640

ctcttccgct tcctcgctca ctgactcgct gcgctcggtc gttcggctgc ggcgagcggt   5700

atcagctcac tcaaaggcgg taatacggtt atccacagaa tcagggggata acgcaggaaa   5760

gaacatgtga gcaaaaggcc agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc   5820

gtttttccat aggctccgcc ccctgacga gcatcacaaa aatcgacgct caagtcagag   5880
```

```
gtggcgaaac  ccgacaggac  tataaagata  ccaggcgttt  ccccctggaa  gctccctcgt      5940

gcgctctcct  gttccgaccc  tgccgcttac  cggatacctg  tccgcctttc  tcccttcggg      6000

aagcgtggcg  ctttctcaat  gctcacgctg  taggtatctc  agttcggtgt  aggtcgttcg      6060

ctccaagctg  ggctgtgtgc  acgaaccccc  cgttcagccc  gaccgctgcg  ccttatccgg      6120

taactatcgt  cttgagtcca  acccggtaag  acacgactta  tcgccactgg  cagcagccac      6180

tggtaacagg  attagcagag  cgaggtatgt  aggcggtgct  acagagttct  tgaagtggtg      6240

gcctaactac  ggctacacta  gaaggacagt  atttggtatc  tgcgctctgc  tgaagccagt      6300

taccttcgga  aaaagagttg  gtagctcttg  atccggcaaa  caaaccaccg  ctggtagcgg      6360

tggttttttt  gtttgcaagc  agcagattac  gcgcagaaaa  aaaggatctc  aagaagatcc      6420

tttgatcttt  tctacggggt  ctgacgctca  gtggaacgaa  aactcacgtt  aagggatttt      6480

ggtcatgaga  ttatcaaaaa  ggatcttcac  ctagatcctt  ttaaattaaa  aatgaagttt      6540

taaatcaatc  taaagtatat  atgagtaaac  ttggtctgac  agttaccaat  gcttaatcag      6600

tgaggcacct  atctcagcga  tctgtctatt  tcgttcatcc  atagttgcct  gactccccgt      6660

cgtgtagata  actacgatac  gggagggctt  accatctggc  cccagtgctg  caatgatacc      6720

gcgagaccca  cgctcaccgg  ctccagattt  atcagcaata  aaccagccag  ccggaagggc      6780

cgagcgcaga  agtggtcctg  caactttatc  cgcctccatc  cagtctatta  attgttgccg      6840

ggaagctaga  gtaagtagtt  cgccagttaa  tagtttgcgc  aacgttgttg  ccattgctac      6900

aggcatcgtg  gtgtcacgct  cgtcgtttgg  tatggcttca  ttcagctccg  gttcccaacg      6960

atcaaggcga  gttacatgat  cccccatgtt  gtgcaaaaaa  gcggttagct  ccttcggtcc      7020

tccgatcgtt  gtcagaagta  agttggccgc  agtgttatca  ctcatggtta  tggcagcact      7080

gcataattct  cttactgtca  tgccatccgt  aagatgcttt  tctgtgactg  gtgagtactc      7140

aaccaagtca  ttctgagaat  agtgtatgcg  gcgaccgagt  tgctcttgcc  cggcgtcaat      7200

acgggataat  accgcgccac  atagcagaac  tttaaaagtg  ctcatcattg  gaaaacgttc      7260

ttcggggcga  aaactctcaa  ggatcttacc  gctgttgaga  tccagttcga  tgtaacccac      7320

tcgtgcaccc  aactgatctt  cagcatcttt  tactttcacc  agcgtttctg  ggtgagcaaa      7380

aacaggaagg  caaaatgccg  caaaaaaggg  aataagggcg  acacggaaat  gttgaatact      7440

catactcttc  ctttttcaat  attattgaag  catttatcag  ggttattgtc  tcatgagcgg      7500

atacatattt  gaatgtattt  agaaaaataa  acaaataggg  gttccgcgca  catttccccg      7560

aaaagtgcca  cctgacgtc                                                       7579
```

<210> 5

<211> 7558

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 5

```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg      60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg     120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc     180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt     240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata     300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc     360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc     420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt     480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt     540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca     600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg     660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc     720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg     780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca     840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga     900

ggtaccaagc ttggatccca ccatggggtc aaccgtcatc ctcgccctcc tcctggctgt     960

tctccaagga gtctgtgccg aggtgcagct ggtgcagtct ggagcagagg tgaaaaagcc    1020

cggggagtct ctgaagatct cctgtaaggg ttctggatac agctttacca gttactggat    1080

cggctgggtg cgccagatgc ccgggaaagg cctggagtgg atggggatca tctatcctgg    1140

tgactctgat accagataca gcccgtcctt ccaaggccag gtcaccatct cagccgacaa    1200

gtccatcagc accgcctacc tgcagtggag cagcctgaag gcctcggaca ccgccatgta    1260

ttactgtgcg agacggatgg cagcagctgg cccctttgac tactggggcc agggaaccct    1320

ggtcaccgtc tcctcagcct ccaccaaggg cccatcggtc ttccccctgg caccctctag    1380

caagagcacc tctgggggca cagcggccct gggctgcctg gtcaaggact acttccccga    1440

accggtgacg gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttcccggc    1500

tgtcctacag tcctcaggac tctactccct cagcagcgtg gtgaccgtgc cctccagcag    1560
```

```
cttgggcacc cagacctaca tctgcaacgt gaatcacaag cccagcaaca ccaaggtgga    1620

caagagagtt ggtgagaggc cagcacaggg agggagggtg tctgctggaa gccaggctca    1680

gcgctcctgc ctggacgcat cccggctatg cagtcccagt ccagggcagc aaggcaggcc    1740

ccgtctgcct cttcacccgg aggcctctgc ccgccccact catgctcagg gagagggtct    1800

tctggctttt tccccaggct ctgggcaggc acaggctagg tgcccctaac ccaggccctg    1860

cacacaaagg ggcaggtgct gggctcagac ctgccaagag ccatatccgg gaggaccctg    1920

cccctgacct aagcccaccc caaaggccaa actctccact ccctcagctc ggacaccttc    1980

tctcctccca gattccagta actcccaatc ttctctctgc agagcccaaa tcttgtgaca    2040

aaactcacac atgcccaccg tgcccaggta agccagccca ggcctcgccc tccagctcaa    2100

ggcgggacag gtgccctaga gtagcctgca tccagggaca ggccccagcc gggtgctgac    2160

acgtccacct ccatctcttc ctcagcacct gaactcctgg ggggaccgtc agtcttcctc    2220

ttccccccaa aacccaagga caccctcatg atctcccgga cccctgaggt cacatgcgtg    2280

gtggtggacg tgagccacga agaccctgag gtcaagttca actggtacgt ggacggcgtg    2340

gaggtgcata atgccaagac aaagccgcgg gaggagcagt acaacagcac gtaccgtgtg    2400

gtcagcgtcc tcaccgtcct gcaccaggac tggctgaatg gcaaggagta caagtgcaag    2460

gtctccaaca aagccctccc agcccccatc gagaaaacca tctccaaagc caaaggtggg    2520

acccgtgggg tgcgagggcc acatggacag aggccggctc ggcccaccct ctgccctgag    2580

agtgaccgct gtaccaacct ctgtccctac agggcagccc cgagaaccac aggtgtacac    2640

cctgccccca tcccgggagg agatgaccaa gaaccaggtc agcctgacct gcctggtcaa    2700

aggcttctat cccagcgaca tcgccgtgga gtgggagagc aatgggcagc cggagaacaa    2760

ctacaagacc acgcctcccg tgctggactc cgacggctcc ttcttcctct atagcaagct    2820

caccgtggac aagagcaggt ggcagcaggg gaacgtcttc tcatgctccg tgatgcatga    2880

ggctctgcac aaccactaca cgcagaagag cctctccctg tctccgggta aatgagaatt    2940

cctcgagtct agagggcccg tttaaacccg ctgatcagcc tcgactgtgc cttctagttg    3000

ccagccatct gttgtttgcc cctcccccgt gccttccttg accctggaag gtgccactcc    3060

cactgtcctt tcctaataaa atgaggaaat tgcatcgcat tgtctgagta ggtgtcattc    3120

tattctgggg ggtggggtgg ggcaggacag caagggggag gattgggaag acaatagcag    3180

gcatgctggg gatgcggtgg ctctatggc ttctgaggcg aaagaacca gctggggctc     3240

taggggtat ccccacgcgc cctgtagcgg cgcattaagc gcggcgggtg tggtggttac     3300

gcgcagcgtg accgctacac ttgccagcgc cctagcgccc gctcctttcg ctttcttccc    3360

ttcctttctc gccacgttcg ccggctttcc ccgtcaagct ctaaatcggg gcatcccttt    3420
```

```
agggttccga  tttagtgctt  tacggcacct  cgaccccaaa  aaacttgatt  agggtgatgg    3480

ttcacgtagt  gggccatcgc  cctgatagac  ggttttttcgc  cctttgacgt  tggagtccac   3540

gttctttaat  agtggactct  tgttccaaac  tggaacaaca  ctcaacccta  tctcggtcta    3600

ttcttttgat  ttataaggga  ttttggggat  ttcggcctat  tggttaaaaa  atgagctgat    3660

ttaacaaaaa  tttaacgcga  attaattctg  tggaatgtgt  gtcagttagg  gtgtggaaag    3720

tccccaggct  ccccaggcag  gcagaagtat  gcaaagcatg  catctcaatt  agtcagcaac    3780

caggtgtgga  aagtccccag  gctccccagc  aggcagaagt  atgcaaagca  tgcatctcaa    3840

ttagtcagca  accatagtcc  cgcccctaac  tccgcccatc  ccgcccctaa  ctccgcccag    3900

ttccgcccat  tctccgcccc  atgctgact  aattttttt  atttatgcag  aggccgaggc    3960

cgcctctgcc  tctgagctat  tccagaagta  gtgaggaggc  ttttttggag  gcctaggctt    4020

ttgcaaaaag  ctcccgggag  cttgtatatc  cattttcgga  tctgatcagc  acgtgatgaa    4080

aaagcctgaa  ctcaccgcga  cgtctgtcga  gaagtttctg  atcgaaaagt  tcgacagcgt    4140

ctccgacctg  atgcagctct  cggagggcga  agaatctcgt  gctttcagct  tcgatgtagg    4200

agggcgtgga  tatgtcctgc  gggtaaatag  ctgcgccgat  ggtttctaca  aagatcgtta    4260

tgtttatcgg  cactttgcat  cggccgcgct  cccgattccg  gaagtgcttg  acattgggga    4320

attcagcgag  agcctgacct  attgcatctc  ccgccgtgca  cagggtgtca  cgttgcaaga    4380

cctgcctgaa  accgaactgc  ccgctgttct  gcagccggtc  gcggaggcca  tggatgcgat    4440

cgctgcggcc  gatcttagcc  agacgagcgg  gttcggccca  ttcggaccgc  aaggaatcgg    4500

tcaatacact  acatggcgtg  atttcatatg  cgcgattgct  gatccccatg  tgtatcactg    4560

gcaaactgtg  atggacgaca  ccgtcagtgc  gtccgtcgcg  caggctctcg  atgagctgat    4620

gctttgggcc  gaggactgcc  ccgaagtccg  gcacctcgtg  cacgcggatt  tcggctccaa    4680

caatgtcctg  acggacaatg  gccgcataac  agcggtcatt  gactggagcg  aggcgatgtt    4740

cggggattcc  caatacgagg  tcgccaacat  cttcttctgg  aggccgtggt  tggcttgtat    4800

ggagcagcag  acgcgctact  tcgagcggag  gcatccggag  cttgcaggat  cgccgcggct    4860

ccgggcgtat  atgctccgca  ttggtcttga  ccaactctat  cagagcttgg  ttgacggcaa    4920

tttcgatgat  gcagcttggg  cgcaggtcg  atgcgacgca  atcgtccgat  ccggagccgg    4980

gactgtcggg  cgtacacaaa  tcgcccgcag  aagcgcggcc  gtctggaccg  atggctgtgt    5040

agaagtactc  gccgatagtg  gaaaccgacg  ccccagcact  cgtccgaggg  caaaggaata    5100

gcacgtgcta  cgagatttcg  attccaccgc  cgccttctat  gaaaggttgg  gcttcggaat    5160

cgttttccgg  gacgccggct  ggatgatcct  ccagcgcggg  gatctcatgc  tggagttctt    5220

cgcccacccc  aacttgttta  ttgcagctta  taatggttac  aaataaagca  atagcatcac    5280
```

```
aaatttcaca aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat    5340

caatgtatct tatcatgtct gtataccgtc gacctctagc tagagcttgg cgtaatcatg    5400

gtcatagctg tttcctgtgt gaaattgtta tccgctcaca attccacaca acatacgagc    5460

cggaagcata aagtgtaaag cctggggtgc ctaatgagtg agctaactca cattaattgc    5520

gttgcgctca ctgcccgctt tccagtcggg aaacctgtcg tgccagctgc attaatgaat    5580

cggccaacgc gcggggagag gcggtttgcg tattgggcgc tcttccgctt cctcgctcac    5640

tgactcgctg cgctcggtcg ttcggctgcg gcgagcggta tcagctcact caaaggcggt    5700

aatacggtta tccacagaat cagggataa cgcaggaaag aacatgtgag caaaaggcca    5760

gcaaaaggcc aggaaccgta aaaaggccgc gttgctggcg tttttccata ggctccgccc    5820

ccctgacgag catcacaaaa atcgacgctc aagtcagagg tggcgaaacc cgacaggact    5880

ataaagatac caggcgtttc cccctggaag ctccctcgtg cgctctcctg ttccgaccct    5940

gccgcttacc ggatacctgt ccgcctttct cccttcggga agcgtggcgc tttctcaatg    6000

ctcacgctgt aggtatctca gttcggtgta ggtcgttcgc tccaagctgg gctgtgtgca    6060

cgaacccccc gttcagcccg accgctgcgc cttatccggt aactatcgtc ttgagtccaa    6120

cccggtaaga cacgacttat cgccactggc agcagccact ggtaacagga ttagcagagc    6180

gaggtatgta ggcggtgcta cagagttctt gaagtggtgg cctaactacg ctacactag    6240

aaggacagta tttggtatct gcgctctgct gaagccagtt accttcggaa aaagagttgg    6300

tagctcttga tccggcaaac aaaccaccgc tggtagcggt ggtttttttg tttgcaagca    6360

gcagattacg cgcagaaaaa aaggatctca agaagatcct ttgatctttt ctacggggtc    6420

tgacgctcag tggaacgaaa actcacgtta agggattttg gtcatgagat tatcaaaaag    6480

gatcttcacc tagatccttt taaattaaaa atgaagtttt aaatcaatct aaagtatata    6540

tgagtaaact tggtctgaca gttaccaatg cttaatcagt gaggcaccta tctcagcgat    6600

ctgtctattt cgttcatcca tagttgcctg actccccgtc gtgtagataa ctacgatacg    6660

ggagggctta ccatctggcc ccagtgctgc aatgataccg cgagacccac gctcaccggc    6720

tccagattta tcagcaataa accagccagc cggaagggcc gagcgcagaa gtggtcctgc    6780

aactttatcc gcctccatcc agtctattaa ttgttgccgg gaagctagag taagtagttc    6840

gccagttaat agtttgcgca acgttgttgc cattgctaca ggcatcgtgg tgtcacgctc    6900

gtcgtttggt atggcttcat tcagctccgg ttcccaacga tcaaggcgag ttacatgatc    6960

ccccatgttg tgcaaaaaag cggttagctc cttcggtcct ccgatcgttg tcagaagtaa    7020

gttggccgca gtgttatcac tcatggttat ggcagcactg cataattctc ttactgtcat    7080

gccatccgta agatgctttt ctgtgactgg tgagtactca accaagtcat tctgagaata    7140
```

```
gtgtatgcgg cgaccgagtt gctcttgccc ggcgtcaata cgggataata ccgcgccaca   7200

tagcagaact ttaaaagtgc tcatcattgg aaaacgttct tcggggcgaa aactctcaag   7260

gatcttaccg ctgttgagat ccagttcgat gtaacccact cgtgcaccca actgatcttc   7320

agcatctttt actttcacca gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc   7380

aaaaaaggga ataagggcga cacggaaatg ttgaatactc atactcttcc tttttcaata   7440

ttattgaagc atttatcagg gttattgtct catgagcgga tacatatttg aatgtattta   7500

gaaaaataaa caaatagggg ttccgcgcac atttccccga aaagtgccac ctgacgtc     7558
```

<210> 6

<211> 7576

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 6
```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg     60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg   120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc   180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt   240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata   300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc   360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc   420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt   480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt   540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca   600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg   660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc   720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg   780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca   840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga   900

ggtaccaagc ttggatctca ccatggagtt gggctgtgc tggattttcc tcgttgctct   960

tttaagaggt gtccagtgtc aggtgcagct ggtggagtct ggggaggcg tggtccagcc   1020
```

```
tgggaggtcc ctgagactct cctgtgcagc ctctggattc accttcatta gctatggcat    1080

gcactgggtc cgccaggctc caggcaaggg gctggagtgg gtggcagtta tatcatatga    1140

tggaagtaat aaatactatg cagactccgt gaagggccga ttcaccatct ccagagacaa    1200

ttccaagaac acgctgtatc tgcaaatgaa cagcctgaga gctgaggaca cggctgtgta    1260

ttactgtgcg agagtattag tgggagcttt atattattat aactactacg ggatggacgt    1320

ctggggccaa gggaccacgg tcaccgtctc ctcagcctcc accaagggcc catcggtctt    1380

ccccctggca ccctctagca agagcacctc tgggggcaca gcggccctgg gctgcctggt    1440

caaggactac ttccccgaac cggtgacggt gtcgtggaac tcaggcgccc tgaccagcgg    1500

cgtgcacacc ttcccggctg tcctacagtc ctcaggactc tactccctca gcagcgtggt    1560

gaccgtgccc tccagcagct tgggcaccca gacctacatc tgcaacgtga atcacaagcc    1620

cagcaacacc aaggtggaca gagagttggt gagaggcca gcacagggag ggagggtgtc    1680

tgctggaagc caggctcagc gctcctgcct ggacgcatcc cggctatgca gtcccagtcc    ·1740

agggcagcaa ggcaggcccc gtctgcctct tcacccggag gcctctgccc gccccactca    1800

tgctcaggga gagggtcttc tggcttttc cccaggctct gggcaggcac aggctaggtg    1860

cccctaaccc aggccctgca cacaaagggg caggtgctgg gctcagacct gccaagagcc    1920

atatccggga ggaccctgcc cctgacctaa gcccacccca aaggccaaac tctccactcc    1980

ctcagctcgg acaccttctc tcctcccaga ttccagtaac tcccaatctt ctctctgcag    2040

agcccaaatc ttgtgacaaa actcacacat gcccaccgtg cccaggtaag ccagcccagg    2100

cctcgccctc cagctcaagg cgggacaggt gccctagagt agcctgcatc cagggacagg    2160

ccccagccgg gtgctgacac gtccacctcc atctcttcct cagcacctga actcctgggg    2220

ggaccgtcag tcttcctctt ccccccaaaa cccaaggaca ccctcatgat ctcccggacc    2280

cctgaggtca catgcgtggt ggtggacgtg agccacgaag accctgaggt caagttcaac    2340

tggtacgtgg acggcgtgga ggtgcataat gccaagacaa agccgcggga ggagcagtac    2400

aacagcacgt accgtgtggt cagcgtcctc accgtcctgc accaggactg gctgaatggc    2460

aaggagtaca agtgcaaggt ctccaacaaa gccctcccag cccccatcga gaaaaccatc    2520

tccaaagcca aaggtgggac ccgtggggtg cgagggccac atggacagag gccggctcgg    2580

cccaccctct gccctgagag tgaccgctgt accaacctct gtccctacag ggcagccccg    2640

agaaccacag gtgtacaccc tgcccccatc ccgggaggag atgaccaaga accaggtcag    2700

cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt gggagagcaa    2760

tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt    2820

cttcctctat agcaagctca ccgtggacaa gagcaggtgg cagcagggga acgtcttctc    2880
```

```
atgctccgtg atgcatgagg ctctgcacaa ccactacacg cagaagagcc tctccctgtc      2940

tccgggtaaa tgagaattcc tcgagtctag agggcccgtt taaacccgct gatcagcctc      3000

gactgtgcct tctagttgcc agccatctgt tgtttgcccc tccccgtgc cttccttgac       3060

cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg catcgcattg      3120

tctgagtagg tgtcattcta ttctgggggg tggggtgggg caggacagca aggggagga      3180

ttgggaagac aatagcaggc atgctgggga tgcggtgggc tctatggctt ctgaggcgga     3240

aagaaccagc tggggctcta ggggggtatcc ccacgcgccc tgtagcggcg cattaagcgc     3300

ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgccc tagcgcccgc     3360

tcctttcgct ttcttccctt cctttctcgc cacgttcgcc ggctttcccc gtcaagctct      3420

aaatcggggc atccctttag ggttccgatt tagtgcttta cggcacctcg accccaaaaa      3480

acttgattag ggtgatggtt cacgtagtgg gccatcgccc tgatagacgg ttttttcgccc     3540

tttgacgttg gagtccacgt tctttaatag tggactcttg ttccaaactg gaacaacact      3600

caaccctatc tcggtctatt cttttgattt ataagggatt ttggggatttt cggcctattg      3660

gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg gaatgtgtgt      3720

cagttagggt gtggaaagtc cccaggctcc ccaggcaggc agaagtatgc aaagcatgca     3780

tctcaattag tcagcaacca ggtgtggaaa gtccccaggc tccccagcag gcagaagtat      3840

gcaaagcatg catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc      3900

gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat      3960

ttatgcagag gccgaggccg cctctgcctc tgagctattc cagaagtagt gaggaggctt      4020

ttttggaggc ctaggctttt gcaaaaagct cccgggagct tgtatatcca ttttcggatc      4080

tgatcagcac gtgatgaaaa agcctgaact caccgcgacg tctgtcgaga gtttctgat      4140

cgaaaagttc gacagcgtct ccgacctgat gcagctctcg gagggcgaag aatctcgtgc     4200

tttcagcttc gatgtaggag ggcgtggata tgtcctgcgg gtaaatagct gcgccgatgg     4260

tttctacaaa gatcgttatg tttatcggca ctttgcatcg gccgcgctcc cgattccgga     4320

agtgcttgac attggggaat tcagcgagag cctgacctat tgcatctccc gccgtgcaca     4380

gggtgtcacg ttgcaagacc tgcctgaaac cgaactgccc gctgttctgc agccggtcgc     4440

ggaggccatg gatgcgatcg ctgcggccga tcttagccag acgagcgggt tcggcccatt     4500

cggaccgcaa ggaatcggtc aatacactac atggcgtgat ttcatatgcg cgattgctga     4560

tccccatgtg tatcactggc aaactgtgat ggacgacacc gtcagtgcgt ccgtcgcgca     4620

ggctctcgat gagctgatgc tttgggccga ggactgcccc gaagtccggc acctcgtgca     4680

cgcggatttc ggctccaaca atgtcctgac ggacaatggc cgcataacag cggtcattga     4740
```

```
ctggagcgag gcgatgttcg gggattccca atacgaggtc gccaacatct tcttctggag    4800

gccgtggttg gcttgtatgg agcagcagac gcgctacttc gagcggaggc atccggagct    4860

tgcaggatcg ccgcggctcc gggcgtatat gctccgcatt ggtcttgacc aactctatca    4920

gagcttggtt gacggcaatt tcgatgatgc agcttgggcg cagggtcgat gcgacgcaat    4980

cgtccgatcc ggagccggga ctgtcgggcg tacacaaatc gcccgcagaa gcgcggccgt    5040

ctggaccgat ggctgtgtag aagtactcgc cgatagtgga aaccgacgcc ccagcactcg    5100

tccgagggca aaggaatagc acgtgctacg agatttcgat tccaccgccg ccttctatga    5160

aaggttgggc ttcggaatcg ttttccggga cgccggctgg atgatcctcc agcgcgggga    5220

tctcatgctg gagttcttcg cccaccccaa cttgtttatt gcagcttata atggttacaa    5280

ataaagcaat agcatcacaa atttcacaaa taaagcattt ttttcactgc attctagttg    5340

tggtttgtcc aaactcatca atgtatctta tcatgtctgt ataccgtcga cctctagcta    5400

gagcttggcg taatcatggt catagctgtt tcctgtgtga aattgttatc cgctcacaat    5460

tccacacaac atacgagccg gaagcataaa gtgtaaagcc tggggtgcct aatgagtgag    5520

ctaactcaca ttaattgcgt tgcgctcact gcccgctttc cagtcgggaa acctgtcgtg    ·5580

ccagctgcat taatgaatcg gccaacgcgc ggggagaggc ggtttgcgta ttgggcgctc    5640

ttccgcttcc tcgctcactg actcgctgcg ctcggtcgtt cggctgcggc gagcggtatc    5700

agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg caggaaagaa    5760

catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt    5820

tttccatagg ctccgccccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg    5880

gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg    5940

ctctcctgtt ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcgggaag    6000

cgtggcgctt tctcaatgct cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc    6060

caagctgggc tgtgtgcacg aacccccgt tcagcccgac cgctgcgcct tatccggtaa    6120

ctatcgtctt gagtccaacc cggtaagaca cgacttatcg ccactggcag cagccactgg    6180

taacaggatt agcagagcga ggtatgtagg cggtgctaca gagttcttga agtggtggcc    6240

taactacggc tacactagaa ggacagtatt tggtatctgc gctctgctga agccagttac    6300

cttcggaaaa agagttggta gctcttgatc cggcaaacaa accaccgctg gtagcggtgg    6360

tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt    6420

gatcttttct acggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttggt    6480

catgagatta tcaaaaagga tcttcaccta gatccttta aattaaaaat gaagttttaa    6540

atcaatctaa agtatatatg agtaaacttg gtctgacagt taccaatgct taatcagtga    6600
```

```
ggcacctatc  tcagcgatct  gtctatttcg  ttcatccata  gttgcctgac  tccccgtcgt   6660

gtagataact  acgatacggg  agggcttacc  atctggcccc  agtgctgcaa  tgataccgcg   6720

agacccacgc  tcaccggctc  cagatttatc  agcaataaac  cagccagccg  gaagggccga   6780

gcgcagaagt  ggtcctgcaa  ctttatccgc  ctccatccag  tctattaatt  gttgccggga   6840

agctagagta  agtagttcgc  cagttaatag  tttgcgcaac  gttgttgcca  ttgctacagg   6900

catcgtggtg  tcacgctcgt  cgtttggtat  ggcttcattc  agctccggtt  cccaacgatc   6960

aaggcgagtt  acatgatccc  ccatgttgtg  caaaaaagcg  gttagctcct  tcggtcctcc   7020

gatcgttgtc  agaagtaagt  tggccgcagt  gttatcactc  atggttatgg  cagcactgca   7080

taattctctt  actgtcatgc  catccgtaag  atgcttttct  gtgactggtg  agtactcaac   7140

caagtcattc  tgagaatagt  gtatgcggcg  accgagttgc  tcttgcccgg  cgtcaatacg   7200

ggataatacc  gcgccacata  gcagaacttt  aaaagtgctc  atcattggaa  aacgttcttc   7260

ggggcgaaaa  ctctcaagga  tcttaccgct  gttgagatcc  agttcgatgt  aacccactcg   7320

tgcacccaac  tgatcttcag  catcttttac  tttcaccagc  gtttctgggt  gagcaaaaac   7380

aggaaggcaa  aatgccgcaa  aaaagggaat  aagggcgaca  cggaaatgtt  gaatactcat   7440

actcttcctt  tttcaatatt  attgaagcat  ttatcagggt  tattgtctca  tgagcggata   7500

catatttgaa  tgtatttaga  aaaataaaca  ataggggtt  ccgcgcacat  ttccccgaaa   7560

agtgccacct  gacgtc                                                       7576
```

<210> 7

<211> 7561

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 7

```
gacggatcgg  gagatctccc  gatcccctat  ggtcgactct  cagtacaatc  tgctctgatg   60

ccgcatagtt  aagccagtat  ctgctccctg  cttgtgtgtt  ggaggtcgct  gagtagtgcg   120

cgagcaaaat  ttaagctaca  acaaggcaag  gcttgaccga  caattgcatg  aagaatctgc   180

ttagggttag  gcgttttgcg  ctgcttcgcg  atgtacgggc  cagatatacg  cgttgacatt   240

gattattgac  tagttattaa  tagtaatcaa  ttacggggtc  attagttcat  agcccatata   300

tggagttccg  cgttacataa  cttacggtaa  atggcccgcc  tggctgaccg  cccaacgacc   360

cccgcccatt  gacgtcaata  atgacgtatg  ttcccatagt  aacgccaata  gggactttcc   420
```

```
attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt    480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720

aaaatcaacg ggactttcca aaatgtcgta caactccgc cccattgacg caaatgggcg     780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga    900

ggtaccggat ctcaccatgg agttggggct gagctgggtt ttcctcgttg ctcttttaag    960

aggtgtccag tgtcaggagc agctggtgga gtctggggga ggcgtggtcc agcctgggag   1020

gtccctgaga ctctcctgtg cagcgtctgg attcaccttc agtacctatg gcatgcactg   1080

ggtccgccag gctccaggca aggggctgga gtgggtggca gttacatggc atgatggaag   1140

taataaatac tatgcagact ccgtgaaggg ccgattcacc atctccagag acaactccaa   1200

gaacacgctg tatctgcaaa tgaacagcct gagagccgag gacacggctg tgtattactg   1260

tgcgagagga ggagtgggag caacttacta ctactactac ggtatggacg tctggggcca   1320

agggaccacg gtcaccgtct cctcagcctc caccaagggc ccatcggtct tccccctggc   1380

accctctagc aagagcacct ctgggggcac agcggccctg ggctgcctgg tcaaggacta   1440

cttccccgaa ccggtgacgg tgtcgtggaa ctcaggcgcc ctgaccagcg gcgtgcacac   1500

cttcccggct gtcctacagt cctcaggact ctactccctc agcagcgtgg tgaccgtgcc   1560

ctccagcagc ttgggcaccc agacctacat ctgcaacgtg aatcacaagc ccagcaacac   1620

caaggtggac aagagagttg gtgagaggcc agcacaggga gggagggtgt ctgctggaag   1680

ccaggctcag cgctcctgcc tggacgcatc ccggctatgc agtcccagtc caggcagca    1740

aggcaggccc cgtctgcctc ttcacccgga ggcctctgcc cgccccactc atgctcaggg   1800

agagggtctt ctggcttttt ccccaggctc tgggcaggca caggctaggt gcccctaacc   1860

caggccctgc acacaaaggg gcaggtgctg ggctcagacc tgccaagagc catatccggg   1920

aggaccctgc ccctgaccta gcccacccc aaaggccaaa ctctccactc cctcagctcg    1980

gacaccttct ctcctcccag attccagtaa ctcccaatct tctctctgca gagcccaaat   2040

cttgtgacaa aactcacaca tgcccaccgt gcccaggtaa gccagcccag gcctcgccct   2100

ccagctcaag gcgggacagg tgccctagag tagcctgcat ccaggacag gccccagccg     2160

ggtgctgaca cgtccacctc catctcttcc tcagcacctg aactcctggg gggaccgtca   2220

gtcttcctct tccccccaaa acccaaggac accctcatga tctcccggac ccctgaggtc   2280
```

```
acatgcgtgg  tggtggacgt  gagccacgaa  gaccctgagg  tcaagttcaa  ctggtacgtg  2340

gacggcgtgg  aggtgcataa  tgccaagaca  aagccgcggg  aggagcagta  caacagcacg  2400

taccgtgtgg  tcagcgtcct  caccgtcctg  caccaggact  ggctgaatgg  caaggagtac  2460

aagtgcaagg  tctccaacaa  agccctccca  gcccccatcg  agaaaaccat  ctccaaagcc  2520

aaaggtggga  cccgtggggt  gcgagggcca  catggacaga  ggccggctcg  gcccaccctc  2580

tgccctgaga  gtgaccgctg  taccaacctc  tgtccctaca  gggcagcccc  gagaaccaca  2640

ggtgtacacc  ctgcccccat  cccgggagga  gatgaccaag  aaccaggtca  gcctgacctg  2700

cctggtcaaa  ggcttctatc  ccagcgacat  cgccgtggag  tgggagagca  atgggcagcc  2760

ggagaacaac  tacaagacca  cgcctcccgt  gctggactcc  gacggctcct  tcttcctcta  2820

tagcaagctc  accgtggaca  agagcaggtg  gcagcagggg  aacgtcttct  catgctccgt  2880

gatgcatgag  gctctgcaca  accactacac  gcagaagagc  ctctccctgt  ctccgggtaa  2940

atgactcgag  tctagagggc  ccgtttaaac  ccgctgatca  gcctcgactg  tgccttctag  3000

ttgccagcca  tctgttgttt  gcccctcccc  cgtgccttcc  ttgaccctgg  aaggtgccac  3060

tcccactgtc  ctttcctaat  aaaatgagga  aattgcatcg  cattgtctga  gtaggtgtca  3120

ttctattctg  gggggtgggg  tggggcagga  cagcaagggg  gaggattggg  aagacaatag  3180

caggcatgct  ggggatgcgg  tgggctctat  ggcttctgag  gcggaaagaa  ccagctgggg  3240

ctctagggggg  tatccccacg  cgccctgtag  cggcgcatta  agcgcggcgg  gtgtggtggt  3300

tacgcgcagc  gtgaccgcta  cacttgccag  cgccctagcg  cccgctcctt  tcgctttctt  3360

cccttccttt  ctcgccacgt  tcgccggctt  tccccgtcaa  gctctaaatc  ggggcatccc  3420

tttagggttc  cgatttagtg  ctttacggca  cctcgacccc  aaaaaacttg  attagggtga  3480

tggttcacgt  agtgggccat  cgccctgata  gacggttttt  cgccctttga  cgttggagtc  3540

cacgttcttt  aatagtggac  tcttgttcca  aactggaaca  acactcaacc  ctatctcggt  3600

ctattctttt  gatttataag  ggattttggg  gatttcggcc  tattggttaa  aaaatgagct  3660

gatttaacaa  aaatttaacg  cgaattaatt  ctgtggaatg  tgtgtcagtt  agggtgtgga  3720

aagtccccag  gctccccagg  caggcagaag  tatgcaaagc  atgcatctca  attagtcagc  3780

aaccaggtgt  ggaaagtccc  caggctcccc  agcaggcaga  agtatgcaaa  gcatgcatct  3840

caattagtca  gcaaccatag  tcccgcccct  aactccgccc  atcccgcccc  taactccgcc  3900

cagttccgcc  cattctccgc  cccatggctg  actaattttt  tttatttatg  cagaggccga  3960

ggccgcctct  gcctctgagc  tattccagaa  gtagtgagga  ggcttttttg  gaggcctagg  4020

cttttgcaaa  aagctcccgg  gagcttgtat  atccattttc  ggatctgatc  agcacgtgat  4080

gaaaagcct  gaactcaccg  cgacgtctgt  cgagaagttt  ctgatcgaaa  agttcgacag  4140
```

```
cgtctccgac  ctgatgcagc  tctcggaggg  cgaagaatct  cgtgctttca  gcttcgatgt      4200

aggagggcgt  ggatatgtcc  tgcgggtaaa  tagctgcgcc  gatggtttct  acaaagatcg      4260

ttatgtttat  cggcactttg  catcggccgc  gctcccgatt  ccggaagtgc  ttgacattgg      4320

ggaattcagc  gagagcctga  cctattgcat  ctcccgccgt  gcacagggtg  tcacgttgca      4380

agacctgcct  gaaaccgaac  tgcccgctgt  tctgcagccg  gtcgcggagg  ccatggatgc      4440

gatcgctgcg  gccgatctta  gccagacgag  cgggttcggc  ccattcggac  cgcaaggaat      4500

cggtcaatac  actacatggc  gtgatttcat  atgcgcgatt  gctgatcccc  atgtgtatca      4560

ctggcaaact  gtgatggacg  acaccgtcag  tgcgtccgtc  gcgcaggctc  tcgatgagct      4620

gatgctttgg  gccgaggact  gccccgaagt  ccggcacctc  gtgcacgcgg  atttcggctc      4680

caacaatgtc  ctgacggaca  atggccgcat  aacagcggtc  attgactgga  gcgaggcgat      4740

gttcggggat  tcccaatacg  aggtcgccaa  catcttcttc  tggaggccgt  ggttggcttg      4800

tatggagcag  cagacgcgct  acttcgagcg  gaggcatccg  gagcttgcag  gatcgccgcg      4860

gctccgggcg  tatatgctcc  gcattggtct  tgaccaactc  tatcagagct  tggttgacgg      4920

caatttcgat  gatgcagctt  gggcgcaggg  tcgatgcgac  gcaatcgtcc  gatccggagc      4980

cgggactgtc  gggcgtacac  aaatcgcccg  cagaagcgcg  gccgtctgga  ccgatggctg      5040

tgtagaagta  ctcgccgata  gtggaaaccg  acgccccagc  actcgtccga  gggcaaagga      5100

atagcacgtg  ctacgagatt  tcgattccac  cgccgccttc  tatgaaaggt  tgggcttcgg      5160

aatcgttttc  cgggacgccg  gctggatgat  cctccagcgc  ggggatctca  tgctggagtt      5220

cttcgcccac  cccaacttgt  ttattgcagc  ttataatggt  tacaaataaa  gcaatagcat      5280

cacaaatttc  acaaataaag  catttttttc  actgcattct  agttgtggtt  tgtccaaact      5340

catcaatgta  tcttatcatg  tctgtatacc  gtcgacctct  agctagagct  tggcgtaatc      5400

atggtcatag  ctgtttcctg  tgtgaaattg  ttatccgctc  acaattccac  acaacatacg      5460

agccggaagc  ataaagtgta  aagcctgggg  tgcctaatga  gtgagctaac  tcacattaat      5520

tgcgttgcgc  tcactgcccg  ctttccagtc  gggaaacctg  tcgtgccagc  tgcattaatg      5580

aatcggccaa  cgcgcgggga  gaggcggttt  gcgtattggg  cgctcttccg  cttcctcgct      5640

cactgactcg  ctgcgctcgg  tcgttcggct  gcggcgagcg  gtatcagctc  actcaaaggc      5700

ggtaatacgg  ttatccacag  aatcaggggа  taacgcagga  aagaacatgt  gagcaaaagg      5760

ccagcaaaag  gccaggaacc  gtaaaaaggc  cgcgttgctg  gcgtttttcc  ataggctccg      5820

cccccctgac  gagcatcaca  aaaatcgacg  ctcaagtcag  aggtggcgaa  acccgacagg      5880

actataaaga  taccaggcgt  ttccccctgg  aagctccctc  gtgcgctctc  ctgttccgac      5940

cctgccgctt  accggatacc  tgtccgcctt  tctcccttcg  ggaagcgtgg  cgctttctca      6000
```

```
atgctcacgc tgtaggtatc tcagttcggt gtaggtcgtt cgctccaagc tgggctgtgt    6060

gcacgaaccc cccgttcagc ccgaccgctg cgccttatcc ggtaactatc gtcttgagtc    6120

caacccggta agacacgact tatcgccact ggcagcagcc actggtaaca ggattagcag    6180

agcgaggtat gtaggcggtg ctacagagtt cttgaagtgg tggcctaact acggctacac    6240

tagaaggaca gtatttggta tctgcgctct gctgaagcca gttaccttcg gaaaaagagt    6300

tggtagctct tgatccggca aacaaaccac cgctggtagc ggtggttttt ttgtttgcaa    6360

gcagcagatt acgcgcagaa aaaaggatc tcaagaagat cctttgatct tttctacggg    6420

gtctgacgct cagtggaacg aaaactcacg ttaagggatt ttggtcatga gattatcaaa    6480

aaggatcttc acctagatcc tttaaatta aaaatgaagt tttaaatcaa tctaaagtat    6540

atatgagtaa acttggtctg acagttacca atgcttaatc agtgaggcac ctatctcagc    6600

gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga taactacgat    6660

acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc cacgctcacc    6720

ggctccagat ttatcagcaa taaaccagcc agccggaagg ccgagcgca gaagtggtcc    6780

tgcaacttta tccgcctcca tccagtctat taattgttgc cgggaagcta gagtaagtag    6840

ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg tggtgtcacg    6900

ctcgtcgttt ggtatggctt cattcagctc cggttcccaa cgatcaaggc gagttacatg    6960

atcccccatg ttgtgcaaaa aagcggttag ctccttcggt cctccgatcg ttgtcagaag    7020

taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt ctcttactgt    7080

catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt cattctgaga    7140

atagtgtatg cggcgaccga gttgctcttg cccggcgtca atacgggata ataccgcgcc    7200

acatagcaga actttaaaag tgctcatcat tggaaaacgt tcttcggggc gaaaactctc    7260

aaggatctta ccgctgttga gatccagttc gatgtaaccc actcgtgcac ccaactgatc    7320

ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa ggcaaaatgc    7380

cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct ccttttttca    7440

atattattga agcatttatc agggttattg tctcatgagc ggatacatat ttgaatgtat    7500

ttagaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc cacctgacgt    7560

c                                                                     7561
```

<210> 8

<211> 6082

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 8

gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg   60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg   120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc   180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt   240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata   300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc   360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc   420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt   480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt   540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca   600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg   660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc   720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg   780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca   840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga   900

aagcttggat ctcaccatga gggtccctgc tcagctcctg ggactcctgc tgctctggct   960

cccagatacc agatgtgaca tccagatgac ccagtctcca tcctccctgt ctgcatctgt   1020

aggagacaga gtcaccatca cttgccgggc gagtcagggc attagcaatt atttagcctg   1080

gtatcagcag aaaacaggga aagttcctaa gttcctgatc tatgaagcat ccactttgca   1140

atcaggggtc ccatctcggt tcagtggcgg tggatctggg acagatttca ctctcaccat   1200

cagcagcctg cagcctgaag atgttgcaac ttattactgt caaaattata acagtgcccc   1260

attcactttc ggccctggga ccaaagtgga tatcaaacga actgtggctg caccctctgt   1320

cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgctagcg ttgtgtgcct   1380

gctgaataac ttctatccca gagaggccaa agtacagtgg aaggtggata cgccctcca   1440

atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct   1500

cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga   1560

agtcacccat cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtta   1620

ggaattcgcg gccgctcgag tctagagggc ccgtttaaac ccgctgatca gcctcgactg   1680

```
tgccttctag ttgccagcca tctgttgttt gccctcccc cgtgccttcc ttgaccctgg    1740

aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga    1800

gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg    1860

aagacaatag caggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa    1920

ccagctgggg ctctaggggg tatccccacg cgccctgtag cggcgcatta agcgcggcgg    1980

gtgtggtggt tacgcgcagc gtgaccgcta cacttgccag cgccctagcg cccgctcctt    2040

tcgctttctt cccttccttt ctcgccacgt tcgccggctt tccccgtcaa gctctaaatc    2100

ggggcatccc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg    2160

attagggtga tggttcacgt agtgggccat cgccctgata gacggttttt cgccctttga    2220

cgttggagtc cacgttcttt aatagtggac tcttgttcca aactggaaca acactcaacc    2280

ctatctcggt ctattctttt gatttataag ggattttggg gatttcggcc tattggttaa    2340

aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt    2400

agggtgtgga aagtccccag gctccccagg caggcagaag tatgcaaagc atgcatctca    2460

attagtcagc aaccaggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa    2520

gcatgcatct caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc    2580

taactccgcc cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg    2640

cagaggccga ggccgcctct gcctctgagc tattccagaa gtagtgagga ggcttttttg    2700

gaggcctagg cttttgcaaa aagctcccgg gagcttgtat atccattttc ggatctgatc    2760

aagagacagg atgaggatcg tttcgcatga ttgaacaaga tggattgcac gcaggttctc    2820

cggccgcttg ggtggagagg ctattcggct atgactgggc acaacagaca atcggctgct    2880

ctgatgccgc cgtgttccgg ctgtcagcgc aggggcgccc ggttcttttt gtcaagaccg    2940

acctgtccgg tgccctgaat gaactgcagg acgaggcagc gcggctatcg tggctggcca    3000

cgacgggcgt tccttgcgca gctgtgctcg acgttgtcac tgaagcggga agggactggc    3060

tgctattggg cgaagtgccg gggcaggatc tcctgtcatc tcaccttgct cctgccgaga    3120

aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgatccg gctacctgcc    3180

cattcgacca ccaagcgaaa catcgcatcg agcgagcacg tactcggatg gaagccggtc    3240

ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgccagcc gaactgttcg    3300

ccaggctcaa ggcgcgcatg cccgacggcg aggatctcgt cgtgacccat ggcgatgcct    3360

gcttgccgaa tatcatggtg gaaaatggcc gctttctgg attcatcgac tgtggccggc     3420

tgggtgtggc ggaccgctat caggacatag cgttggctac ccgtgatatt gctgaagagc    3480

ttggcggcga atgggctgac cgcttcctcg tgctttacgg tatcgccgct cccgattcgc    3540
```

```
agcgcatcgc cttctatcgc cttcttgacg agttcttctg agcgggactc tggggttcga   3600

aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttcgattcca ccgccgcctt   3660

ctatgaaagg ttgggcttcg gaatcgtttt ccgggacgcc ggctggatga tcctccagcg   3720

cggggatctc atgctggagt tcttcgccca ccccaacttg tttattgcag cttataatgg   3780

ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc   3840

tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctgtatac cgtcgacctc   3900

tagctagagc ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct   3960

cacaattcca cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaatg   4020

agtgagctaa ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct   4080

gtcgtgccag ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg   4140

gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg gtcgttcggc tgcggcgagc   4200

ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg   4260

aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct   4320

ggcgtttttc cataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca   4380

gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct   4440

cgtgcgctct cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc   4500

gggaagcgtg gcgctttctc aatgctcacg ctgtaggtat ctcagttcgg tgtaggtcgt   4560

tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc   4620

cggtaactat cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc   4680

cactggtaac aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg   4740

gtggcctaac tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc   4800

agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag   4860

cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaggat ctcaagaaga   4920

tcctttgatc ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat   4980

tttggtcatg agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag   5040

ttttaaatca atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat   5100

cagtgaggca cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc   5160

cgtcgtgtag ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat   5220

accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag   5280

ggccgagcgc agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg   5340

ccgggaagct agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc   5400
```

```
tacaggcatc gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca    5460

acgatcaagg cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg    5520

tcctccgatc gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc    5580

actgcataat tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta    5640

ctcaaccaag tcattctgag aatagtgtat gcggcgaccg agttgctctt ccccggcgtc    5700

aatacgggat aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg    5760

ttcttcgggg cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc    5820

cactcgtgca cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc    5880

aaaaacagga aggcaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatgttgaat    5940

actcatactc ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag    6000

cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc    6060

ccgaaaagtg ccacctgacg tc                                            6082
```

<210> 9

<211> 6082

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 9
```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg     60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg    120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc    180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt    240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata    300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc    360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc    420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt    480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720
```

```
aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg    780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga    900

aagcttggat ctcaccatga gggtccccgc tcagctcctg gggctcctgc tgctctgttt    960

cccaggtgcc agatgtgaca tccagatgac ccagtctcca tcctcactgt ctgcatctgt   1020

aggagacaga gtcaccatca cttgtcgggc gagtcagggc attaccaatt atttagcctg   1080

gtttcagcag aaaccaggga aagcccctaa gtcccttatc tatgctgcat ccagtttgca   1140

aagtggggtc ccatcaaagt tcagcggcag tggatctggg acagatttca gtctcaccat   1200

cagcagcctg cagcctgaag attttgcaac ttattactgc aacagtata atagttaccc   1260

gatcaccttc ggccaaggga cacgactgga gattaaacga actgtggctg caccatctgt   1320

cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgctagcg ttgtgtgcct   1380

gctgaataac ttctatccca gagaggccaa agtacagtgg aaggtggata acgccctcca   1440

atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct   1500

cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga   1560

agtcacccat cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtta   1620

ggaattcgcg gccgctcgag tctagagggc ccgtttaaac ccgctgatca gcctcgactg   1680

tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg   1740

aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga   1800

gtaggtgtca ttctattctg ggggtgggg tggggcagga cagcaagggg gaggattggg   1860

aagacaatag caggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa   1920

ccagctgggg ctctaggggg tatccccacg cgccctgtag cggcgcatta agcgcggcgg   1980

gtgtggtggt tacgcgcagc gtgaccgcta cacttgccag cgccctagcg cccgctcctt   2040

tcgctttctt cccttccttt ctcgccacgt tcgccggctt tccccgtcaa gctctaaatc   2100

ggggcatccc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg   2160

attagggtga tggttcacgt agtgggccat cgccctgata cacggttttt cgcctttga   2220

cgttggagtc cacgttcttt aatagtggac tcttgttcca aactggaaca cactcaacc   2280

ctatctcggt ctattctttt gatttataag gattttggg gatttcggcc tattggttaa   2340

aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt   2400

agggtgtgga aagtccccag gctccccagg caggcagaag tatgcaaagc atgcatctca   2460

attagtcagc aaccaggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa   2520

gcatgcatct caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc   2580
```

```
taactccgcc cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg      2640

cagaggccga ggccgcctct gcctctgagc tattccagaa gtagtgagga ggctttttg       2700

gaggcctagg cttttgcaaa aagctcccgg gagcttgtat atccattttc ggatctgatc      2760

aagagacagg atgaggatcg tttcgcatga ttgaacaaga tggattgcac gcaggttctc      2820

cggccgcttg ggtggagagg ctattcggct atgactgggc acaacagaca atcggctgct      2880

ctgatgccgc cgtgttccgg ctgtcagcgc aggggcgccc ggttcttttt gtcaagaccg      2940

acctgtccgg tgccctgaat gaactgcagg acgaggcagc gcggctatcg tggctggcca      3000

cgacgggcgt tccttgcgca gctgtgctcg acgttgtcac tgaagcggga agggactggc      3060

tgctattggg cgaagtgccg gggcaggatc tcctgtcatc tcaccttgct cctgccgaga      3120

aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgatccg gctacctgcc      3180

cattcgacca ccaagcgaaa catcgcatcg agcgagcacg tactcggatg gaagccggtc      3240

ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgccagcc gaactgttcg      3300

ccaggctcaa ggcgcgcatg cccgacggcg aggatctcgt cgtgacccat ggcgatgcct      3360

gcttgccgaa tatcatggtg gaaaatggcc gcttttctgg attcatcgac tgtggccggc      3420

tgggtgtggc ggaccgctat caggacatag cgttggctac ccgtgatatt gctgaagagc      3480

ttggcggcga atgggctgac cgcttcctcg tgctttacgg tatcgccgct cccgattcgc      3540

agcgcatcgc cttctatcgc cttcttgacg agttcttctg agcgggactc tggggttcga      3600

aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttcgattcca ccgccgcctt      3660

ctatgaaagg ttgggcttcg gaatcgtttt ccgggacgcc ggctggatga tcctccagcg      3720

cggggatctc atgctggagt tcttcgccca ccccaacttg tttattgcag cttataatgg      3780

ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc      3840

tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctgtatac cgtcgacctc      3900

tagctagagc ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct      3960

cacaattcca cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaatg      4020

agtgagctaa ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct      4080

gtcgtgccag ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg      4140

gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg tcgttcggc  tgcggcgagc      4200

ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg      4260

aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct      4320

ggcgtttttc cataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca      4380

gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct      4440
```

```
cgtgcgctct   cctgttccga   ccctgccgct   taccggatac   ctgtccgcct   ttctcccttc    4500

gggaagcgtg   gcgctttctc   aatgctcacg   ctgtaggtat   ctcagttcgg   tgtaggtcgt    4560

tcgctccaag   ctgggctgtg   tgcacgaacc   ccccgttcag   cccgaccgct   gcgccttatc    4620

cggtaactat   cgtcttgagt   ccaacccggt   aagacacgac   ttatcgccac   tggcagcagc    4680

cactggtaac   aggattagca   gagcgaggta   tgtaggcggt   gctacagagt   tcttgaagtg    4740

gtggcctaac   tacggctaca   ctagaaggac   agtatttggt   atctgcgctc   tgctgaagcc    4800

agttaccttc   ggaaaaagag   ttggtagctc   ttgatccggc   aaacaaacca   ccgctggtag    4860

cggtggtttt   tttgtttgca   agcagcagat   tacgcgcaga   aaaaaggat   ctcaagaaga    4920

tcctttgatc   ttttctacgg   ggtctgacgc   tcagtggaac   gaaaactcac   gttaagggat    4980

tttggtcatg   agattatcaa   aaaggatctt   cacctagatc   cttttaaatt   aaaaatgaag    5040

ttttaaatca   atctaaagta   tatatgagta   aacttggtct   gacagttacc   aatgcttaat    5100

cagtgaggca   cctatctcag   cgatctgtct   atttcgttca   tccatagttg   cctgactccc    5160

cgtcgtgtag   ataactacga   tacgggaggg   cttaccatct   ggccccagtg   ctgcaatgat    5220

accgcgagac   ccacgctcac   cggctccaga   tttatcagca   ataaaccagc   cagccggaag    5280

ggccgagcgc   agaagtggtc   ctgcaacttt   atccgcctcc   atccagtcta   ttaattgttg    5340

ccgggaagct   agagtaagta   gttcgccagt   taatagtttg   cgcaacgttg   ttgccattgc    5400

tacaggcatc   gtggtgtcac   gctcgtcgtt   tggtatggct   tcattcagct   ccggttccca    5460

acgatcaagg   cgagttacat   gatcccccat   gttgtgcaaa   aaagcggtta   gctccttcgg    5520

tcctccgatc   gttgtcagaa   gtaagttggc   cgcagtgtta   tcactcatgg   ttatggcagc    5580

actgcataat   tctcttactg   tcatgccatc   cgtaagatgc   ttttctgtga   ctggtgagta    5640

ctcaaccaag   tcattctgag   aatagtgtat   gcggcgaccg   agttgctctt   gcccggcgtc    5700

aatacgggat   aataccgcgc   cacatagcag   aactttaaaa   gtgctcatca   ttggaaaacg    5760

ttcttcgggg   cgaaaactct   caaggatctt   accgctgttg   agatccagtt   cgatgtaacc    5820

cactcgtgca   cccaactgat   cttcagcatc   ttttactttc   accagcgttt   ctgggtgagc    5880

aaaaacagga   aggcaaaatg   ccgcaaaaaa   gggaataagg   gcgacacgga   aatgttgaat    5940

actcatactc   ttcctttttc   aatattattg   aagcatttat   cagggttatt   gtctcatgag    6000

cggatacata   tttgaatgta   tttagaaaaa   taaacaaata   ggggttccgc   gcacatttcc    6060

ccgaaaagtg   ccacctgacg   tc                                                  6082
```

<210> 10

<211> 6082

```
<212>  DNA

<213>  Artificial Sequence

<220>

<223>  Plasmid

<400>  10
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg      60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg     120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc     180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt     240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata     300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc     360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc     420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt     480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt     540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca     600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg     660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc     720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg     780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca     840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga     900

aagcttggat ctcaccatga gggtccctgc tcagctcctg gggctcctgc tgctctgttt     960

cccaggtgcc agatgtgaca tccagatgac ccagtctcca tcctcactgt ctgcatctgt    1020

aggagacaga gtcaccatca cttgtcgggc gagtcagggc attagccatt atttagcctg    1080

gtttcagcag aaaccaggga agcccctaa gtccctgatc tatgctgcat ccagtttgca    1140

aagtggggtc ccatcaaagt tcagcggcag tggatctggg acagatttca ctctcaccat    1200

cagcagccta cagcctgaag attttgcaac ttattactgc caacagtata atagtttccc    1260

gctcactttc ggcggaggga ccaaggtgga gatcaaacga actgtggctg caccatctgt    1320

cttcatcttc ccgccatctg atgagcagtt gaaatctgga actgctagcg ttgtgtgcct    1380

gctgaataac ttctatccca gagaggccaa agtacagtgg aaggtggata acgccctcca    1440

atcgggtaac tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct    1500

cagcagcacc ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga    1560

agtcacccat cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtta    1620
```

```
ggaattcgcg gccgctcgag tctagagggc ccgtttaaac ccgctgatca gcctcgactg   1680

tgccttctag ttgccagcca tctgttgttt gcccctcccc cgtgccttcc ttgaccctgg   1740

aaggtgccac tcccactgtc ctttcctaat aaaatgagga aattgcatcg cattgtctga   1800

gtaggtgtca ttctattctg gggggtgggg tggggcagga cagcaagggg gaggattggg   1860

aagacaatag caggcatgct ggggatgcgg tgggctctat ggcttctgag gcggaaagaa   1920

ccagctgggg ctctaggggg tatccccacg cgccctgtag cggcgcatta agcgcggcgg   1980

gtgtggtggt tacgcgcagc gtgaccgcta cacttgccag cgccctagcg cccgctcctt   2040

tcgctttctt cccttccttt ctcgccacgt tcgccggctt tccccgtcaa gctctaaatc   2100

ggggcatccc tttagggttc cgatttagtg ctttacggca cctcgacccc aaaaaacttg   2160

attagggtga tggttcacgt agtgggccat cgccctgata gacggttttt cgccctttga   2220

cgttggagtc cacgttcttt aatagtggac tcttgttcca aactggaaca acactcaacc   2280

ctatctcggt ctattctttt gatttataag ggattttggg gatttcggcc tattggttaa   2340

aaaatgagct gatttaacaa aaatttaacg cgaattaatt ctgtggaatg tgtgtcagtt   2400

agggtgtgga aagtccccag gctccccagg caggcagaag tatgcaaagc atgcatctca   2460

attagtcagc aaccaggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa   2520

gcatgcatct caattagtca gcaaccatag tcccgcccct aactccgccc atcccgcccc   2580

taactccgcc cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg   2640

cagaggccga ggccgcctct gcctctgagc tattccagaa gtagtgagga ggcttttttg   2700

gaggcctagg cttttgcaaa aagctcccgg gagcttgtat atccattttc ggatctgatc   2760

aagagacagg atgaggatcg tttcgcatga ttgaacaaga tggattgcac gcaggttctc   2820

cggccgcttg ggtggagagg ctattcggct atgactgggc acaacagaca atcggctgct   2880

ctgatgccgc cgtgttccgg ctgtcagcgc aggggcgccc ggttcttttt gtcaagaccg   2940

acctgtccgg tgccctgaat gaactgcagg acgaggcagc gcggctatcg tggctggcca   3000

cgacgggcgt tccttgcgca gctgtgctcg acgttgtcac tgaagcggga agggactggc   3060

tgctattggg cgaagtgccg gggcaggatc tcctgtcatc tcaccttgct cctgccgaga   3120

aagtatccat catggctgat gcaatgcggc ggctgcatac gcttgatccg gctacctgcc   3180

cattcgacca ccaagcgaaa catcgcatcg agcgagcacg tactcggatg gaagccggtc   3240

ttgtcgatca ggatgatctg gacgaagagc atcaggggct cgcgccagcc gaactgttcg   3300

ccaggctcaa ggcgcgcatg cccgacggcg aggatctcgt cgtgacccat ggcgatgcct   3360

gcttgccgaa tatcatggtg gaaaatggcc gcttttctgg attcatcgac tgtggccggc   3420

tgggtgtggc ggaccgctat caggacatag cgttggctac ccgtgatatt gctgaagagc   3480
```

```
ttggcggcga atgggctgac cgcttcctcg tgctttacgg tatcgccgct cccgattcgc   3540

agcgcatcgc cttctatcgc cttcttgacg agttcttctg agcgggactc tggggttcga   3600

aatgaccgac caagcgacgc ccaacctgcc atcacgagat ttcgattcca ccgccgcctt   3660

ctatgaaagg ttgggcttcg gaatcgtttt ccgggacgcc ggctggatga tcctccagcg   3720

cggggatctc atgctggagt tcttcgccca ccccaacttg tttattgcag cttataatgg   3780

ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt cactgcattc   3840

tagttgtggt ttgtccaaac tcatcaatgt atcttatcat gtctgtatac cgtcgacctc   3900

tagctagagc ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct   3960

cacaattcca cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaatg   4020

agtgagctaa ctcacattaa ttgcgttgcg ctcactgccc gctttccagt cgggaaacct   4080

gtcgtgccag ctgcattaat gaatcggcca acgcgcgggg agaggcggtt tgcgtattgg   4140

gcgctcttcc gcttcctcgc tcactgactc gctgcgctcg tcgttcggc tgcggcgagc   4200

ggtatcagct cactcaaagg cggtaatacg gttatccaca gaatcagggg ataacgcagg   4260

aaagaacatg tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct   4320

ggcgtttttc cataggctcc gccccctga cgagcatcac aaaaatcgac gctcaagtca   4380

gaggtggcga aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct   4440

cgtgcgctct cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc   4500

gggaagcgtg gcgctttctc aatgctcacg ctgtaggtat ctcagttcgg tgtaggtcgt   4560

tcgctccaag ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc   4620

cggtaactat cgtcttgagt ccaacccggt aagacgac ttatcgccac tggcagcagc   4680

cactggtaac aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg   4740

gtggcctaac tacggctaca ctagaaggac agtatttggt atctgcgctc tgctgaagcc   4800

agttaccttc ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag   4860

cggtggtttt tttgtttgca agcagcagat tacgcgcaga aaaaaggat ctcaagaaga   4920

tcctttgatc ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat   4980

tttggtcatg agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag   5040

ttttaaatca atctaaagta tatatgagta aacttggtct gacagttacc aatgcttaat   5100

cagtgaggca cctatctcag cgatctgtct atttcgttca tccatagttg cctgactccc   5160

cgtcgtgtag ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgat   5220

accgcgagac ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag   5280

ggccgagcgc agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg   5340
```

```
ccgggaagct agagtaagta gttcgccagt taatagtttg cgcaacgttg ttgccattgc      5400

tacaggcatc gtggtgtcac gctcgtcgtt tggtatggct tcattcagct ccggttccca      5460

acgatcaagg cgagttacat gatcccccat gttgtgcaaa aaagcggtta gctccttcgg      5520

tcctccgatc gttgtcagaa gtaagttggc cgcagtgtta tcactcatgg ttatggcagc      5580

actgcataat tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta      5640

ctcaaccaag tcattctgag aatagtgtat gcggcgaccg agttgctctt gcccggcgtc      5700

aatacgggat aataccgcgc cacatagcag aactttaaaa gtgctcatca ttggaaaacg      5760

ttcttcgggg cgaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc      5820

cactcgtgca cccaactgat cttcagcatc ttttactttc accagcgttt ctgggtgagc      5880

aaaaacagga aggcaaaatg ccgcaaaaaa gggaataagg cgacacgga aatgttgaat      5940

actcatactc ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag      6000

cggatacata tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc      6060

ccgaaaagtg ccacctgacg tc                                               6082
```

<210> 11

<211> 6085

<212> DNA

<213> Artificial Sequence

<220>

<223> Plasmid

<400> 11
```
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg       60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg      120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc      180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt      240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata      300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc      360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc      420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt      480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt      540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca      600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg      660
```

```
actcacggggg atttccaagt ctccaccccca ttgacgtcaa tgggagtttg ttttggcacc   720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg   780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca   840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga   900

aagcttggat ctcaccatga gggtccccgc tcagcttctc ttccttctgc tactctggct   960

cccagatacc actggaggaa tagtgatgac gcagtctcca gccaccctgt ctgtgtctcc   1020

aggggaaaga gccaccctct cctgcaggac cagtcagagt attggctgga acttagcctg   1080

gtaccaacag aaacctggcc aggctcccag gctcctcatc tatggtgcat cttccaggac   1140

cactggtatc ccagccaggt tcagtggcag tgggtctggg acagagttca ctctcaccat   1200

cagcagcctg cagtctgaag attctgcagt ttattactgt cagcattatg ataactggcc   1260

catgtgcagt tttggccagg ggaccgagct ggagatcaaa cgaactgtgg ctgcaccatc   1320

tgtcttcatc ttcccgccat ctgatgagca gttgaaatct ggaactgcta gcgttgtgtg   1380

cctgctgaat aacttctatc ccagagaggc caaagtacag tggaaggtgg ataacgccct   1440

ccaatcgggt aactcccagg agagtgtcac agagcaggac agcaaggaca gcacctacag   1500

cctcagcagc accctgacgc tgagcaaagc agactacgag aaacacaaag tctacgcctg   1560

cgaagtcacc catcagggcc tgagctcgcc cgtcacaaag agcttcaaca ggggagagtg   1620

ttaggaattc gcggccgctc gagtctagag ggcccgttta aacccgctga tcagcctcga   1680

ctgtgccttc tagttgccag ccatctgttg tttgcccctc ccccgtgcct tccttgaccc   1740

tggaaggtgc cactcccact gtcctttcct aataaaatga ggaaattgca tcgcattgtc   1800

tgagtaggtg tcattctatt ctggggggtg gggtggggca ggacagcaag ggggaggatt   1860

gggaagacaa tagcaggcat gctggggatg cggtgggctc tatggcttct gaggcggaaa   1920

gaaccagctg gggctctagg gggtatcccc acgcgccctg tagcggcgca ttaagcgcgg   1980

cgggtgtggt ggttacgcgc agcgtgaccg ctacacttgc cagcgcccta gcgcccgctc   2040

ctttcgcttt cttcccttcc tttctcgcca cgttcgccgg ctttccccgt caagctctaa   2100

atcggggcat ccctttaggg ttccgattta gtgctttacg gcacctcgac cccaaaaaac   2160

ttgattaggg tgatggttca cgtagtgggc catcgccctg atagacggtt tttcgccctt   2220

tgacgttgga gtccacgttc tttaatagtg gactcttgtt ccaaactgga acaacactca   2280

accctatctc ggtctattct tttgatttat aagggatttt ggggatttcg cctattggt   2340

taaaaaatga gctgatttaa caaaaattta cgcgaatta attctgtgga atgtgtgtca   2400

gttagggtgt ggaaagtccc caggctcccc aggcaggcag aagtatgcaa agcatgcatc   2460

tcaattagtc agcaaccagg tgtggaaagt ccccaggctc cccagcaggc agaagtatgc   2520
```

```
aaagcatgca tctcaattag tcagcaacca tagtcccgcc cctaactccg cccatcccgc   2580

ccctaactcc gcccagttcc gcccattctc cgccccatgg ctgactaatt tttttattt    2640

atgcagaggc cgaggccgcc tctgcctctg agctattcca gaagtagtga ggaggctttt   2700

ttggaggcct aggctttgc aaaaagctcc cgggagcttg tatatccatt ttcggatctg    2760

atcaagagac aggatgagga tcgtttcgca tgattgaaca agatggattg cacgcaggtt   2820

ctccggccgc ttgggtggag aggctattcg gctatgactg gcacaacag acaatcggct     2880

gctctgatgc cgccgtgttc cggctgtcag cgcaggggcg cccggttctt tttgtcaaga    2940

ccgacctgtc cggtgccctg aatgaactgc aggacgaggc agcgcggcta tcgtggctgg    3000

ccacgacggg cgttccttgc gcagctgtgc tcgacgttgt cactgaagcg ggaagggact    3060

ggctgctatt gggcgaagtg ccggggcagg atctcctgtc atctcacctt gctcctgccg    3120

agaaagtatc catcatggct gatgcaatgc ggcggctgca tacgcttgat ccggctacct    3180

gcccattcga ccaccaagcg aaacatcgca tcgagcgagc acgtactcgg atggaagccg    3240

gtcttgtcga tcaggatgat ctggacgaag agcatcaggg gctcgcgcca gccgaactgt    3300

tcgccaggct caaggcgcgc atgcccgacg gcgaggatct cgtcgtgacc catggcgatg    3360

cctgcttgcc gaatatcatg gtggaaaatg gccgcttttc tggattcatc gactgtggcc    3420

ggctgggtgt ggcggaccgc tatcaggaca tagcgttggc tacccgtgat attgctgaag    3480

agcttggcgg cgaatgggct gaccgcttcc tcgtgcttta cggtatcgcc gctcccgatt    3540

cgcagcgcat cgccttctat cgccttcttg acgagttctt ctgagcggga ctctggggtt    3600

cgaaatgacc gaccaagcga cgcccaacct gccatcacga gatttcgatt ccaccgccgc    3660

cttctatgaa aggttgggct tcggaatcgt tttccgggac gccggctgga tgatcctcca    3720

gcgcggggat ctcatgctgg agttcttcgc ccaccccaac ttgtttattg cagcttataa    3780

tggttacaaa taaagcaata gcatcacaaa tttcacaaat aaagcatttt tttcactgca    3840

ttctagttgt ggtttgtcca aactcatcaa tgtatcttat catgtctgta taccgtcgac    3900

ctctagctag agcttggcgt aatcatggtc atagctgttt cctgtgtgaa attgttatcc    3960

gctcacaatt ccacacaaca tacgagccgg aagcataaag tgtaaagcct ggggtgccta    4020

atgagtgagc taactcacat taattgcgtt gcgctcactg cccgctttcc agtcgggaaa    4080

cctgtcgtgc cagctgcatt aatgaatcgg ccaacgcgcg gggagaggcg gtttgcgtat    4140

tgggcgctct tccgcttcct cgctcactga ctcgctgcgc tcggtcgttc ggctgcggcg    4200

agcggtatca gctcactcaa aggcggtaat acggttatcc acagaatcag gggataacgc    4260

aggaaagaac atgtgagcaa aaggccagca aaaggccagg aaccgtaaaa aggccgcgtt    4320

gctggcgttt ttccataggc tccgcccccc tgacgagcat cacaaaaatc gacgctcaag    4380
```

```
tcagaggtgg cgaaacccga caggactata aagataccag gcgtttcccc ctggaagctc    4440

cctcgtgcgc tctcctgttc cgaccctgcc gcttaccgga tacctgtccg cctttctccc    4500

ttcgggaagc gtggcgcttt ctcaatgctc acgctgtagg tatctcagtt cggtgtaggt    4560

cgttcgctcc aagctgggct gtgtgcacga accccccgtt cagcccgacc gctgcgcctt    4620

atccggtaac tatcgtcttg agtccaaccc ggtaagacac gacttatcgc cactggcagc    4680

agccactggt aacaggatta gcagagcgag gtatgtaggc ggtgctacag agttcttgaa    4740

gtggtggcct aactacggct acactagaag gacagtattt ggtatctgcg ctctgctgaa    4800

gccagttacc ttcggaaaaa gagttggtag ctcttgatcc ggcaaacaaa ccaccgctgg    4860

tagcggtggt ttttttgttt gcaagcagca gattacgcgc agaaaaaaag gatctcaaga    4920

agatcctttg atcttttcta cggggtctga cgctcagtgg aacgaaaact cacgttaagg    4980

gattttggtc atgagattat caaaaaggat cttcacctag atccttttaa attaaaaatg    5040

aagttttaaa tcaatctaaa gtatatatga gtaaacttgg tctgacagtt accaatgctt    5100

aatcagtgag gcacctatct cagcgatctg tctatttcgt tcatccatag ttgcctgact    5160

ccccgtcgtg tagataacta cgatacggga gggcttacca tctggcccca gtgctgcaat    5220

gataccgcga gacccacgct caccggctcc agatttatca gcaataaacc agccagccgg    5280

aagggccgag cgcagaagtg gtcctgcaac tttatccgcc tccatccagt ctattaattg    5340

ttgccgggaa gctagagtaa gtagttcgcc agttaatagt ttgcgcaacg ttgttgccat    5400

tgctacaggc atcgtggtgt cacgctcgtc gtttggtatg gcttcattca gctccggttc    5460

ccaacgatca aggcgagtta catgatcccc catgttgtgc aaaaaagcgg ttagctcctt    5520

cggtcctccg atcgttgtca gaagtaagtt ggccgcagtg ttatcactca tggttatggc    5580

agcactgcat aattctctta ctgtcatgcc atccgtaaga tgcttttctg tgactggtga    5640

gtactcaacc aagtcattct gagaatagtg tatgcggcga ccgagttgct cttgcccggc    5700

gtcaatacgg ataataccg cgccacatag cagaacttta aaagtgctca tcattggaaa    5760

acgttcttcg gggcgaaaac tctcaaggat cttaccgctg ttgagatcca gttcgatgta    5820

acccactcgt gcacccaact gatcttcagc atcttttact ttcaccagcg tttctgggtg    5880

agcaaaaaca ggaaggcaaa atgccgcaaa aaagggaata agggcgacac ggaaatgttg    5940

aatactcata ctcttccttt ttcaatatta ttgaagcatt tatcagggtt attgtctcat    6000

gagcggatac atatttgaat gtatttagaa aaataaacaa ataggggttc cgcgcacatt    6060

tccccgaaaa gtgccacctg acgtc                                          6085
```

<210> 12

```
<211>  6097

<212>  DNA

<213>  Artificial Sequence

<220>

<223>  Plasmid

<400>  12
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg     60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg    120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc    180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt    240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata    300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc    360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc    420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt    480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600

tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg    780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga    900

aagcttggat ctcaccatga gggtccctgc tcagctcctg gggctgctaa tgctctggat    960

acctggatcc agtgcagata ttgtgatgac ccagactcca ctctctctgt ccgtcacccc   1020

tggacagccg gcctccatct cctgcaagtc tagtcagagc ctcctgcata gtgatggaaa   1080

gacctttttg tattggtatc tgcagaagcc aggccagcct ccacagctcc tgatctatga   1140

ggtttccaac cggttctctg gagtgccaga taggttcagt ggcagcgggt cagggacaga   1200

tttcacactg aaaatcagcc gggtggaggc tgaggatgtt gggctttatt actgcatgca   1260

aagtatacag cttccgctca ctttcggcgg agggaccaag gtggagatca aacgaactgt   1320

ggctgcacca tctgtcttca tcttcccgcc atctgatgag cagttgaaat ctggaactgc   1380

tagcgttgtg tgcctgctga ataacttcta tcccagagag gccaaagtac agtggaaggt   1440

ggataacgcc ctccaatcgg gtaactccca ggagagtgtc acagagcagg acagcaagga   1500

cagcacctac agcctcagca gcaccctgac gctgagcaaa gcagactacg agaaacacaa   1560
```

```
agtctacgcc tgcgaagtca cccatcaggg cctgagctcg cccgtcacaa agagcttcaa    1620

caggggagag tgttaggaat tcgcggccgc tcgagtctag agggcccgtt taaacccgct    1680

gatcagcctc gactgtgcct tctagttgcc agccatctgt tgtttgcccc tcccccgtgc    1740

cttccttgac cctggaaggt gccactccca ctgtcctttc ctaataaaat gaggaaattg    1800

catcgcattg tctgagtagg tgtcattcta ttctggggg tggggtgggg caggacagca    1860

aggggagga ttgggaagac aatagcaggc atgctgggga tgcggtgggc tctatggctt    1920

ctgaggcgga aagaaccagc tggggctcta gggggtatcc ccacgcgccc tgtagcggcg    1980

cattaagcgc ggcgggtgtg gtggttacgc gcagcgtgac cgctacactt gccagcgccc    2040

tagcgcccgc tcctttcgct ttcttccctt cctttctcgc cacgttcgcc ggctttcccc    2100

gtcaagctct aaatcggggc atccctttag ggttccgatt tagtgcttta cggcacctcg    2160

accccaaaaa acttgattag ggtgatggtt cacgtagtgg gccatcgccc tgatagacgg    2220

tttttcgccc tttgacgttg gagtccacgt tctttaatag tggactcttg ttccaaactg    2280

gaacaacact caaccctatc tcggtctatt cttttgattt ataagggatt ttggggattt    2340

cggcctattg gttaaaaaat gagctgattt aacaaaaatt taacgcgaat taattctgtg    2400

gaatgtgtgt cagttagggt gtggaaagtc cccaggctcc ccaggcaggc agaagtatgc    2460

aaagcatgca tctcaattag tcagcaacca ggtgtggaaa gtccccaggc tccccagcag.    2520

gcagaagtat gcaaagcatg catctcaatt agtcagcaac catagtcccg ccctaactc    .2580

cgcccatccc gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa    2640

ttttttttat ttatgcagag gccgaggccg cctctgcctc tgagctattc cagaagtagt    2700

gaggaggctt ttttggaggc ctaggctttt gcaaaaagct cccgggagct tgtatatcca    2760

ttttcggatc tgatcaagag acaggatgag gatcgtttcg catgattgaa caagatggat    2820

tgcacgcagg ttctccggcc gcttgggtgg agaggctatt cggctatgac tgggcacaac    2880

agacaatcgg ctgctctgat gccgccgtgt tccggctgtc agcgcagggg cgcccggttc    2940

tttttgtcaa gaccgacctg tccggtgccc tgaatgaact gcaggacgag gcagcgcggc    3000

tatcgtggct ggccacgacg ggcgttcctt gcgcagctgt gctcgacgtt gtcactgaag    3060

cgggaaggga ctggctgcta ttgggcgaag tgccggggca ggatctcctg tcatctcacc    3120

ttgctcctgc cgagaaagta tccatcatgg ctgatgcaat gcggcggctg catacgcttg    3180

atccggctac ctgcccattc gaccaccaag cgaaacatcg catcgagcga gcacgtactc    3240

ggatggaagc cggtcttgtc gatcaggatg atctggacga agagcatcag gggctcgcgc    3300

cagccgaact gttcgccagg ctcaaggcgc gcatgcccga cggcgaggat ctcgtcgtga    3360

cccatggcga tgcctgcttg ccgaatatca tggtggaaaa tggccgcttt tctggattca    3420
```

```
tcgactgtgg ccggctgggt gtggcggacc gctatcagga catagcgttg gctacccgtg    3480

atattgctga agagcttggc ggcgaatggg ctgaccgctt cctcgtgctt tacggtatcg    3540

ccgctcccga ttcgcagcgc atcgccttct atcgccttct tgacgagttc ttctgagcgg    3600

gactctgggg ttcgaaatga ccgaccaagc gacgcccaac ctgccatcac gagatttcga    3660

ttccaccgcc gccttctatg aaaggttggg cttcggaatc gttttccggg acgccggctg    3720

gatgatcctc cagcgcgggg atctcatgct ggagttcttc gcccacccca acttgtttat    3780

tgcagcttat aatggttaca aataaagcaa tagcatcaca aatttcacaa ataaagcatt    3840

tttttcactg cattctagtt gtggtttgtc caaactcatc aatgtatctt atcatgtctg    3900

tataccgtcg acctctagct agagcttggc gtaatcatgg tcatagctgt ttcctgtgtg    3960

aaattgttat ccgctcacaa ttccacacaa catacgagcc ggaagcataa agtgtaaagc    4020

ctggggtgcc taatgagtga gctaactcac attaattgcg ttgcgctcac tgcccgcttt    4080

ccagtcggga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg    4140

cggtttgcgt attgggcgct cttccgcttc ctcgctcact gactcgctgc gctcggtcgt    4200

tcggctgcgg cgagcggtat cagctcactc aaaggcggta atacggttat ccacagaatc    4260

agggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa    4320

aaaggccgcg ttgctggcgt ttttccatag gctccgcccc cctgacgagc atcacaaaaa    4380

tcgacgctca agtcagaggt ggcgaaaccc gacaggacta taaagatacc aggcgtttcc    4440

ccctggaagc tccctcgtgc gctctcctgt tccgaccctg ccgcttaccg gatacctgtc    4500

cgcctttctc ccttcgggaa gcgtggcgct ttctcaatgc tcacgctgta ggtatctcag    4560

ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccga    4620

ccgctgcgcc ttatccggta actatcgtct tgagtccaac ccggtaagac acgacttatc    4680

gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac    4740

agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg    4800

cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaca    4860

aaccaccgct ggtagcggtg gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa    4920

aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa    4980

ctcacgttaa gggattttgg tcatgagatt atcaaaaagg atcttcacct agatcctttt    5040

aaattaaaaa tgaagtttta aatcaatcta agtatatat gagtaaactt ggtctgacag    5100

ttaccaatgc ttaatcagtg aggcacctat ctcagcgatc tgtctatttc gttcatccat    5160

agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc    5220

cagtgctgca atgataccgc gagacccacg ctcaccggct ccagatttat cagcaataaa    5280
```

```
ccagccagcc ggaagggccg agcgcagaag tggtcctgca actttatccg cctccatcca    5340

gtctattaat tgttgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa    5400

cgttgttgcc attgctacag gcatcgtggt gtcacgctcg tcgtttggta tggcttcatt    5460

cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc    5520

ggttagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact    5580

catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc    5640

tgtgactggt gagtactcaa ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg    5700

ctcttgcccg gcgtcaatac gggataatac cgcgccacat agcagaactt taaaagtgct    5760

catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc    5820

cagttcgatg taacccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag    5880

cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taagggcgac    5940

acggaaatgt tgaatactca tactcttcct ttttcaatat tattgaagca tttatcaggg    6000

ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaataggggt    6060

tccgcgcaca tttccccgaa aagtgccacc tgacgtc                              6097
```

```
<210>   13

<211>   6094

<212>   DNA

<213>   Artificial Sequence

<220>

<223>   Plasmid

<400>   13
gacggatcgg gagatctccc gatcccctat ggtcgactct cagtacaatc tgctctgatg     60

ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg    120

cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc    180

ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt    240

gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata    300

tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc    360

cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc    420

attgacgtca atgggtggac tatttacggt aaactgccca cttggcagta catcaagtgt    480

atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540

atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600
```

```
tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660

actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720

aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg    780

gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840

ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctaga    900

aagcttggat ctcaccatgg tgttgcagac ccaggtcttc atttctctgt tactctggat    960

ctctggtgcc tacggggaca tcgtgatgac ccagtctcca gactccctgg ctgtgtctct   1020

gggcgagagg gccaccatca actgcaagtc caaccagagt gtcttacaca gctccaacaa   1080

taagaactat ttagcttggt accagcagaa accaggacag cctcctaaat tgctcattta   1140

ttgggcattc ctccgggaat ccggggtccc tgaccgcttc agtggcagcg ggtctgggac   1200

agatttcact ctcaccatca gcagcctgca ggctgaagat gtggcagttt attactgtca   1260

ccaatattat tctactttat atactttcgg cggagggacc aaggtagaga tcaaacgaac   1320

ygtggctgca ccatctgtct tcatcttccc gccatctgat gagcagttga aatctggaac   1380

tgctagcgtt gtgtgcctgc tgaataactt ctatcccaga gaggccaaag tacagtggaa   1440

ggtggataac gccctccaat cgggtaactc ccaggagagt gtcacagagc aggacagcaa   1500

ggacagcacc tacagcctca gcagcaccct gacgctgagc aaagcagact acgagaaaca   1560

caaagtctac gcctgcgaag tcacccatca gggcctgagc tcgcccgtca caaagagctt   1620

caacagggga gagtgttagg cggccgctcg agtctagagg gcccgtttaa acccgctgat   1680

cagcctcgac tgtgccttct agttgccagc catctgttgt tgcccctcc cccgtgcctt   1740

ccttgaccct ggaaggtgcc actcccactg tcctttccta ataaaatgag gaaattgcat   1800

cgcattgtct gagtaggtgt cattctattc tggggggtgg ggtggggcag gacagcaagg   1860

gggaggattg ggaagacaat agcaggcatg ctggggatgc ggtgggctct atggcttctg   1920

aggcggaaag aaccagctgg ggctctaggg ggtatcccca cgcgccctgt agcggcgcat   1980

taagcgcggc gggtgtggtg gttacgcgca gcgtgaccgc tacacttgcc agcgccctag   2040

cgcccgctcc tttcgctttc ttcccttcct ttctcgccac gttcgccggc tttccccgtc   2100

aagctctaaa tcggggcatc cctttagggt tccgatttag tgctttacgg cacctcgacc   2160

ccaaaaaact tgattagggt gatggttcac gtagtgggcc atcgccctga tagacggttt   2220

ttcgcccttt gacgttggag tccacgttct ttaatagtgg actcttgttc caaactggaa   2280

caacactcaa ccctatctcg gtctattctt ttgatttata agggattttg gggatttcgg   2340

cctattggtt aaaaaatgag ctgatttaac aaaaatttaa cgcgaattaa ttctgtggaa   2400

tgtgtgtcag ttagggtgtg gaaagtcccc aggctcccca ggcaggcaga agtatgcaaa   2460
```

```
gcatgcatct caattagtca gcaaccaggt gtggaaagtc cccaggctcc ccagcaggca   2520

gaagtatgca aagcatgcat ctcaattagt cagcaaccat agtcccgccc ctaactccgc   2580

ccatcccgcc cctaactccg cccagttccg cccattctcc gccccatggc tgactaattt   2640

tttttatttta tgcagaggcc gaggccgcct ctgcctctga gctattccag aagtagtgag   2700

gaggcttttt tggaggccta ggcttttgca aaaagctccc gggagcttgt atatccattt   2760

tcggatctga tcaagagaca ggatgaggat cgtttcgcat gattgaacaa gatggattgc   2820

acgcaggttc tccggccgct tgggtggaga ggctattcgg ctatgactgg gcacaacaga   2880

caatcggctg ctctgatgcc gccgtgttcc ggctgtcagc gcagggcgc ccggttcttt   2940

ttgtcaagac cgacctgtcc ggtgccctga atgaactgca ggacgaggca gcgcggctat   3000

cgtggctggc cacgacgggc gttccttgcg cagctgtgct cgacgttgtc actgaagcgg   3060

gaagggactg gctgctattg ggcgaagtgc cggggcagga tctcctgtca tctcaccttg   3120

ctcctgccga gaaagtatcc atcatggctg atgcaatgcg gcggctgcat acgcttgatc   3180

cggctacctg cccattcgac caccaagcga aacatcgcat cgagcgagca cgtactcgga   3240.

tggaagccgg tcttgtcgat caggatgatc tggacgaaga gcatcagggg ctcgcgccag · .3300

ccgaactgtt cgccaggctc aaggcgcgca tgcccgacgg cgaggatctc gtcgtgaccc .   3360

atggcgatgc ctgcttgccg aatatcatgg tggaaaatgg ccgcttttct ggattcatcg   3420.

actgtggccg gctgggtgtg gcggaccgct atcaggacat agcgttggct acccgtgata   3480

ttgctgaaga gcttggcggc gaatgggctg accgcttcct cgtgctttac ggtatcgccg   3540

ctcccgattc gcagcgcatc gccttctatc gccttcttga cgagttcttc tgagcgggac   3600

tctggggttc gaaatgaccg accaagcgac gcccaacctg ccatcacgag atttcgattc   3660

caccgccgcc ttctatgaaa ggttgggctt cggaatcgtt ttccgggacg ccggctggat   3720

gatcctccag cgcggggatc tcatgctgga gttcttcgcc caccccaact tgtttattgc   3780

agcttataat ggttacaaat aaagcaatag catcacaaat ttcacaaata aagcattttt   3840

ttcactgcat tctagttgtg gtttgtccaa actcatcaat gtatcttatc atgtctgtat   3900

accgtcgacc tctagctaga gcttggcgta atcatggtca tagctgtttc ctgtgtgaaa   3960

ttgttatccg ctcacaattc cacacaacat acgagccgga agcataaagt gtaaagcctg   4020

gggtgcctaa tgagtgagct aactcacatt aattgcgttg cgctcactgc ccgctttcca   4080

gtcgggaaac ctgtcgtgcc agctgcatta atgaatcggc caacgcgcgg ggagaggcgg   4140

tttgcgtatt gggcgctctt ccgcttcctc gctcactgac tcgctgcgct cggtcgttcg   4200

gctgcggcga gcggtatcag ctcactcaaa ggcggtaata cggttatcca cagaatcagg   4260

ggataacgca ggaaagaaca tgtgagcaaa aggccagcaa aaggccagga accgtaaaaa   4320
```

```
ggccgcgttg ctggcgtttt tccataggct ccgccccct gacgagcatc acaaaaatcg    4380

acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg cgtttccccc    4440

tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat acctgtccgc    4500

ctttctccct tcgggaagcg tggcgctttc tcaatgctca cgctgtaggt atctcagttc    4560

ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc agcccgaccg    4620

ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg acttatcgcc    4680

actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg gtgctacaga    4740

gttcttgaag tggtggccta actacggcta cactagaagg acagtatttg gtatctgcgc    4800

tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg gcaaacaaac    4860

caccgctggt agcggtggtt ttttgtttg caagcagcag atta cgcgca gaaaaaaagg   · 4920

atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga cgaaaactc     4980

acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga tccttttaaa    5040

ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt ctgacagtta    5100

ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt catccatagt    5160

tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat ctggccccag    5220

tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag caataaacca    5280

gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct ccatccagtc   ,5340

tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt tgcgcaacgt    5400

tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg cttcattcag    5460

ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca aaaaagcggt    5520

tagctccttc ggtcctccga tcgttgtcag aagtaagttg ccgcagtgt tatcactcat     5580

ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat gctttctgt     5640

gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac cgagttgctc    5700

ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa aagtgctcat    5760

cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt tgagatccag    5820

ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt tcaccagcgt    5880

ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg    5940

gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt atcagggtta    6000

ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa tagggggttcc   6060

gcgcacattt ccccgaaaag tgccacctga cgtc                                6094
```

<210> 14

<211> 481

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/Bg1II cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 14

```
ggatctcacc atggagttgg gactgcgctg gggcttcctc gttgctcttt taagaggtgt      60

ccagtgtcag gtgcaattgg tggagtctgg gggaggcgtg gtccagcctg ggaggtccct     120

gagactctcc tgtgcagcgt ctggattcgc cttcagtaga tatggcatgc actgggtccg     180

ccaggctcca ggcaaggggc tggagtgggt ggcagttata tggtatgatg gaagtaataa     240

atactatgca gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac     300

gcagtatctg caaatgaaca gcctgagagc cgaggacacg gctgtgtatt actgtgcgag    ·360

·aggcggtgac ttcctctact·actactatta cggtatggac gtctggggcc aagggaccac     420

ggtcaccgtc tcctcagcct ccaccaaggg cccatcggtc ttccccctgg caccctctag     480

c                                                                      481
```

<210> 15

<211> 142

<212> PRT

<213> Homo sapiens

<400> 15

```
Met Glu Leu Gly Leu Arg Trp Gly Phe Leu Val Ala Leu Leu Arg Gly
1               5                   10                  15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
            20                  25                  30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe
        35                  40                  45

Ser Arg Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
    50                  55                  60

Glu Trp Val Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
65                  70                  75                  80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
                85                  90                  95
```

Thr Gln Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
            100   105   110

Tyr Tyr Cys Ala Arg Gly Gly Asp Phe Leu Tyr Tyr Tyr Tyr Tyr Gly
        115   120   125

Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
    130   135   140

<210> 16

<211> 463

<212> DNA

<213> Artificial Sequence

<220>

<223>   Includes BamHI/BglII cloning junction, signal peptide, V region,
portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning
junction

<400> 16
ggatctcacc atgagggtcc ctgctcagct cctgggactc ctgctgctct ggctcccaga   60

taccagatgt gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga   120

cagagtcacc atcacttgcc gggcgagtca gggcattagc aattatttag cctggtatca   180

gcagaaaaca gggaaagttc ctaagttcct gatctatgaa gcatccactt tgcaatcagg   . 240

ggtcccatct cggttcagtg gcggtggatc tgggacagat ttcactctca ccatcagcag   300

cctgcagcct gaagatgttg caacttatta ctgtcaaaat tataacagtg ccccattcac   , 360

tttcggccct gggaccaaag tggatatcaa cgaactgtg gctgcaccct ctgtcttcat   420

cttcccgcca tctgatgagc agttgaaatc tggaactgct agc   463

<210> 17

<211> 127

<212> PRT

<213> Homo sapiens

<400> 17

Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp Leu Pro
1   5   10   15

Asp Thr Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
            20   25   30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
        35   40   45

Ile Ser Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Thr Gly Lys Val Pro
    50   55   60

```
Lys Phe Leu Ile Tyr Glu Ala Ser Thr Leu Gln Ser Gly Val Pro Ser
65              70              75              80

Arg Phe Ser Gly Gly Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
                85              90              95

Ser Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Asn
            100             105             110

Ser Ala Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
        115             120             125
```

<210> 18

<211> 508

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/Bg1II cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

```
<400> 18
ggatctcacc atggggtcaa ccgccatcct caccatggag ttggggctgc gctgggttct     60

cctcgttgct cttttaagag gtgtccagtg tcaggtgcag ctggtggagt ctggggggagg    120

cgtggtccag cctgggaggt ccctgagact ctcctgtgca gcgtctggat tcaccttcag    180

taactatgtc atgcactggg tccgccaggc tccaggcaag gggctggagt gggtggcaat    240

tatatggtat gatggaagta taaaatacta tgcagactcc gtgaagggcc gattcaccat    300

ctccagagac aattccaaga acacgctgta tctgcaaatg aacagcctga gagccgagga    360

cacggctgtg tattactgtg cgggtggata taactggaac tacgagtacc actactacgg    420

tatggacgtc tggggccaag ggaccacggt caccgtctcc tcagcctcca ccaagggccc    480

atcggtcttc cccctggcac cctctagc                                        508
```

<210> 19

<211> 143

<212> PRT

<213> Homo sapiens

<400> 19

```
Met Glu Leu Gly Leu Arg Trp Val Leu Leu Val Ala Leu Leu Arg Gly
1           5               10              15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
            20              25              30
```

```
    Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        35                  40                  45

    Ser Asn Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
        50                  55                  60

    Glu Trp Val Ala Ile Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
    65                  70                  75                  80

    Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
                    85                  90                  95

    Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
                100                 105                 110

    Tyr Tyr Cys Ala Gly Gly Tyr Asn Trp Asn Tyr Glu Tyr His Tyr Tyr
            115                 120                 125

    Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
        130                 135                 140
```

<210> 20

<211> 463

<212> DNA

<213> Artificial Sequence
<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 20

```
ggatctcacc atgagggtcc ccgctcagct cctggggctc ctgctgctct gtttcccagg      60

tgccagatgt gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgtaggaga     120

cagagtcacc atcacttgtc gggcgagtca gggcattacc aattatttag cctggtttca     180

gcagaaacca gggaaagccc ctaagtccct tatctatgct gcatccagtt tgcaaagtgg     240

ggtcccatca aagttcagcg gcagtggatc tgggacagat ttcagtctca ccatcagcag     300

cctgcagcct gaagattttg caacttatta ctgccaacag tataatagtt acccgatcac     360

cttcggccaa gggacacgac tggagattaa acgaactgtg ctgcaccat ctgtcttcat     420

cttcccgcca tctgatgagc agttgaaatc tggaactgct agc                      463
```

<210> 21

<211> 127

<212> PRT

<213> Homo sapiens

<400> 21

```
Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Cys Phe Pro
1               5               10              15
Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
            20              25              30
Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
        35              40              45
Ile Thr Asn Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro
    50              55              60
Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
65              70              75              80
Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Ser
            85              90              95
Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
            100             105             110
Ser Tyr Pro Ile Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys
        115             120             125
```

<210> 22

<211> 490

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/Bg1II cloning junction, signal peptide, V region,
portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning
junction

<400> 22
```
ggatctcacc atggagttgg gacttagctg ggttttcctc gttgctcttt taagaggtgt      60

ccagtgtcag gtccagctgg tggagtctgg gggaggcgtg tccagcctg ggaggtccct      120

gagactctcc tgtgcagcgt ctggattcac cttcagtagc tatggcatgc actgggtccg      180

ccaggctcca ggcaaggggc tggactgggt ggcaattatt tggcatgatg gaagtaataa      240

atactatgca gactccgtga agggccgatt caccatctcc agagacaatt ccaagaagac      300

gctgtacctg caaatgaaca gtttgagagc cgaggacacg gctgtgtatt actgtgcgag      360

agcttgggcc tatgactacg gtgactatga atactacttc ggtatggacg tctggggcca      420

agggaccacg gtcaccgtct cctcagcctc caccaagggc ccatcggtct tccccctggc      480

accctctagc                                                             490
```

<210> 23

<211> 145

<212> PRT

<213> Homo sapiens

<400> 23

```
Met Glu Leu Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly
1               5                   10                  15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
            20                  25                  30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
            35                  40                  45

Ser Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
    50                  55                  60

Asp Trp Val Ala Ile Ile Trp His Asp Gly Ser Asn Lys Tyr Tyr Ala
65                  70                  75                  80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys
                85                  90                  95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
        100                 105                 110

Tyr Tyr Cys Ala Arg Ala Trp Ala Tyr Asp Tyr Gly Asp Tyr Glu Tyr
        115                 120                 125

Tyr Phe Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
    130                 135                 140

Ser
145
```

<210> 24

<211> 463

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region,
portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning
junction

<400> 24
```
ggatctcacc atgagggtcc ctgctcagct cctggggctc ctgctgctct gtttcccagg      60

tgccagatgt gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgtaggaga     120

cagagtcacc atcacttgtc gggcgagtca gggcattagc cattatttag cctggtttca     180

gcagaaacca gggaaagccc ctaagtccct gatctatgct gcatccagtt tgcaaagtgg     240

ggtcccatca aagttcagcg gcagtggatc tgggacagat ttcactctca ccatcagcag     300
```

```
cctacagcct gaagattttg caacttatta ctgccaacag tataatagtt tcccgctcac    360

tttcggcgga gggaccaagg tggagatcaa acgaactgtg gctgcaccat ctgtcttcat    420

cttcccgcca tctgatgagc agttgaaatc tggaactgct agc                      463
```

<210> 25

<211> 127

<212> PRT

<213> Homo sapiens

<400> 25

```
Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Cys Phe Pro
1               5              10              15

Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser
            20              25              30

Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly
        35              40              45

Ile Ser His Tyr Leu Ala Trp Phe Gln Gln Lys Pro Gly Lys Ala Pro
    50              55              60

Lys Ser Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser
65              70              75              80

Lys Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
            85              90              95

Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn
            100             105             110

Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
        115             120             125
```

<210> 26

<211> 469

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 26
```
ggatcccacc atggggtcaa ccgtcatcct cgccctcctc ctggctgttc tccaaggagt     60

ctgtgccgag gtgcagctgg tgcagtctgg agcagaggtg aaaaagcccg gggagtctct    120

gaagatctcc tgtaagggtt ctggatacag ctttaccagt tactggatcg gctgggtgcg    180
```

```
ccagatgccc gggaaaggcc tggagtggat ggggatcatc tatcctggtg actctgatac    240

cagatacagc ccgtccttcc aaggccaggt caccatctca gccgacaagt ccatcagcac    300

cgcctacctg cagtggagca gcctgaaggc ctcggacacc gccatgtatt actgtgcgag    360

acggatggca gcagctggcc cctttgacta ctggggccag ggaaccctgg tcaccgtctc    420

ctcagcctcc accaagggcc catcggtctt ccccctggca ccctctagc               469
```

<210> 27

<211> 138

<212> PRT

<213> Homo sapiens

<400> 27

```
Met Gly Ser Thr Val Ile Leu Ala Leu Leu Leu Ala Val Leu Gln Gly
1               5                   10                  15

Val Cys Ala Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys
            20                  25                  30

Pro Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe
        35                  40                  45

Thr Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu
    50                  55                  60

Glu Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser
65                  70                  75                  80

Pro Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser
                85                  90                  95

Thr Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met
            100                 105                 110

Tyr Tyr Cys Ala Arg Arg Met Ala Ala Ala Gly Pro Phe Asp Tyr Trp
        115                 120                 125

Gly Gln Gly Thr Leu Val Thr Val Ser Ser
    130                 135
```

<210> 28

<211> 466

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region,
portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning
junction

<400> 28

```
ggatctcacc atgagggtcc ccgctcagct tctcttcctt ctgctactct ggctcccaga   60

taccactgga ggaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga  120

aagagccacc ctctcctgca ggaccagtca gagtattggc tggaacttag cctggtacca  180

acagaaacct ggccaggctc ccaggctcct catctatggt gcatcttcca ggaccactgg  240

tatcccagcc aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag  300

cctgcagtct gaagattctg cagtttatta ctgtcagcat tatgataact ggcccatgtg  360

cagttttggc caggggaccg agctggagat caaacgaact gtggctgcac catctgtctt  420

catcttcccg ccatctgatg agcagttgaa atctggaact gctagc               466
```

<210> 29

<211> 128

<212> PRT

<213> Homo sapiens

<400> 29

```
Met Arg Val Pro Ala Gln Leu Leu Phe Leu Leu Leu Trp Leu Pro
1               5                   10                  15

Asp Thr Thr Gly Gly Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser
            20                  25                  30

Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Thr Ser Gln Ser
        35                  40                  45

Ile Gly Trp Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
    50                  55                  60

Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Thr Thr Gly Ile Pro Ala
65                  70                  75                  80

Arg Phe Ser Gly Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
                85                  90                  95

Ser Leu Gln Ser Glu Asp Ser Ala Val Tyr Tyr Cys Gln His Tyr Asp
                100                 105                 110

Asn Trp Pro Met Cys Ser Phe Gly Gln Gly Thr Glu Leu Glu Ile Lys
            115                 120                 125
```

<210> 30

<211> 487

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/Bg1II cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 30

```
ggatctcacc atggagtttg ggctgtgctg gattttcctc gttgctcttt taagaggtgt      60

ccagtgtcag gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggtccct     120

gagactctcc tgtgcagcct ctggattcac cttcattagc tatggcatgc actgggtccg     180

ccaggctcca ggcaaggggc tggagtgggt ggcagttata tcatatgatg gaagtaataa     240

atactatgca gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac     300

gctgtatctg caaatgaaca gcctgagagc tgaggacacg gctgtgtatt actgtgcgag     360

agtattagtg ggagctttat attattataa ctactacggg atggacgtct ggggccaagg     420

gaccacggtc accgtctcct cagcctccac caagggccca tcggtcttcc ccctggcacc     480

ctctagc                                                               487
```

<210> 31

<211> 144

<212> PRT

<213> Homo sapiens

<400> 31

```
Met Glu Phe Gly Leu Cys Trp Ile Phe Leu Val Ala Leu Leu Arg Gly
1               5                   10                  15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln
            20                  25                  30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
        35                  40                  45

Ile Ser Tyr Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
    50                  55                  60

Glu Trp Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala
65                  70                  75                  80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
                85                  90                  95

Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
            100                 105                 110

Tyr Tyr Cys Ala Arg Val Leu Val Gly Ala Leu Tyr Tyr Tyr Asn Tyr
        115                 120                 125

Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
    130                 135                 140
```

<210> 32

<211> 478

<212> DNA

<213> Artificial Sequence

<220>

<223> Includes BamHI/BglII cloning junction, signal peptide, V region, portion of C region and 3'XbaI/NheI (heavy) or NheI (light) cloning junction

<400> 32
```
ggatctcacc atgagggtcc ctgctcagct cctggggctg ctaatgctct ggatacctgg      60

atccagtgca gatattgtga tgacccagac tccactctct ctgtccgtca cccctggaca     120

gccggcctcc atctcctgca agtctagtca gagcctcctg catagtgatg gaaagacctt     180

tttgtattgg tatctgcaga agccaggcca gcctccacag ctcctgatct atgaggtttc     240

caaccggttc tctggagtgc cagataggtt cagtggcagc gggtcaggga cagatttcac ·    300

actgaaaatc agccgggtgg aggctgagga tgttgggctt tattactgca tgcaaagtat      360

acagcttccg ctcactttcg gcggagggac caaggtggag atcaaacgaa ctgtggctgc      420

accatctgtc ttcatcttcc cgccatctga tgagcagttg aaatctggaa ctgctagc       478
```

<210> 33

<211> 132

<212> PRT

<213> Homo sapiens

<400> 33

```
Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Met Leu Trp Ile Pro
1               5                  10                  15

Gly Ser Ser Ala Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser
                20              25                  30

Val Thr Pro Gly Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser
            35              40              45

Leu Leu His Ser Asp Gly Lys Thr Phe Leu Tyr Trp Tyr Leu Gln Lys
        50              55              60

Pro Gly Gln Pro Pro Gln Leu Leu Ile Tyr Glu Val Ser Asn Arg Phe
65              70              75                  80

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe
                85              90                  95

Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Leu Tyr Tyr
            100             105                 110
```

Cys Met Gln Ser Ile Gln Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys
        115   120   125

Val Glu Ile Lys
    130

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number
WO 03/034903 A3

(54) Title: PSMA ANTIBODIES AND PROTEIN MULTIMERS

(57) Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/33944

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/04; C12N 5/12; C07K 16/00; A61K 39/395; G01N 33/53

US CL : 530/387.1, 388.85, 350, 388.85, 391.7; 424/130.1, 156.1, 181.1; 536/23.53; 435/7.1/326

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/387.1, 388.85, 350, 388.85, 391.7; 424/130.1, 156.1, 181.1; 536/23.53; 435/7.1/326

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97/35616 A1 (PACIFIC NORTHWEST CANCER FOUNDATION) 02 October 1997 (02/10/97), see entire document, especially page 4-5, Figure 2, page 12, page 16, page 18-26.	1-33, 35-53, 56-87, 98-384
Y	US 6,107,090 A (BANDER) 22 August 2000 (22/08/00), see entire document, especially column 7-15.	1-33, 35-52, 56-87, 98-384
Y	US 5,804,602 A (SLUSHER et al) 08 September 1998 (08/08/98), see entire document, especially column 18, lines 25-43.	263-268

☐ Further documents are listed in the continuation of Box C.   ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance		
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
13 March 2003 (13.03.2003)	07 MAY 2003
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Larry R. Helms Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998)

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-33, 56-85, 88-140, 143-172, 175-215, drawn to an antibody that competes for binding to a second antibody that binds to PSMA.

Group II, claim(s) 34-55, 141-142, drawn to DNA

Group III, claim(s) 86-87, 173-174, drawn to hybridomas.

Group IV, claim(s) 216, 221, 222, drawn to a method of detecting PSMA.

Group V, claim(s) 217-221, 222, drawn to a method of diagnosing PSMA.

Group VI, claim(s) 223, 225, 226, 118, 229, drawn to a method of assessing the prognosis of a subject withPSMA.

Group VII, claim(s) 224, 225, 226, 227-229, drawn to a method of assessing the effectiveness of treatment.

Group VIII, claim(s) 231-233, drawn to a method of inducing cytolysis of a cell.

Group IX, claim(s) 234-250, drawn to a method of treating a PSMA disease.

Group X, claim(s) 251-256, drawn to a method of inhibiting folate hydrolase activity.

Group XI, claim(s) 257-262, drawn to a method of enhancing folate hydrolase activity.

Group XII, claim(s) 263-268, drawn to a method of inhibiting NAALADase activity.

Group XIII, claim(s) 269-274, drawn to a method of enhancing NAADLADase activity.

Group XIV, claim(s) 275-286, drawn to a method of inhibiting dipeptidyl dipeptidase IV peptide.

Group XV, claim(s) 287-298, drawn to a method of inhibiting gamma glutamyl hydrolase activity.

Group XVI, claim(s) 299-308, drawn to a method of specific delivery of a therapeutic agent to a PSMA cell.

Group XVII, claim(s) 309-361, drawn to a an antibody that binds a multimer.

Group XVIII, claim(s) 362 drawn to a method of inducing an immune response.

Group XIX, claim(s) 363-369, drawn to a recombinant PSMA multimer.

Group XX, claim(s) 370-375, drawn to a method of screening for a candidate that inhibits enzymatic activity of PSMA.

Group XXI, claim(s) 376-381, drawn to a method of screening for a candidate that enhances enzymatic activity of PSMA.

Group XXII, claim(s) 382, drawn to a method of identifying a compound.

Group XXIII, claim(s) 383, drawn to a method of identifying a compound.

Group XXIV, claim(s) 384, drawn to a method of identifying a compound.

The inventions listed as Groups I-XXIV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the technical feature recited in Groups I-XXIV is an antibody that competes for binding to a second antibody that binds PSMA. However, WO 97/35616 teaches antibodies to PSMA and as such they would compete for binding to a second antibody recited in Group I. Therefore the technical feature linking Groups I-XXIV does not contribute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Continuation of B. FIELDS SEARCHED Item 3:
CAPLUS, MEDLINE, BIOSIS, WEST, USPATFULL, PIR, SWISSPROT, GENEMBL
Search terms: PSMA, antibody, prostate specific membrane antigen, SEQ ID Nos, expression vector, host cell, monoclonal, polyclonal, Fab, label, diagnosing, treatment, NAALADase, folate hydrolase, dipeptidyl dipeptidase IV, gamma glutamyl hydrolasePSMA multimer, dimer.

(54) Title: PSMA ANTIBODIES AND PROTEIN MULTIMERS

(57) Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.

AMENDED CLAIMS
[received by the International Bureau on 23 May 2003 (23.05.03);
original claims 12-384 replaced by amended claims 13-385;
remaining claims unchanged (46 pages)]

Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix
4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix
4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-
binding fragments thereof.

5

9.   The isolated antibody or antigen-binding fragment thereof according to claim 1,
wherein said antibody or antigen-binding fragment thereof is selected from the group
consisting of antibodies comprising:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain
10   coding region or regions of a nucleotide sequence selected from the group consisting of
nucleotide sequences set forth as SEQ ID NOs: 2-7, and

        (b) a light chain encoded by a nucleic acid molecule comprising the light chain coding
region or regions of a nucleotide sequence selected from the group consisting of nucleotide
sequences set forth as SEQ ID NOs: 8-13,

15   and antigen-binding fragments thereof.

10.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second
antibody comprises:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or
20   regions of a nucleotide sequence set forth as SEQ ID NO: 2, and

        (b) a light chain encoded by a nucleic acid molecule comprising the coding region or
regions of a nucleotide sequence set forth as SEQ ID NO: 8.

11.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second
25   antibody comprises:

        (a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or
regions of a nucleotide sequence set forth as SEQ ID NO: 3, and

        (b) a light chain encoded by a nucleic acid molecule comprising the coding region or
regions of a nucleotide sequence set forth as SEQ ID NO: 9.

30

12.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second
antibody comprises:

AMENDED SHEET (ARTICLE 19)

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 4, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 10.

13.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 5, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 11.

14.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 6, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or • regions of a nucleotide sequence set forth as SEQ ID NO: 12.

15.   The isolated antibody or antigen-binding fragment of claim 9, wherein the second antibody comprises:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 7, and

(b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 13.

16.   An isolated antibody which specifically binds to an extracellular domain of prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 9.

17.   The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

AMENDED SHEET (ARTICLE 19)

18.   The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

5   19.   The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

20.   The isolated antibody of claim 16, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

10

21.   An antigen-binding fragment of the isolated antibody of claim 9, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and

15   (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

22.   An antigen-binding fragment of the isolated antibody of claim 21, comprising:

20   (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 14, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 16.

25   23.   An antigen-binding fragment of the isolated antibody of claim 21, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 18, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 20.

30

24.   An antigen-binding fragment of the isolated antibody of claim 21, comprising:

(a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 22, and

(b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 24.

25.   An antigen-binding fragment of the isolated antibody of claim 21, comprising:
         (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 26, and
         (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 28.

26.   An antigen-binding fragment of the isolated antibody of claim 21, comprising:
         (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 30, and
         (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence set forth as SEQ ID NO: 32.

27.   The antigen-binding fragment of the isolated antibody of claim 9, comprising:
         (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and
         (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

28.   An antigen-binding fragment of the isolated antibody of claim 27, comprising:
         (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 15, and
         (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 17.

29.   An antigen-binding fragment of the isolated antibody of claim 27, comprising:
         (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 19, and
         (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO: 21.

AMENDED SHEET (ARTICLE 19)

30.   An antigen-binding fragment of the isolated antibody of claim 27, comprising:

        (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ
ID NO: 23, and

5   (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO:
25.

31.   An antigen-binding fragment of the isolated antibody of claim 27, comprising:

        (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ
10   ID NO: 27, and

        (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO:
29.

32.   An antigen-binding fragment of the isolated antibody of claim 27, comprising:

15   (a) a heavy chain variable region comprising an amino acid sequence set forth as SEQ
ID NO: 31, and

        (b) a light chain variable region comprising an amino acid set forth as SEQ ID NO:
33.

20   33.   An isolated antigen-binding fragment which comprises a CDR of the antigen-binding
fragment according to claim 21 or claim 27.

34.   The isolated antigen-binding fragment of claim 33, wherein the CDR is CDR3.

25   35.   An expression vector comprising an isolated nucleic acid molecule encoding the
isolated antibody or antigen-binding fragment of any one of claims 1-34.

36.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the
30   coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 2.

37.   An expression vector comprising an isolated nucleic acid molecule encoding the light
chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding
region or regions of the nucleotide sequence set forth as SEQ ID NO: 8.

38.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules
comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID
NOs: 2 and 8.

39.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the
coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 3.

40.   An expression vector comprising an isolated nucleic acid molecule encoding the light
chain of AB-PG1-XG1-026 encoded by a nucleic acid molecules comprising the coding
region or regions of the nucleotide sequence set forth as SEQ ID NO: 9.

41.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy and light chains of AB-PG1-XG1-026 encoded by the nucleic acid molecules
comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID
NOs: 3 and 9.

42.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the
coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 4.

43.   An expression vector comprising an isolated nucleic acid molecule encoding the light
chain of AB-PG1-XG1-051 encoded by a nucleic acid molecules comprising the coding
region or regions of the nucleotide sequence set forth as SEQ ID NO: 10.

44.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy and light chains of AB-PG1-XG1-051 encoded by the nucleic acid molecules

comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID
NOs: 4 and 10.

45.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the
coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 5.

46.   An expression vector comprising an isolated nucleic acid molecule encoding the light
chain of AB-PG1-XG1-069 encoded by a nucleic acid molecules comprising the coding
region or regions of the nucleotide sequence set forth as SEQ ID NO: 11.

47.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy and light chains of AB-PG1-XG1-069 encoded by the nucleic acid molecules
comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID
NOs: 5 and 11.

48.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the
coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 6.

49.   An expression vector comprising an isolated nucleic acid molecule encoding the light
chain of AB-PG1-XG1-077 encoded by a nucleic acid molecules comprising the coding
region or regions of the nucleotide sequence set forth as SEQ ID NO: 12.

50.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy and light chains of AB-PG1-XG1-077 encoded by the nucleic acid molecules
comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID
NOs: 6 and 12.

51.   An expression vector comprising an isolated nucleic acid molecule encoding the
heavy chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the
coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 7.

52.   An expression vector comprising an isolated nucleic acid molecule encoding the light chain of AB-PG1-XG1-006 encoded by a nucleic acid molecules comprising the coding region or regions of the nucleotide sequence set forth as SEQ ID NO: 13.

5   53.   An expression vector comprising an isolated nucleic acid molecule encoding the heavy and light chains of AB-PG1-XG1-006 encoded by the nucleic acid molecules comprising the coding region or regions of the nucleotide sequences set forth as SEQ ID NOs: 7 and 13.

10   54.   A host cell transformed or transfected by the expression vector of claim 35.

55.   A plasmid which produces the antibody or antigen binding fragments of any one of claims 1-34.

15   56.   The plasmid of claim 55, wherein the plasmid is selected from the group consisting of: AB-PG1-XG1-006 Heavy Chain (SEQ ID NO: 2), AB-PG1-XG1-006 Light Chain (SEQ ID NO: 8), AB-PG1-XG1-026 Heavy Chain (SEQ ID NO: 3), AB-PG1-XG1-026 Light Chain (SEQ ID NO: 9), AB-PG1-XG1-051 Heavy Chain (SEQ ID NO: 4), AB-PG1-XG1-051 Light Chain (SEQ ID NO: 10), AB-PG1-XG1-069 Heavy Chain (SEQ ID NO: 5), AB-

20   PG1-XG1-069 Light Chain (SEQ ID NO: 11), AB-PG1-XG1-077 Heavy Chain (SEQ ID NO: 6), AB-PG1-XG1-077 Light Chain (SEQ ID NO: 12), PSMA 10.3 Heavy Chain (SEQ ID NO: 7), and PSMA 10.3 Kappa (SEQ ID NO: 13).

57.   The isolated antibody or antigen-binding fragment thereof according to claim 1,

25   wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

58.   The isolated antibody or antigen-binding fragment thereof of claim 57, wherein the cell is a tumor cell.

30

59.   The isolated antibody or antigen-binding fragment thereof of claim 58, wherein the tumor cell is a prostate tumor cell.

60.   The isolated antibody or antigen-binding fragment thereof of claim 59, wherein the tumor cell is a LNCaP cell.

61.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA.

62.   The isolated antibody or antigen-binding fragment thereof of claim 61 wherein cytolysis of cells expressing PSMA is mediated by effector cells.

63.   The isolated antibody or antigen-binding fragment thereof of claim 61 wherein cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

64.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA.

65.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind to the epitope on PSMA.

66.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD or IgE.

67.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a recombinant antibody.

68.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a polyclonal antibody.

69.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a monoclonal antibody.

70.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a humanized antibody.

71.   The isolated antibody or antigen-binding fragment thereof according to claim 70, wherein said antibody is a monoclonal antibody.

72.   The isolated antibody or antigen-binding fragment thereof according to claim 70, wherein said antibody is a polyclonal antibody.

73.   The isolated antibody or antigen-binding fragment thereof according to claim 70, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

74.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a chimeric antibody.

75.   The isolated antibody or antigen-binding fragment thereof according to claim 74, wherein said antibody is a monoclonal antibody.

76.   The isolated antibody or antigen-binding fragment thereof according to claim 74, wherein said antibody is a polyclonal antibody.

77.   The isolated antibody or antigen-binding fragment thereof according to claim 74, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

78.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a human antibody.

79.   The isolated antibody or antigen-binding fragment thereof according to claim 78, wherein said antibody is a monoclonal antibody.

AMENDED SHEET (ARTICLE 19)

80.   The isolated antibody or antigen-binding fragment thereof according to claim 78, wherein said antibody is a polyclonal antibody.

81.   The isolated antibody or antigen-binding fragment thereof according to claim 78, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

82.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein said antibody is a bispecific or multispecific antibody.

83.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')$_2$ fragment, and a Fv fragment CDR3.

84.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

85.   The isolated antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

86.   The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof is internalized into a cell with the prostate specific membrane antigen.

87.   A hybridoma cell line that produces an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA A3.1.3, PSMA A3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

88.   The hybridoma cell line of claim 87, wherein the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA A3.1.3 (PTA-3904), PSMA A3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1 (PTA-4653).

89.   A composition comprising:
        an antibody or antigen-binding fragment thereof according to any one of claims 1-34 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

90.   The composition of claim 89, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

91.   The composition of claim 90, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

AMENDED SHEET (ARTICLE 19)

92.   The composition of claim 90, wherein the immunomodulator is α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof.   .

93.   The composition of claim 90, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

94.   A composition comprising:

        a combination of two or more antibodies or antigen-binding fragments thereof according to any one of claims 1-34 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

95.   The composition of claim 94, further comprising an antitumor agent, an immunostimulatory agent, an immunomodulator, or a combination thereof.

96.   The composition of claim 95, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

97.   The composition of claim 95, wherein the immunomodulator is α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof.

98.   The composition of claim 95, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

99.   The isolated antibody or antigen-binding fragment thereof of claim 1, bound to a label.

100.   The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 99, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

101.   A composition comprising:

        an antibody or antigen-binding fragment thereof according to claim 99 and

AMENDED SHEET (ARTICLE 19)

a pharmaceutically acceptable carrier, excipient, or stabilizer.

102.   The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or rsPSMA with a binding affinity of about 1×10^{-9}M or less.

103.   The isolated antibody or antigen-binding fragment thereof of claim 102, wherein the binding affinity is about 1×10^{-10}M or less.

104.   The isolated antibody or antigen-binding fragment thereof of claim 103, wherein the binding affinity is about 1×10^{-11}M or less.

105.   The isolated antibody or antigen-binding fragment thereof of claim 102, wherein the binding affinity is less than about 5×10^{-10}M.

106.   The isolated antibody or antigen-binding fragment thereof of claim 1, bound to at least one therapeutic moiety .

107.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC_{50} of less than about 1×10^{-10}M.

108.   The isolated antibody or antigen-binding fragment thereof of claim 107, wherein the IC_{50} is less than about 1×10^{-11}M.

109.   The isolated antibody or antigen-binding fragment thereof of claim 108, wherein the IC_{50} is less than about 1×10^{-12}M.

110.   The isolated antibody or antigen-binding fragment thereof of claim 107, wherein the IC_{50} is less than about 1.5×10^{-11}M.

111.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is a drug.

112.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is a replication selective virus.

113.   The isolated antibody or antigen-binding fragment thereof of claim 111, wherein the drug is a cytotoxic drug.

114.   The isolated antibody or antigen-binding fragment thereof of claim 113, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

115.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is a toxin or a fragment thereof.

116.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is an enzyme or a fragment thereof.

117.   The isolated antibody or antigen-binding fragment thereof of claim 106, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

118.   The isolated antibody or antigen-binding fragment thereof of claim 117, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

119.   A composition comprising:
        the antibody or antigen-binding fragment of claim 106 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

120.   The isolated antibody or antigen-binding fragment thereof of 1, bound to a radioisotope.

121. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope emits α radiations.

122. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope emits β radiations.

123. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope emits γ radiations.

124. The isolated antibody or antigen-binding fragment thereof according to claim 120, wherein the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

125. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 120 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

126. A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising:
the isolated labeled antibody or antigen-binding fragment thereof of claim 99, and one or more compounds for detecting the label.

127. A kit according to claim 126, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

128. The isolated antibody or antigen-binding fragment thereof of any of claims 1, 99, 106 or 120 packaged in lyophilized form.

129. The isolated antibody or antigen-binding fragment thereof of any of claims 1, 99, 106 or 120 packaged in an aqueous medium.

139. An isolated antibody or an antigen-binding fragment thereof which specifically binds to an epitope on prostate specific membrane antigen (PSMA) defined by an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4,

AMENDED SHEET (ARTICLE 19)

PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix

5 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1, and antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

10 (b) a light chain encoded by a nucleic acid molecule comprising the coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13.

131. The isolated antibody or antigen-binding fragment thereof according to claim 130,

15 wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix

20 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1, Abgenix 4.152.1 and antigen-binding fragments thereof.

132. The isolated antibody or antigen-binding fragment thereof according to claim 130,

25 wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of antibodies comprising:

(a) a heavy chain encoded by a nucleic acid molecule comprising the heavy chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 2-7, and

30 (b) a light chain encoded by a nucleic acid molecule comprising the light chain coding region or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as SEQ ID NOs: 8-13, and antigen-binding fragments thereof.

133.   An isolated antibody which specifically binds to an epitope on prostate specific membrane antigen, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 90% identical to the nucleotide sequence encoding the antibody of claim 132.

134.   The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 95% identical.

135.   The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 97% identical.

136.   The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 98% identical.

137.   The isolated antibody of claim 133, wherein the antibody is encoded by a nucleic acid molecule comprising a nucleotide sequence that is at least about 99% identical.

138.   An antigen-binding fragment of the isolated antibody of claim 132, comprising:
        (a) a heavy chain variable region encoded by a nucleic acid molecule comprising the coding regions or regions of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 14, 18, 22, 26 and 30, and
        (b) a light chain variable region encoded by a nucleic acid molecule comprising the coding region or region of a nucleotide sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 16, 20, 24, 28 and 32.

139.   The antigen-binding fragment of the isolated antibody of claim 132, comprising:
        (a) a heavy chain variable region comprising an amino acid sequence selected from the group consisting of amino acid sequences set forth as: SEQ ID NOs: 15, 19, 23, 27 and 31, and
        (b) a light chain variable region comprising an amino acid sequence selected from the group consisting of nucleotide sequences set forth as: SEQ ID NOs: 17, 21, 25, 29 and 33.

140. An isolated antigen-binding fragment which comprises a CDR of the antigen-binding fragment according to claim 138 or claim 139.

141. The isolated antigen-binding fragment of claim 140, wherein the CDR is CDR3.

5

142. An expression vector comprising an isolated nucleic acid molecule encoding the isolated antibody or antigen-binding fragment of any one of claims 130-138.

143. A host cell transformed or transfected by the expression vector of claim 142.

10

144. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof is selected for its ability to bind live cells.

15 145. The isolated antibody or antigen-binding fragment thereof of claim 144 , wherein the cell is a tumor cell.

146. The isolated antibody or antigen-binding fragment thereof of claim 145, wherein the tumor cell is a prostate tumor cell.

20

147. The isolated antibody or antigen-binding fragment thereof of claim 146, wherein the tumor cell is a LNCaP cell.

148. The isolated antibody or antigen-binding fragment thereof according to claim 130,
25 wherein said antibody or antigen-binding fragment thereof mediates cytolysis of cells expressing PSMA.

149. The isolated antibody or antigen-binding fragment thereof of claim 148 wherein cytolysis of cells expressing PSMA is mediated by effector cells.

30

150. The isolated antibody or antigen-binding fragment thereof of claim 148 wherein cytolysis of cells expressing PSMA is complement mediated in the presence of effector cells.

151.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof inhibits the growth of cells expressing PSMA.

5   152.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody or antigen-binding fragment thereof does not require cell lysis to bind to the epitope on PSMA.

153.   The isolated antibody or antigen-binding fragment thereof according to claim 130,
10   wherein said antibody or antigen-binding fragment thereof is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgD, IgE or has immunoglobulin constant and/or variable domain of IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgAsec, IgA or IgE.

15   154.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a recombinant antibody.

155.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a polyclonal antibody.
20

156.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a monoclonal antibody.

157.   The isolated antibody or antigen-binding fragment thereof according to claim 130,
25   wherein said antibody is a humanized antibody.

158.   The isolated antibody or antigen-binding fragment thereof according to claim 157, wherein said antibody is a monoclonal antibody.

30   159.   The isolated antibody or antigen-binding fragment thereof according to claim 157, wherein said antibody is a polyclonal antibody.

160.   The isolated antibody or antigen-binding fragment thereof according to claim 157, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

161.   The isolated antibody or antigen-binding fragment thereof according to claim 130, 5   wherein said antibody is a chimeric antibody.

162.   The isolated antibody or antigen-binding fragment thereof according to claim 161, wherein said antibody is a monoclonal antibody.

10   163.   The isolated antibody or antigen-binding fragment thereof according to claim 161, wherein said antibody is a polyclonal antibody.

164.   The isolated antibody or antigen-binding fragment thereof according to claim 161, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.
15

165.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a human antibody.

166.   The isolated antibody or antigen-binding fragment thereof according to claim 165, 20   wherein said antibody is a monoclonal antibody.

167.   The isolated antibody or antigen-binding fragment thereof according to claim 165, wherein said antibody is a polyclonal antibody.

25   168.   The isolated antibody or antigen-binding fragment thereof according to claim 165, wherein said antibody is a mixture of monoclonal and/or polyclonal antibodies.

169.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein said antibody is a bispecific or multispecific antibody.
30

170.   The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein the isolated antigen-binding fragment is selected from the group consisting of a Fab fragment, a F(ab')2 fragment, and a Fv fragment CDR3.

171. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein the antibody is a monoclonal antibody produced by a hybridoma cell line selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904), PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428), Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557), Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359), Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362), Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367), Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388), Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391), Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

172. The isolated antibody or antigen-binding fragment thereof according to claim 130, wherein the antibody or antigen-binding fragment thereof binds to a conformational epitope.

173. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 130, wherein the antibody or antigen-binding fragment thereof is internalized into a cell with the prostate specific membrane antigen.

174. A hybridoma cell line that produces an antibody selected from the group consisting of PSMA 3.7, PSMA 3.8, PSMA 3.9, PSMA 3.11, PSMA 5.4, PSMA 7.1, PSMA 7.3, PSMA 10.3, PSMA 1.8.3, PSMA B3.1.3, PSMA B3.3.1, Abgenix 4.248.2, Abgenix 4.360.3, Abgenix 4.7.1, Abgenix 4.4.1, Abgenix 4.177.3, Abgenix 4.16.1, Abgenix 4.22.3, Abgenix 4.28.3, Abgenix 4.40.2, Abgenix 4.48.3, Abgenix 4.49.1, Abgenix 4.209.3, Abgenix 4.219.3, Abgenix 4.288.1, Abgenix 4.333.1, Abgenix 4.54.1, Abgenix 4.153.1, Abgenix 4.232.3, Abgenix 4.292.3, Abgenix 4.304.1, Abgenix 4.78.1 and Abgenix 4.152.1.

175. The hybridoma cell line of claim 174, wherein the hybridoma cell line is selected from the group consisting of PSMA 3.7 (PTA-3257), PSMA 3.8, PSMA 3.9 (PTA-3258), PSMA 3.11 (PTA-3269), PSMA 5.4 (PTA-3268), PSMA 7.1 (PTA-3292), PSMA 7.3 (PTA-

3293), PSMA 10.3 (PTA-3247), PSMA 1.8.3 (PTA-3906), PSMA B3.1.3 (PTA-3904),

PSMA B3.3.1 (PTA-3905), Abgenix 4.248.2 (PTA-4427), Abgenix 4.360.3 (PTA-4428),

Abgenix 4.7.1 (PTA-4429), Abgenix 4.4.1 (PTA-4556), Abgenix 4.177.3 (PTA-4557),

Abgenix 4.16.1 (PTA-4357), Abgenix 4.22.3 (PTA-4358), Abgenix 4.28.3 (PTA-4359),

5   Abgenix 4.40.2 (PTA-4360), Abgenix 4.48.3 (PTA-4361), Abgenix 4.49.1 (PTA-4362),

Abgenix 4.209.3 (PTA-4365), Abgenix 4.219.3 (PTA-4366), Abgenix 4.288.1 (PTA-4367),

Abgenix 4.333.1 (PTA-4368), Abgenix 4.54.1 (PTA-4363), Abgenix 4.153.1 (PTA-4388),

Abgenix 4.232.3 (PTA-4389), Abgenix 4.292.3 (PTA-4390), Abgenix 4.304.1 (PTA-4391),

Abgenix 4.78.1 (PTA-4652), and Abgenix 4.152.1(PTA-4653).

10

176.   A composition comprising:

an antibody or antigen-binding fragment thereof according to any one of claims 130-

141 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

15   177.   The composition of claim 176, further comprising an antitumor agent, an

immunostimulatory agent, an immunomodulator, or a combination thereof.

178.   The composition of claim 177, wherein the antitumor agent is a cytotoxic agent, an

agent that acts on tumor neovasculature, or a combination thereof.

20

179.   The composition of claim 177, wherein the immunomodulator is α-interferon, γ-

interferon, tumor necrosis factor-α or a combination thereof.

180.   The composition of claim 177, wherein the immunostimulatory agent is interleukin-2,

25   immunostimulatory oligonucleotides, or a combination thereof.

181.   A composition comprising:

a combination of two or more antibodies or antigen-binding fragments thereof

according to any one of claims 130-141 and a pharmaceutically acceptable carrier, excipient,

30   or stabilizer.

182.   The composition of claim 181, further comprising an antitumor agent, an

immunostimulatory agent, an immunomodulator, or a combination thereof.

183. The composition of claim 182, wherein the antitumor agent is a cytotoxic agent, an agent that acts on tumor neovasculature, or a combination thereof.

5   184. The composition of claim 182, wherein the immunomodulator is α-interferon, γ-interferon, tumor necrosis factor-α or a combination thereof.

185. The composition of claim 182, wherein the immunostimulatory agent is interleukin-2, immunostimulatory oligonucleotides, or a combination thereof.

10

186. The isolated antibody or antigen-binding fragment thereof of claim 130, bound to a label.

187. The isolated monoclonal antibody or antigen-binding fragment thereof according to
15   claim 186, wherein the label is selected from the group consisting of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

188. A composition comprising:
20   an antibody or antigen-binding fragment thereof according to claim 186 and
a pharmaceutically acceptable carrier, excipient, or stabilizer.

189. The isolated antibody or antigen-binding fragment thereof of claim 130, wherein the antibody or antigen-binding fragment thereof specifically binds cell-surface PSMA and/or
25   rsPSMA with a binding affinity of about 1×10^{-9} M or less.

190. The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is about 1×10^{-10} M or less.

30   191. The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is about 1×10^{-11} M or less.

192.   The isolated antibody or antigen-binding fragment thereof of claim 189, wherein the binding affinity is less than about 5×10^{-10}M.

193.   The isolated antibody or antigen-binding fragment thereof of claim 130, bound to at least one therapeutic moiety .

194   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the antibody or antigen-binding fragment thereof mediates specific cell killing of PSMA-expressing cells with an IC_{50} of less than about 1×10^{-10}M.

195.   The isolated antibody or antigen-binding fragment thereof of claim 194, wherein the IC_{50} is less than about 1×10^{-11}M.

196.   The isolated antibody or antigen-binding fragment thereof of claim 195, wherein the IC_{50} is less than about 1×10^{-12}M.

197.   The isolated antibody or antigen-binding fragment thereof of claim 194, wherein the IC_{50} is less than about 1.5×10^{-11}M.

198.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is a drug.

199.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is a replication-selective virus.

200.   The isolated antibody or antigen-binding fragment thereof of claim 198, wherein the drug is a cytotoxic drug.

201.   The isolated antibody or antigen-binding fragment thereof of claim 200, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

166

202.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is a toxin or a fragment thereof.

5   203.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is an enzyme or a fragment thereof.

204.   The isolated antibody or antigen-binding fragment thereof of claim 193, wherein the therapeutic moiety is an immunostimulatory or immunomodulating agent.

10

205.   The isolated antibody or antigen-binding fragment thereof of claim 204, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

15   206.   A composition comprising:
        the antibody or antigen-binding fragment of claim 193 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

207.   The isolated antibody or antigen-binding fragment thereof of 130, bound to a
20   radioisotope.

208.   The isolated antibody or antigen-binding fragment thereof according to claim 207, wherein the radioisotope emits α radiations.

25   209.   The isolated antibody or antigen-binding fragment thereof according to claim 207, wherein the radioisotope emits β radiations.

210.   The isolated antibody or antigen-binding fragment thereof according to claim 207, wherein the radioisotope emits γ radiations.

30

211.   The isolated antibody or antigen-binding fragment thereof according to claim 207, wherein the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

212.   A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 207 and a pharmaceutically acceptable carrier, excipient, or stabilizer.

5   213.   A kit for detecting prostate cancer for diagnosis, prognosis or monitoring comprising:
        the isolated labeled antibody or antigen-binding fragment thereof of claim 186, and one or more compounds for detecting the label.

214.   A kit according to claim 213, wherein the label is selected from the group consisting
10 of a fluorescent label, an enzyme label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

215.   The isolated antibody or antigen-binding fragment thereof of any of claims 130, 186, 193 or 207 packaged in lyophilized form.

15

216.   The isolated antibody or antigen-binding fragment thereof of any of claims 130, 186, 193 or 207 packaged in an aqueous medium.

217.   A method for detecting the presence of PSMA, or a cell expressing PSMA, in a
20 sample comprising:
        contacting the sample with an antibody or antigen-binding fragment thereof according to claim 1 or 130 for a time sufficient to allow the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA, and
        detecting the PSMA-antibody complex or PSMA-antigen-binding fragment complex,
25   wherein the presence of a complex in the sample is indicative of the presence in the sample of PSMA or a cell expressing PSMA.

218.   A method for diagnosing a PSMA-mediated disease in a subject comprising:
        administering to a subject suspected of having or previously diagnosed with PSMA-
30 mediated disease an isolated amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130,
        allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

detecting the formation of the PSMA-antibody complex or PSMA-antigen-binding fragment complex to the target epitope,

wherein the presence of a complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the presence of a PSMA-mediated
5   disease.

219.   The method of claim 218 wherein the PSMA-mediated disease is prostate cancer.

220.   The method of claim 218 wherein the PSMA-mediated disease is a non-prostate
10   cancer.

221.   The method of claim 220 wherein the non-prostate cancer is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma;
15   kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.
20

221.   The method of claim 217 or claim 218 wherein the antibody or antigen-binding fragment thereof is labeled.

223.   The method of claim 217 or claim 218 wherein a second antibody is administered to
25   detect the first antibody or antigen-binding fragment thereof.

224.   A method for assessing the prognosis of a subject with a PSMA-mediated disease:
administering to a subject suspected of having or previously diagnosed with PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof
30   according to claim 1 or 130,
allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,
detecting the formation of the complex to the target epitope,

AMENDED SHEET (ARTICLE 19)

wherein the amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the prognosis.

225.   A method for assessing the effectiveness of a treatment of a subject with a PSMA-
5   mediated disease:

administering to a subject suspected treated for a PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130,

allowing the formation of a complex between the antibody or antigen-binding fragment thereof and PSMA,

10   detecting the formation of the complex to the target epitope,

wherein the amount of the complex in the subject suspected of having or previously diagnosed with PSMA-mediated disease is indicative of the effectiveness of the treatment.

226.   The method of claim 224 or claim 225 wherein the PSMA-mediated disease is
15   prostate cancer.

227.   The method of claim 224 or claim 225 wherein the PSMA-mediated disease is a non-prostate cancer.

20   228.   The method of claim 227 wherein the non-prostate cancer is selected from the group consisting of bladder cancer including transitional cell carcinoma; pancreatic cancer . including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma
25   multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

229.   The method of claim 224 or claim 225 wherein the antibody or antigen-binding
30   fragment thereof is labeled.

230.   The method of claim 224 or claim 225 wherein a second antibody is administered to detect the first antibody or antigen-binding fragment thereof.

231. A method for inhibiting the growth of a cell expressing PSMA comprising:

contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 which specifically binds to an extracellular

5   domain of PSMA effective to inhibit the growth of the cell expressing PSMA.

232. A method for inducing cytolysis of a cell expressing PSMA comprising:

contacting a cell expressing PSMA with an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 which specifically binds to an extracellular

10   domain of PSMA effective to induce cytolysis of the cell expressing PSMA.

233. The method of claim 232 wherein the cytolysis occurs in the presence of an effector cell.

15 234. The method of claim 232 wherein the cytolysis is complement mediated.

235. A method for treating or preventing a PSMA-mediated disease comprising: administering to a subject having a PSMA-mediated disease or at risk of having a PSMA-mediated disease an effective amount of an antibody or antigen-binding fragment thereof

20   according to claim 1 or 130 to treat or prevent the PSMA-mediated disease.

236. The method of claim 235 wherein the PSMA-mediated disease is a cancer.

237. The method for claim 236 wherein the cancer is a prostate cancer.

25

238. The method for claim 236 wherein the cancer is a non-prostate cancer.

239. A method for treating or preventing a PSMA-mediated disease comprising: administering to a subject having a PSMA-mediated disease or at risk of having a

30   PSMA-mediated disease an amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 effective to treat or prevent the PSMA-mediated disease.

240. The method of claim 239, wherein the PSMA-mediated disease is a cancer.

AMENDED SHEET (ARTICLE 19)

241.   The method of claim 240, wherein the cancer is prostate cancer.

242.   The method of claim 240, wherein the cancer is a non-prostate cancer.

243.   The method of claim 242, wherein the non-prostate cancer is selected from the group consisting of: bladder cancer including transitional cell carcinoma; pancreatic cancer including pancreatic duct carcinoma; lung cancer including non-small cell lung carcinoma; kidney cancer including conventional renal cell carcinoma; sarcoma including soft tissue sarcoma; breast cancer including breast carcinoma; brain cancer including glioblastoma multiforme; neuroendocrine carcinoma; colon cancer including colonic carcinoma; testicular cancer including testicular embryonal carcinoma; and melanoma including malignant melanoma.

244.   The method of claim 239, further comprising administering another therapeutic agent to treat or prevent the PSMA-mediated disease at any time before, during or after the administration of the antibody or antigen-binding fragment thereof.

245.   The method of claim 244, wherein the therapeutic agent is a vaccine.

246.   The method of claim 245, wherein the vaccine immunizes the subject against PSMA.

247.   The method of claim 244, wherein the antibody or antigen-binding fragment thereof is bound to at least one therapeutic moiety.

248.   The method of claim 247, wherein the therapeutic moiety is a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof.

249.   The method of claim 248, wherein the cytotoxic drug is selected from the group consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

AMENDED SHEET (ARTICLE 19)

250.   The method of claim 247, wherein the antibody or antigen-binding fragment thereof is bound to a radioisotope, wherein the radiations emitted by the radioisotope is selected from the group consisting of α, β and γ radiations.

251.   The method of claim 250, wherein the radioisotope is selected from the group consisting of ^{225}Ac, ^{211}At, ^{212}Bi, ^{213}Bi, ^{186}Rh, ^{188}Rh, ^{177}Lu, ^{90}Y, ^{131}I, ^{67}Cu, ^{125}I, ^{123}I, ^{77}Br, ^{153}Sm, ^{166}Ho, ^{64}Cu, ^{212}Pb, ^{224}Ra and ^{223}Ra.

252.   A method for inhibiting folate hydrolase activity comprising:
        contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits the folate hydrolase activity.

253.   The method of claim 252 wherein the folate hydrolase polypeptide is isolated.

254.   The method of claim 252 wherein the folate hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

255.   The method of claim 252 wherein the folate hydrolase polypeptide is contained in an organism.

256.   The method of claim 255 wherein the organism is an animal.

257.   The method of claim 256 wherein the animal is a mammal.

258.   A method for enhancing folate hydrolase activity comprising:
        contacting a folate hydrolase polypeptide with an amount of isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances the folate hydrolase activity.

259.   The method of claim 258 wherein the folate hydrolase polypeptide is isolated.

260.   The method of claim 258 wherein the folate hydrolase polypeptide is contained in a
sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue
homogenate.

261.   The method of claim 258 wherein the folate hydrolase polypeptide is contained in an
organism.

262.   The method of claim 261 wherein the organism is an animal.

263.   The method of claim 262 wherein the animal is a mammal.

264.   A method for inhibiting N-acetylated α-linked acidic dipeptidase (NAALADase)
activity comprising:
        contacting a NAALADase polypeptide with an amount of an isolated antibody or
antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein
the isolated antibody or antigen-binding fragment thereof inhibits NAALADase activity.

265.   The method for claim 264 wherein the NAALADase polypeptide is isolated.

266.   The method for claim 264 wherein the NAALADase polypeptide is contained in a
sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue
homogenate.

267.   The method for claim 264 wherein the NAALADase polypeptide is contained in an
organism.

268.   The method for claim 267 wherein the organism is an animal.

269.   The method for claim 268 wherein the animal is a mammal.

270.   A method for enhancing N-acetylated α-linked acidic dipeptidase (NAALADase) activity comprising:

contacting a NAALADase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof enhances NAALADase activity.

271.   The method for claim 270 wherein the NAALADase polypeptide is isolated.

272.   The method for claim 270 wherein the NAALADase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

273.   The method for claim 270 wherein the NAALADase polypeptide is contained in an organism.

274.   The method for claim 273 wherein the organism is an animal.

275.   The method for claim 274 wherein the animal is a mammal.

276.   A method for inhibiting dipeptidyl dipeptidase IV activity comprising:

contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits dipeptidyl dipeptidase IV activity.

277.   The method for claim 276 wherein the dipeptidyl dipeptidase IV polypeptide is isolated.

278.   The method for claim 276 wherein the dipeptidyl dipeptidase IV polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

279.   The method for claim 276 wherein the dipeptidyl dipeptidase IV polypeptide is contained in an organism.

280.   The method for claim 279 wherein the organism is an animal.

281.   The method for claim 280 wherein the animal is a mammal.

282.   A method for inhibiting dipeptidyl dipeptidase IV activity comprising:

contacting a dipeptidyl dipeptidase IV polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits dipeptidyl dipeptidase IV activity.

283.   The method for claim 282 wherein the dipeptidyl dipeptidase IV polypeptide is isolated.

284.   The method for claim 282 wherein the dipeptidyl dipeptidase IV polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

285.   The method for claim 282 wherein the dipeptidyl dipeptidase IV polypeptide is contained in an organism.

286.   The method for claim 285 wherein the organism is an animal.

287.   The method for claim 286 wherein the animal is a mammal.

288.   A method for inhibiting γ–glutamyl hydrolase activity comprising:

contacting a γ–glutamyl hydrolase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ–glutamyl hydrolase activity.

AMENDED SHEET (ARTICLE 19)

289.   The method for claim 288 wherein the γ–glutamyl hydrolase polypeptide is isolated.

290.   The method for claim 288 wherein the γ–glutamyl hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a

5   tissue homogenate.

291.   The method for claim 288 wherein the γ–glutamyl hydrolase polypeptide is contained in an organism.

10   292.   The method for claim 291 wherein the organism is an animal.

293.   The method for claim 292 wherein the animal is a mammal.

294.   A method for inhibiting γ–glutamyl hydrolase activity comprising:

15   contacting a γ–glutamyl hydrolase polypeptide with an amount of an isolated antibody or antigen-binding fragment thereof according to claim 1 or claim 130 under conditions wherein the isolated antibody or antigen-binding fragment thereof inhibits γ–glutamyl hydrolase activity.

20   295.   The method for claim 294 wherein the γ–glutamyl hydrolase polypeptide is isolated.

296.   The method for claim 294 wherein the γ–glutamyl hydrolase polypeptide is contained in a sample selected from the group consisting of a cell, a cell homogenate, a tissue, or a tissue homogenate.

25

297.   The method for claim 294 wherein the γ–glutamyl hydrolase polypeptide is contained in an organism.

298.   The method for claim 297 wherein the organism is an animal.

30

299.   The method for claim 298 wherein the animal is a mammal.

AMENDED SHEET (ARTICLE 19)

300.   A method of specific delivery of at least one therapeutic agent to PSMA-expressing cells, comprising:

administering an effective amount of an antibody or antigen-binding fragment thereof according to claim 1 or 130 conjugated to the at least one therapeutic agent.

5

301.   The method of claim 300, wherein the therapeutic agent is a nucleic acid molecule.

302.   The method of claim 300, wherein the therapeutic agent is an antitumor drug.

10   303.   The method of claim 302, wherein the antitumor drug is selected from the group consisting of: a cytotoxic drug, a drug which acts on the tumor neovasculature and combinations thereof.

304.   The method of claim 303, wherein the cytotoxic drug is selected from the group
15   consisting of: calicheamicin, esperamicin, methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cis-platinum, etoposide, bleomycin, 5-fluorouracil, estramustine, vincristine, etoposide, doxorubicin, paclitaxel, docetaxel, dolastatin 10, auristatin E and auristatin PHE.

20   305.   The method of claim 300, wherein the therapeutic moiety is a toxin or a fragment thereof.

306.   The method of claim 300, wherein the therapeutic moiety is an enzyme or a fragment thereof.

25

307.   The method of claim 300, wherein the therapeutic moiety is a replication-selective virus.

308.   The method of claim 300, wherein the therapeutic moiety is an immunostimulatory or
30   immunomodulating agent.

309.   The method of claim 308, wherein the immunostimulatory or immunomodulating agent is selected from the group consisting of: a cytokine, chemokine and adjuvant.

310.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer.

5   311.   The isolated antibody or antigen-binding fragment thereof of claim 310, wherein the PSMA protein multimer is a dimer.

312.   The isolated antibody or antigen-binding fragment thereof of claim 311, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA

10   (rsPSMA) polypeptide.

313.   The isolated antibody or antigen-binding fragment thereof of claim 312, wherein the rsPSMA polypeptide consists essentially of amino acids 44-750 of SEQ ID NO:1.

15   314.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody inhibits at least one enzymatic activity of the PSMA protein multimer.

315.   The isolated antibody or antigen-binding fragment thereof of claim 314, wherein the

20   enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

316.   The isolated antibody or antigen-binding fragment thereof of claim 314, wherein the

25   enzymatic activity is in the extracellular domain of the PSMA molecule.

317.   The isolated antibody or antigen-binding fragment thereof of claim 314, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

30

318.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody enhances at least one enzymatic activity of the PSMA protein multimer.

319.   The isolated antibody or antigen-binding fragment thereof of claim 318, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

320.   The isolated antibody or antigen-binding fragment thereof of claim 318, wherein the enzymatic activity is in the extracellular domain of the PSMA molecule.

321.   The isolated antibody or antigen-binding fragment thereof of claim 318, wherein the antibody or antigen-binding fragment thereof specifically binds to an extracellular domain of PSMA.

322.   A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 310 – 321, and an immunostimulatory oligonucleotide.

323.   A composition comprising an isolated antibody or antigen-binding fragment thereof as in any of claims 310 – 321, and a cytokine.

324.   The composition of claim 323, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

325.   The composition of any of claims 322 – 324, further comprising a pharmaceutically-acceptable carrier.

326.   A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the isolated antibody or composition of any of claims 310-325.

327.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and inhibits at least one enzymatic activity of PSMA.

328.   The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

329.   The isolated antibody or antigen-binding fragment thereof of claim 328, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ-glutamyl hydrolase.

330.   The isolated antibody or antigen-binding fragment thereof of claim 329, wherein the hydrolase is folate hydrolase and the antibody is mAb 5.4 or mAb 3.9.

331.   The isolated antibody or antigen-binding fragment thereof of claim 328, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

332.   The isolated antibody or antigen-binding fragment thereof of claim 327, wherein the enzyme is active in cancer cells and has lesser activity in normal cells than in cancer cells or no activity in normal cells.

333.   The isolated antibody or antigen-binding fragment thereof of claim 332, wherein the cancer cells are prostate cancer cells.

334.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer and enhances at least one enzymatic activity of PSMA.

335.   The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the enzyme is selected from the group consisting of hydrolases and peptidases.

336.   The isolated antibody or antigen-binding fragment thereof of claim 335, wherein the hydrolase is selected from the group consisting of folate hydrolase and γ-glutamyl hydrolase.

337.   The isolated antibody or antigen-binding fragment thereof of claim 335, wherein the peptidase is selected from the group consisting of NAALADase and dipeptidyl dipeptidase IV.

338.   The isolated antibody or antigen-binding fragment thereof of claim 334, wherein the enzyme is active in normal cells and has lesser activity in cancer cells than in normal cells or no activity in cancer cells.

5   339.   The isolated antibody or antigen-binding fragment thereof of claim 338, wherein the cancer cells are prostate cancer cells.

340.   An isolated antibody or antigen-binding fragment thereof that selectively binds a PSMA protein multimer, wherein the isolated antibody is raised by immunizing an animal

10   with a preparation comprising a PSMA protein multimer.

341.   A composition comprising the isolated antibody or antigen-binding fragment thereof of claims 327 – 340, and a pharmaceutically acceptable carrier.

15   342.   A composition comprising an isolated PSMA protein multimer.

343.   The composition of claim 342, wherein the PSMA protein multimer is a dimer.

344.   The composition of claim 342, wherein the composition comprises at least about 10%

20   PSMA protein multimer.

345.   The composition of claim 344, wherein the composition comprises at least about 20% PSMA protein multimer.

25   346.   The composition of claim 345, wherein the composition comprises at least about 30% PSMA protein multimer.

347.   The composition of claim 346, wherein the composition comprises at least about 40% PSMA protein multimer.

30
348.   The composition of claim 347, wherein the composition comprises at least about 50% PSMA protein multimer.

349   The composition of claim 348, wherein the composition comprises at least about 75% PSMA protein multimer.

350.   The composition of claim 349, wherein the composition comprises at least about 90% PSMA protein multimer.

351.   The composition of claim 350, wherein the composition comprises at least about 95% PSMA protein multimer.

352.   The composition of claim 342, wherein the PSMA protein multimer comprises noncovalently associated PSMA proteins.

353.   The composition of claim 352, wherein the PSMA proteins are noncovalently associated under nondenaturing conditions.

354.   The composition of any of claims 342-353, wherein at least one of the PSMA proteins forming the multimer is a recombinant, soluble PSMA (rsPSMA) polypeptide.

355.   The composition of claim 342, wherein the PSMA protein multimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

356.   The composition of claim 342, wherein the PSMA protein multimer comprises PSMA proteins in a native conformation.

357.   The composition of claim 342, wherein the PSMA multimer is enzymatically active.

358.   The composition of claim 357, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

359.   The composition of any of claims 342-358, further comprising an adjuvant.

360.   The composition of any of claims 342-358, further comprising a cytokine.

361. The composition of claim 360, wherein the cytokine is selected from the group consisting of IL-2, IL-12, IL-18 and GM-CSF.

5   362. The composition of any of claims 342-361, further comprising a pharmaceutically acceptable carrier.

363. A method for inducing an immune response comprising administering to a subject in need of such treatment an effective amount of the composition of any of claims 342-362.

10

364. An isolated recombinant soluble PSMA (rsPSMA) protein multimer.

365. An isolated rsPSMA protein dimer.

15   366. The isolated rsPSMA protein dimer of claim 365, wherein the dimer comprises noncovalently associated rsPSMA proteins.

367. The isolated rsPSMA protein dimer of claim 366, wherein the rsPSMA proteins are noncovalently associated under nondenaturing conditions.

20

368. The isolated rsPSMA protein dimer of claim 365, wherein the isolated rsPSMA dimer is reactive with a conformation-specific antibody that specifically recognizes PSMA.

369. The isolated rsPSMA protein dimer of claim 365, wherein the isolated rsPSMA dimer

25   is enzymatically active.

370. The isolated rsPSMA protein dimer of claim 369, wherein the enzymatic activity is selected from the group consisting of folate hydrolase activity, NAALADase activity, dipeptidyl dipeptidase IV activity, γ-glutamyl hydrolase activity and combinations thereof.

30

371. A method of screening for a candidate agent that inhibits at least one enzymatic activity of a PSMA enzyme comprising

a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by

b) adding a substrate for the PSMA enzyme to the reaction mixture, and

c) determining the amount of a product formed from the substrate by the PSMA

5   enzyme, wherein a decrease in the amount of product formed in comparison to a control is indicative of an agent capable of inhibiting at least one enzymatic activity of the PSMA enzyme.

372.   The method of screening of claim 371, wherein the PSMA enzyme is selected from

10   the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ-glutamyl hydrolase.

373.   The method of screening of claim 371, wherein the PSMA multimer comprises recombinant soluble PSMA.

15

374.   The method of screening of claim 371, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

375.   A candidate agent that inhibits at least one enzymatic activity of PSMA identified

20   according to the method of claim 371.

376.   The candidate agent according to claim 375, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

25

377.   A method of screening for a candidate agent that enhances at least one enzymatic activity of a PSMA enzyme comprising

a) mixing the candidate agent with an isolated PSMA protein multimer to form a reaction mixture, followed by

30   b) adding a substrate for the PSMA enzyme to the reaction mixture, and

c) determining the amount of a product formed from the substrate by the PSMA enzyme, wherein an increase in the amount of product formed in comparison to a control is

AMENDED SHEET (ARTICLE 19)

indicative of an agent capable of enhancing at least one enzymatic activity of the PSMA enzyme.

378.   The method of screening of claim 377, wherein the PSMA enzyme is selected from the group consisting of NAALADase, folate hydrolase, dipeptidyl dipeptidase IV and γ-glutamyl hydrolase.

379.   The method of screening of claim 377, wherein the PSMA multimer comprises recombinant soluble PSMA.

380.   The method of screening of claim 377, wherein the candidate agent is selected from the group consisting of an antibody, a small organic compound, or a peptide.

381.   A candidate agent that enhances at least one enzymatic activity of PSMA identified according to the method of claim 377.

382.   The candidate agent according to claim 381, wherein the agent is selected from a combinatorial antibody library, a combinatorial protein library, or a small organic molecule library.

383.   A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

measuring the amount of PSMA monomer; and

comparing the amount of PSMA monomer measured in the presence of the compound with that observed in the absence of the compound;

wherein an increase in the amount of PSMA monomer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

384.   A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

AMENDED SHEET (ARTICLE 19)

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

measuring the amount of PSMA dimer; and

comparing the amount of PSMA dimer measured in the presence of the compound

5   with that observed in the absence of the compound;

wherein a decrease in the amount of PSMA dimer measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.

10   385.   A method for identifying a compound that promotes dissociation of PSMA dimers, comprising

contacting a PSMA dimer with a compound under conditions that do not promote dissociation of the PSMA dimer in the absence of the compound;

measuring the amounts of PSMA monomer and PSMA dimer;

15   calculating a ratio of PSMA monomer to PSMA dimer; and

comparing the ratio obtained in the presence of the compound with that obtained in the absence of the compound;

wherein an increase in the ratio measured in the presence of the compound indicates that the compound is capable of promoting dissociation of the PSMA dimer.